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me mean prediction error (measure of absolute bias)
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mse Mean squared prediction error (measure of
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o . d . once daily
ODS Octadecylsilane
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programme)
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Time following dosing (h)
Half-life (may have sub-script relating to 
different phases (eg. t|8 ) (h)
Tuberculosis
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SUMMARY
This thesis has examined aspects of the pharmco- 
kinetics and assay of some antimicrobial chemotherapeutic 
agents with particular reference to the kinetics of 
fixed dose combinations and methods of predicting plasma 
concentration. .
An extracted diazotisation procedure for the assay 
of sulphonamides was evaluated and found to be satisfactory 
for estimation of both serum and urine concentrations.
An analytical procedure was devised for the liquid 
chromatographic determination of trimethoprim and was 
used to conduct pharmacokinetic studies of trimethoprim 
in serum, urine, saliva and sputum.
The disposition of trimethoprim and sulphonamide 
following the use of the fixed dose trimethoprim/ 
sulphonamide combinations co-trimoxazole and co-trifamole 
were determined; the kinetics of sulphamethoxazole and 
sulphamoxole, the constituent sulphonamides, and 
trimethoprim were compared; for sulphamoxole this was 
the first full charaterisation of its kinetics. From 
the ratios of trimethoprim to either of the sulph- 
omamides it was evident that the ratios achieved in 
urine were notably inferior to those found in vitro 
to have synergistic effect. Interpolation of these 
results with the clinical, bacteriological and 
pharmacokinetic findings of other workers strongly 
suggested that trimethoprim alone should be an effective
treatment in uncomplicated urinary tract infection.
A comparison of two trimethoprim formulations 
with different dosing schedules showed equivalent 
bioavailability and urine trimethoprim levels likely 
to be effective against susceptible organisms. A 
relationship between urinary trimethoprim concentrations 
and urine pH was noted. However serum concentrations 
were found to fall below the minimum inhibitory 
concentrations when the dosage schedule for 300 mg 
trimethoprim once daily was used; the 200 mg twice 
daily regimen was found to give rise to more acceptable 
plasma concentrations.
Saliva concentrations of trimethoprim were obtained 
simultaneously with serum concentrations to allow 
consideration of the relationship between drug conc­
entrations in these fluids for a drug which is highly 
ionized at physiological serum and saliva pH. Trimethoprim 
was an ideal probe for such an investigation, association 
between saliva and serum concentrations was established 
and there was a non-linear correlation between saliva 
flow rate and hydrogen-ion concentration. The prediction 
of serum trimethoprim concentrations from saliva 
concentration read from the regression line with 
observed serum concentration, was compared with a 
predictive equation based upon the Henderson-Hasselbalch 
equation and was found to be superior.
In a double blind trial of trimethoprim and 
ampicillin in a general practice study of treatment
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of exacerbations of chronic bronchitis, the levels of 
trimethoprim in sputum were compared with clinical and 
bacteriological cure. There was no clear relationship 
but sputum trimethoprim levels well in excess of the 
minimum inhibitory concentration of sensitive organisms 
were shown to be acheived. The study demonstrated that 
trimethoprim was as effective as ampicillin in the 
treatment of exacerbations of chronic bronchitis.
A further examination of prediction of serum 
trimethoprim concentration, using the data from the 
bioequivalence study was undertaken, using a computer 
programme, OPT. The programme uses Bayesian forecasting 
with estimates of maximum likelihood. The precision 
and bias of forecasts of future serum concentration were 
acceptable provided care was exercised in interpretation 
this would require a user having an appreciation of 
kinetic principles.
Liquid chromatographic assays were developed for 
the determination of clavulanic acid and the isomers 
of ticarcillin in serum and urine. These assays were 
applied to the investigation of the kinetics of the 
combination of these drugs in subjects with various 
degrees of renal failure and undergiong dialysis.
Both drugs showed notable renal clearance and their 
serum clearances decreased with increasing renal 
impairment, however the clearance of clavulanic acid 
in anephric subjects was greater than anticipated and 
it is postulated that this may be due to induction of
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metabolism. Haemodialysis cleared both drugs more 
efficiently than continuous ambulatory peritoneal 
dialysis, the former was associated with significant 
rebound levels of ticarcillin on cessation of dialysis. 
From the observed kinetics a dosing scheme for the 
administration of the ticarcillin/clavulanic acid 
combination was proposed.
The limitations of current pharmacokinetic 
models and investigations are discussed and the 
relationship between antimicrobial and antineoplastic 
chemotherapy considered. It is anticipated that intra­
cellular aspects of chemotherapy may be usefully 
examined.
Knowledge is of two kinds. We know a subject 
ourselves, or we know where we can find information 
upon it .
Samuel 3ohnson 1709-1784 
Letter to 3. McPherson
18th April 1775
CHAPTER 1 
GENERAL INTRODUCTION
1INTRODUCTION
l.i. PHARMACOKINETICS
1.1.1. History
From ancient times Man has made use of the pharmacol­
ogical effects of natural products eg. for catharsis or 
to alter mood as part of a religious ceremony; although 
many formulations of supposed medicinal use were in 
reality ineffective, some did have an effect on the body. 
The pharmacological effect of a drug is termed its 
pharmacodynamics. Often on the basis of empirical 
experiment therapeutically effective dosing schedules 
were designed. The dose and frequency of dosing could 
be related to effect but natural products can so vary in 
their potency that a dose-effect relationship could 
be hard to establish.
With the chemical synthesis of drugs and their 
introduction to therapeutic practice,potency could be 
better controlled; with consistency of production the 
rate, extent and duration of effect of a drug were more 
dependent on how the body handled the drug i.e. its 
pharmacokinetics. A drug's disposition may be influenced 
in a number of ways: the dose given, the route of
administration, the extent of its* penetration to different 
sites within the body and the rate of removal of the 
active principle. Although this may seem intuitively 
obvious this aspect of therapeutics did not receive 
formal consideration until about forty years ago.
' ■ 2
There is general consensus that theoretical consid­
eration of pharmacokinetics originated with two papers 
by Teorell in 1937 entitled 'Kinetics of distribution of 
substances administered to the body! in which the mode 
and type of administration and the relationship of these 
to distribution and elimination were considered.
During the 19301s the.relationship between drug 
concentration and response, either therapeutic or toxic, 
was studied eg. for sulphanilamide (Marshall, Emerson, 
and Cutting, 1937a). Examination of routes of adminis­
tration and plasma concentration-time curves, (Marshall, 
Emerson and Cutting, 1937b: Fuller, 1937), the extent of 
drug distribution, expressed as a distribution ratio 
(Marshall, Emerson and Cutting, 1937c), consideration of 
disposition as related to dose, achievement of steady- 
state and the relevance of peak and trough levels 
(Marshall, Cutting and Emerson, 1938: Stewart Rourke and 
Allen, 1938) laid the observational foundation of modern 
pharmacokinetics, indeed one of the fundamental reasons 
stated for performing therapeutic drug monitoring on 
drugs with a low therapeutic index was made by Stewart 
et al (1938) viz. "Another point of practical signif­
icance is the variability of blood level in different 
patients resulting from similar doses of the drug 
per pound. The need for doing frequent blood determin­
ations in patients under intensive therapy is clear." 
Within ten years terminology and concepts relating 
to half-life of elimination , elimination rate 
constant and volume of distribution had been developed
3(Boxer, et al, 1948). Establishment of these principles 
did not mean they were always heeded - phenobarbitone 
was introduced in slow release form to allow once daily 
dosing, a pharmacokinetic study of these and the 'ordinary' 
preparation, showed that no advantage in terms of blood level 
could be demonstrated (Butler, Mahaffee and Waddell, 1954) 
as the authors state for a drug with such a long half-life- 
"Of all the drugs in current use, phenobarbital is one 
of the most inappropriate for this ingenious method of 
administration".
Growth in pharmacokinetics was relatively slow, 
the first review was not published until 1961 (Nelson,
1961), but the second was published only seven years 
later (Wagner, 1968), in the intervening period a number 
of limitations in the early models had been demonstrated 
and alternatives proposed, including: articles on the
need for a re-appraisal of methods of calculation of 
volume of distribution (Wagner and Northam, 1967;
Riegelman, Loo and Rowland, 1968a, Riegelman, Loo and 
Rowland 1968b), consideration of absorption rates (Wagner 
and Nelson, 1964-; Wagner, 1967; Wagner and Hetzler, 1967; 
Riegelman et al, 1968a; Loo and Riegelman, 1968) and 
elimination rates (Wagner, 1967; Wagner and Metzler,
1967; Riegelman et al 1968). Determination of these 
parameters was also possible using an iterative computer 
least squares regression fitting program (Wagner, 1967).
' . Although the mathematical descriptions were adequate
and could be complex, the early observations often relied
upon inaccurate and/or imprecise assays or were based on studies 
with radio-labelled drugs. The investigative impetus was 
enhanced by methodological developments such as gas- 
liquid chromatography and radio-immunoassay which permitted 
direct, accurate and precise determination of the drug and 
its metabolites.
1.1.2. Simple Concepts
A brief outline of the principles of pharmacokinetics 
is given below, more detailed information may be obtained 
from a number of sources (eg. Rowland and Tozer, 1980; 
Gibaldi and Perrier, 1982; Benet, Massoud and Gambertoglio, 
198*0 • The period of drug duration in vivo is a balance 
of the factors considered below,
i ) Administration
If a drug is not administered directly 
into the blood stream it must be absorbed from its site 
of administration eg. gut, muscle etc. the extent and 
rate of absorption depends on a number of factors including 
the drugs pKa , blood flow to the site of administration, 
the drug stability and the pharmaceutical presentation,
ii) Distribution
Once in the circulation, or more accurately 
in the plasma water, the drug is distributed to various 
sites in the body and will accumulate preferentially 
depending on its lipophilicity at physiological pH, 
organ blood flow and tissue protein binding.
5iii) Elimination
Removal of active drugs is usually 
effected by renal excretion or hepatic metabolism 
followed by excretion of metabolites in the urine 
and possibly bile. Hepatic removal is by metabolic 
modification of the original nucleus and this may 
be considered in two phases with first an oxidation 
product formed often, but not exclusively, by cytochrome 
P450 and then with subsequent conjugation with a 
highly polar moiety eg. glucuronide. Reductive metab­
olism may also occur. There are a large number of 
possible routes of drug metabolism and. a drug may 
be metabolised by several routes, some of these routes 
are not mutually exclusive.
Polar drugs and metabolites are usually readily 
excreted renally, the extent of clearance is dependant 
on a number of factors including percent and avidity 
of plasma protein binding, rate of delivery and hence 
filtration, tubular secretion and tubular reabsorption.
As elimination proceeds the whole body drug load 
declines, the plasma water drug concentration declines, 
reflecting a decrease in abundance at receptor level 
and hence a decline in pharmacodynamic effect, 
iv) Multiple dosing
Few drugs are taken as a single dose 
for short-term effect and it is more common for drug 
use to be required over an extended period. The
6only method of maintaining a steady plasma concentration 
once steady-state had been r e a c h e d w o u l d  be to use 
continuous infusion . Regular i.v. bolus or oral dosing, 
at appropriate intervals and doses, may achieve the 
average steady-state plasma levels seen with continuous 
infusion due to the intermittance of the dosing there 
will be peaks just after dosing and troughs just 
prior to dosing, this ’sawtooth’ plasma profile is 
often referred to as ’steady-state1. Dosing at the 
frequency equivalent to the drug half-life will lead 
to accumulation of plasma levels towards steady- 
state, which for practical purposes, can be considered 
complete after such dosing has been continued for 
a period equivalent to five half-lives.
1.1.3. Uses of Pharmacokinetics
Knowledge of the rate constants of drug absorption 
and elimination and extent of distribution can be 
the basis of designing a rational drug regimen for 
the population in. whom the data has been determined. 
Generally such information is widely applicable, 
however disease states may alter pharmacokinetics, 
there may be population sub-sets with kinetics 
markedly different from the general population. Even 
within the population there is a wide spread of 
clearance and distribution and hence blood levels 
following a standard dose, thus individualization
7of therapy is required.
The pharmacokinetics of most drugs are usually 
well documented, and antimicrobial agents are no 
exception; where this class differs from others is 
that there is often a strong rationale for using 
such agents in combination; this may be to extend 
antimicrobial cover, but in some situations one 
agent potentiates the action of another, enhancing 
its effect. Potentiation of action may be an option 
that can be reserved until required with the addition 
of the appropriate drug to the regimen, however 
an alternative is to use the agents in fixed com­
bination in pre-formulated presentations. Usually 
such preparations require the constituents to be 
formulated in a fixed ratio to ensure appropriate 
levels or ratio for action in vivo in the majority 
of the population in which it is to be used; 
from the rationale of these formulations it follows 
that achievement of inappropriate levels due to 
incorrect formulation, effect of disease etc 
means that the fixed combination is inappropriate; 
if the drugs present do not parallel each other in 
their deviation it becomes more difficult to design 
appropriate alternative dosage schemes. The 
pharmacokinetics of such combinations, and prediction 
of plasma drug concentration, required more study 
than 'they had received hitherto..
1.2. ANTIMICROBIAL AGENTS
Antimicrobial agents are structurally diverse and 
range from simple inorganic molecules eg. Arsenic Oxide 
to complex proteins (bacteriocins); the majority are 
intermediate in size comprising a group of structurally 
unrelated molecules with molecular weights of between 
about 150 andl200 daltons.
Their mechanisms of action reflect their structural 
diversity and no facet of microbial activity remains 
unchallenged by antimicrobial agents (Fig 1.1). Such 
agents are most frequently produced by other micro­
organisms in the natural environment and exert evolutionary 
pressure through competition and natural selection.
Similar mechanisms have also resulted in the development 
of resistance.
Man has harnessed a small proportion of these 
compounds to combat a range of infectious diseases; 
our current understanding of the mechanisms of action of, 
and development of resistance to,effective antimicrobial 
agents are largely based on the investigation of these 
compounds.
The range of their mechanisms of action inevitably 
implies that antimicrobial agents exhibit variability 
in their action against different species. If they are 
effective against a wide range of organisms i.e. both 
Gram positive and Gram negative bacteria then they are 
termed broad spectrum agents.
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1.2.1. History
Use of natural antimicrobial agents was reputedly
practised in antiquity, Selwyn, Lacey and Bakhtiar (1980) note that the 
line "purge me with hyssop and I shall be clean" occurs
in Psalm 51 verse 7 and that Penicillium notatum was first
isolated from the hyssop plant. In mediaevel times many
apparently strange medications were used; Phaire(1560)-
stated that "For quinsy and swellynge under the eares.
Take the musherim that groweth vpon an elder tre, called
in englysshe ievves eares (for it is in dede e r o d e d  and
flat, mouch lyke an eare) heate it agaist the fyer, and
put it hote in any drynke, the same drynke is good and
holsome for the quynsy." Selwyn et al- (1980) suggest that
the symptoms were consistent with haemolytic Streptococcal
infection and the "mushroom" has been found to be infected
with Penicillium.
In the late 19th Century Lord Lister (1875) noted 
the effects of Penicillium glaucum on bacteria during 
the course of studies on the Germ Theory; he has been 
reported as utilising the effect clinically in 1888 
(Selwyn et al, 1980).
The modern age of chemotherapy began with the work 
of Ehrlich on organic arsenicals, resulting in the 
production of Salvarsan which was remarkably effective 
against spirochaetal infections, particularly syphilis.
From this and earlier work Ehrlich developed the concept
of: "a medicament   (that) ......would ......strike
the parasites with full force and, in this.sense, corres­
pond to the immune substances which, in the manner of
1 0  .
magic bullets, seek out the enemy." ( Ehrlich,
1913).
The rationale for the magic bullet concept was 
that as there was differential uptake of dyes by bacteria 
eg. Gram’s stain, then this discriminatory uptake could 
be linked to a toxic substance which would selectively 
kill the bacteria i.e. selective toxicity.
Pursuit of this approach resulted in the discovery 
of Prontosil (sulphonamido — chryosidin) in 1932, and 
successful clinical trials were reported in 1935 by Domagk.
The necessity for the Chyrosidin part of the compound was 
questioned by Trefouel et al (1935) who suggested that 
para-aminobenzene sulphonamide was released and was the 
antimicrobially active moeity. Fuller (1937) confirmed 
that para-aminobenzene sulphonamide (sulphanilamide) was 
formed from Prontosil and was the active component (Fig 1.2). 
Ironically sulphanilamide had been synthesised thirty 
years earlier (Gelmo,1908) during a series of investigations 
on azo dyes but its antimicrobial properties passed 
unnoticed.
The discovery of the sulphonamides therefore has 
a direct link with the research initiated by Ehrlich in 
his search for 'magic bullets 1. .
The description of penicillin by Fleming (1929) 
pre dated the discovery of Prontosil by five years.
Although Fleming recognised the clinical possibilities 
of penicillin the emphasis in his original report was 
on its use for typing bacteria; that he did not pursue 
the clinical aspects of penicillin was most probably
Prontosil
- U  NH;
so2nh2 so2nhr
Sulphonamide
R
h Sulphanilamide
Sulphadiazine
Y l l
o - ^ch 3 
CH,
Sulphamethoxazole
Sulphamoxole
'o CH
FIGURE 1.2. Structure of Prontosil, sulphonamide, 
sulphanilamide, sulphamethoxazole 
and sulphamoxole.
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due to the difficulties of isolating therapeutically 
useful quantities. It was not until Florey and Chain 
published their observations on the clinical efficacy of 
penicillin that its true potential was realised (Chain 
et a l , 194-0 ; Abraham et a l , 194-1) .
Due to the military requirements of World War II 
British and American teams investigated penicillin in 
an attempt to improve the yield:df product following 
culture of the Penicillium mould and to modify, and thus 
enhance, the antimicrobial effect. Large scale deep- 
fermentation techniques provided an adequate supply of 
the most active penicillin,.penicillin G; however due to 
the instability of the molecule it proved very difficult 
to determine the exact molecular structure (Sheehan, 1982). 
It was possible by changing the precursor to phenoxy- 
acetic acid to produce penicillin V. The discovery of 
6 -amino-penicillanic acid (Batchelor et al, 1959) in the 
fermentation media led to the use of this product for 
subsequent substituent group modification, allowing a 
relatively cheap and flexible approach to modification 
of the properties of penicillins and gave rise to the 
semi-synthetic penicillins. Although penicillin has 
been totally synthesised chemically (Sheehan, 1982) 
this is an expensive method of production.
Both sulphonamides and penicillin principally 
affect Gram-positive organisms. As the sulphonamides 
W e r e  found to competitively inhibit para-aminobenzoate, 
the principle of antimetabolite chemotherapy was exten­
sively investigated in the search for new antimicrobials,
12
but proved fruitless due to the fact that the metabolism 
of eukaryotic and prokaryotic cells is very similar and 
thus most antimetabolites are toxic to Man.
Penicillin however indicated that micro-organisms 
could inhibit each others growth by the secretion of 
metabolites. Study of saprophytes for such compounds, 
led to the discovery of the first useful antibiotic 
streptomycin, for use in infections by Gram negative 
organisms (Schatz, Bugie and Waksman, 1944).
Thus by the end of the Second World War the 
principle of modern antimicrobial chemotherapy had become 
established.
1.2.2. Resistance
Even as the therapeutic successes of penicillin 
were being described there were reports of resistant 
bacteria (Abraham and Chain, 1940). From this early 
recognition of the phenomenon of resistance it rapidly 
grew to become a major problem.
Resistance to antimicrobial agents may arise in 
a number of ways:
i) Antimicrobial inhibition of the bacterial 
enzyme is no longer effective due to structural modification 
the normal physiological role of the enzyme continues but 
may be impaired and possibly be reflected in a more 
fastidious organism. Such modification is the mechanism 
of pneumococcal resistance to- sulphonamides.
ii) The target area of the agent can be bypassed 
either by supplying the product lost due to the inhibition
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or by synthesis of the product through an alternative 
pathway; the net effect is the same, avoidance of the 
effects of the antibiotic e g . Penicillin resistant Gram- 
negative species may be able to survive a reduced 
peptidoglycan component in their wall structure.
iii) One of the principle causes of antimicrobial 
insensitivity in Gram negative bacteria is the difficulty 
of penetration of antibiotics through the cell wall. 
Modification of permeability can confer resistance, and 
is the basis for low level resistance to many unrelated 
antimicrobial agents.
iv) Inactivation of an antibiotic by metabolic 
degradation is a common source of resistance; a classic 
example being the inactivation of penicillins and 
cephalosporins by 3-lactamases which cleave the • 3-lactam 
ring to produce the microbiologically inactive acids.
The acquisition of resistance is genetically 
mediated; any evolution that is advantageous will be 
phenotypically expressed, and in the presence of an anti­
biotic expression as resistance, although it might normally 
be physiologically disadvantageous, will • be important in 
terms of survival value. In eukaryotic cells genetic 
material is invariably chromosomal, however prokaryotic 
cells are able to transfer genes through exchange of 
genetic material. Resistance can thus be transferred 
or may be intrinsic to the species.
Resistance to antibiotics is encoded by the bacterial 
chromosome or carried on a plasmid (extrachromosoma1 DNA),
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both are self-replicating although some plasmids require 
vectors. Chromosomal and plasmid DNA are not inter­
dependent and on cell division they will replicate and 
be present in each daughter cell. However while anti­
biotic resistance will only be a small part of the 
information carried on the chromosome it can be a dominant 
part of the plasmid information.
In certain bacteria it is not uncommon for the 
plasmid to integrate with the chromosome, this process 
may be irreversible, however of major significance is 
the fact that the plasmid is of a sufficient size to be 
readily transferred between cells and is able to express 
its resistance.
Plasmid transfer is achieved either through a 
bacteriophage vector (transduction) or by direct cellular 
contact between two cells (conjugation). There may be 
more than one plasmid in a cell and resistance factors 
(R-factors) may be whole or part of a plasmid and may or 
may not be self replicating. Each R-factor may have 
several resistance markers on it, although the rate of 
plasmid loss on transfer is such that this information 
may be lost if the pressure of selection is no longer 
present.
The transmissibility of resistance information 
has resulted in bacterial populations rapidly adapting 
to new antibiotics, this is particularly so in the 
hospital environment. Transfer of resistance is important, 
however once established an antibiotic may well be faced
15
with an initial and continuing resistant bacterial 
population.
Microbial drug sensitivity is only determinable 
in vitro. Discs impregnated with antimicrobial agents 
are placed on agar plates innoculated with a lawn of 
isolated organism. Subsequent diffusion of the agent 
into the medium results in the production of a circular 
zone of inhibition if the organism is sensitive. Microbial 
sensitivity to antimicrobial agents is quantItativley 
characterised by determination of the minimum inhibitory 
concentration (MIC) which is the concentration required 
to produce a bacteriostatic, or inhibitory, effect on 
growth in vitro, this allows an empirical correlation 
with efficacy. MIC determinations can be adversly 
affected by a number of factors such as the size of the 
inoculum, media used and pH of the medium.
MIC's can be used in general terms to describe 
the concentration at which sensitive organisms W i l l  be 
susceptible; higher figures will apply to strains with 
some resistance and will be relevant to particular 
isolates, but therapeutic concentrations can usually be 
achieved, very resistant strains, characterised by high 
MIC's will remain unaffected by the drug at the concen­
trations achievable in vivo, and an alternative anti­
microbial should be considered.
Selection of resistant strains is caused by the 
inhibition of sensitive organisms and the subsequent 
proliferation of resistant variants within the original 
population. Uncritical use of antimicrobial agents
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selects for resistance, by rational use of agents it 
would be possible to decrease the trend of increasing 
resistance.
In addition to microbial resistance there may be 
failures in treatment i .e. 1 therapeutic 1 resistance .
Examples of therapeutic resistance include; delay in 
commencement of therapy such that institution is too 
late to significantly affect the course of the infection, 
inability to achieve and maintain therapeutic concen­
trations from whatever cause eg. malabsorption of an 
oral dose, or difficulty of penetration to the infected 
site due to e g . ischaemia, there may be a drug interaction 
or perhaps adverse conditions at the site of action 
eg. pus, that antagonise the antibiotic's.action.
The use of antibiotics in combination may also 
reduce the emergence of resistant strains (Oawetz, 1968). 
One of the commercially most succesful antimicrobial 
combination has been that of sulphamethoxazole (SMZ) 
and trimethoprim (TMP) i.e. co-trimoxazole; more recently 
clavulanate potentiated penicillin combinations have been 
introduced.
This thesis is concerned with the pharmacokinetics 
of these combinations as measured using chemical methods 
of assay.
1.3. BETA-LACTAMS
There are two main classes of antibiotic in this 
group, penicillins and cephalosporins., plus other compounds 
containing the 8 -lactam ring eg. clavulanic acid.
. .1 7 ;
This thesis is concerned with a penicillin and clavulanic 
acid, it is therefore proposed to confine discussion to 
these groups.
1.3.1. Penicillins
a) Mechanism of Action
Penicillin (Structure .Fig. 1.3) inhibits the 
formation of peptidoglycan from UDP N-acetylmuramic acid 
pentapeptide forming a peptide bond with the N-acetyl- 
glucosamine portion of a second mucopeptide with elimination 
of D-alanine. It is thought that penicillin’s main role 
is as a structural analogue for the terminal D-alanyl- 
D-alanine of the pentapeptide and this is the reason for 
its interference in the final transpeptidation. There 
is also evidence that it acts as a carboxypeptidase, 
there are seven penicillin binding proteins (Spratt,1983).
b) Microbial Resistance and Spectrum of Activity
Resistance to penicillins is most commonly caused
by destruction of the penicillin by bacterial ^lactamase 
which cleaves the 3 1 actam ring at the position shown in 
Fig. 1.3. The widespread resistance of hospital 
staphylococci is due to the prevalence of $ lactamase in 
this species.
Beta-lactamase production may be chromosomally 
mediated or R-plasmid mediated, the latter produce the 
greatest amount of enzyme and result in a higher level 
of resistance. Of the $ lactamases,types II-V act on 
penicillins, types II and IV are chromosomal and III 
and V plasmid mediated (Sykes and Matthew, 1976).
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FIGURE 1.3. Structure of some penicillins, including 
ticarcillin showing the site of beta- 
lactamase cleavage.
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Penicillin G is active against most Gram positive organisms, 
in these bacteria the (3-lactamase diffuses from the cell 
into the bacteria's surroundings and thus attacks 3 lactam 
antibiotics, obviously a number of similar bacteria would 
be required to ensure survival. As access and egress to 
the cell is uncomplicated the penetration of an antibiotic 
is unhindered.
In Gram-negative bacteria the cell wall structure 
is more sophisticated than in Gram positive organisms, 
this wall acts as a barrier to penetration by antibiotics 
and is a cause of microbial insensitivity to antibiotics, 
changes in permeability can cause resistance to agents 
that could previously penetrate. In addition 8 lactamases 
are present as wall bound enzymes and can therefore 
inactivate susceptible 8 lactam antibiotics. Modification 
of Penicillin G to give Ampicillin (Fig. 1.3) increases 
the spectrum of susceptible Gram negative bacteria from 
Neisseria to include eg. enteric Escherichia coli, 
further modification of the side-chain eg. ticarcillin 
will include Pseudomonas aeruginosa.
Some penicillins are 8-lactamase stable, but this 
depends on the type of enzyme encountered.
Penicillins are not effective against cells with 
minimal metabolic activity,
c )Pharmacokinetics
Penicillin G is acid labile; following an oral 
dose, less than 30% of the dose will be absorbed (Weinstein 
1973 a.) this ' proportion is not increased for the acid
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stable Penicillin V. Absorption is dependent on the 
particular salt used, the rate of tablet dissolution and 
the presence or absence of food in the stomach. The 
semi-synthetic penicillins (eg. amoxycillin) are more 
acid stable and are well absorbed after oral administration. 
Other semi-synthetic penicillins are penicillinase 
resistant, this is of much greater significance than 
acid resistance although the available MIC data suggests 
that they are less potent. (Garrod et al, 1981). The 
degree of protein binding determines the amount of 'free1 
penicillin available and thus the achievable in vivo 
concentration available for antimicrobial action. The 
isoxazolyl penicillins eg. flucloxacillin are both acid 
resistant and B-lactanase resistant whereas methicillin is 
acid labile and requires intramuscular or intravenous 
administration.
Of particular relevance to this study are the 
antipseudomonal 1 broad-spectrum * penicillins carbenicillin 
and ticarcillin. They.are acid labile and £ lactamase 
sensitive, they are more susceptible to TEM type enzymes 
than some of the chromosomal enzymes; the usual route of 
administration is i.v.
Ticarcillin has a rapid distribution phase with a 
volume of distribution of around 13-15 litres (Davies 
et al, 1982; Gouyette et al, 1982) and the high concen­
trations achievable ensure the' maintenance of effective 
anti-pseQdomonal concentrations.
Active renal tubular secretion is the principal
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route of penicillin elimination. The carrier system is 
common for a variety Of organic acids and they compete 
with each other for transport, the binding affinity for 
the carrier protein determining the proportion of the 
compound excreted. Probenecid blocks penicillin excretion 
by this mechanism; it has a high affinity for the carrier 
protein and its activity is further potentiated by tubular 
reabsorption (Weiner, Washington and Mu'dge, 1960) As a 
result penicillins with short elimination half-lives 
have delayed excretion, which maintains the blood level 
and improves efficacy.
d ) Toxicity and Adverse Reactions
A great number of adverse reactions to penicillins 
have been reported, ranging from the minor to the fatal.
The most common adverse effect is hypersensitivity 
occurring at a rate between 0.7 and 10% (Idstfe et al,
1968). Antipenicillin antibodies can be detected in 
patients who have received the drug and in some individuals 
who have not been knowingly exposed (Klaus and Fellner, 
1973).
Dermatological reactions to penicillins are fairly 
common and moderate or mild reactions often spontaneously 
resolve whilst therapy continues. Penicillin rash may 
be seen during an initial course of treatment but is not 
noted on a subsequent course. However rapid, life- 
threatening anaphylactic reactions can occur on the first 
known exposure to even small doses of the drug. Between
0.015 and 0.04% of penicillin treated patients have
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anaphylactic reactions and about 0.002% of all such 
patients die (Ids^e et al, 1968). Sensitivity to one 
penicillin greatly increases the risk of a reaction to 
another as does a family history of severe reaction.
Penicillins may cause pain following i.v. injections 
and it was for this reason that procaine-penicillin 
became available. One of the major side-effects of 
penicillin therapy is electrolyte imbalance. Some 
penicillins for injection are sodium salts, to improve 
their solubility, however the large doses of penicillin 
that can be given can result in sodium overload, the _ ■; 
resultant hypervolaemia is particularly dangerous for 
patients with cardiac failure or hypertension. A further 
problem is occasional cases of hypokalaemia, the additional 
sodium load may contribute to the urinary loss of potassium 
and it has been suggested that penicillin can act as an 
anionic ion-pair for potassium in the renal tubule 
(Brunner and Frick, 1968), blockage of ticarcillin 
excretion with probenecid resulted in decreased urinary 
potassium losses but did not reverse the hypokalaemia 
(Mittal, Pierce and Priestley, 1980) . This lends support 
to the suggestion that the alkalosis induced increase in 
intracellular potassium may also be compounded by a direct, 
but undefined, effect of the penicillin on the sodium/ 
potassium pump; redistribution of potassium from the 
extracellular compartment is significant (Tattersall, 
Battersby and Spiers, 1972)
Finally there have been reports that carbenicillin
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causes defects in platelet function, related to impaired 
ADP-induced platelet aggregation (Brown et al, 1974-).
1.3.2. Clavulanic Acid
Although it is possible to obtain penicillins 
which have either a broad spectrum or are 3-lactamase 
resistant, it has not yet proved possible to produce a : 
potent 8-lactamase resistant broad spectrum penicillin.
Clavulanic acid is structurally similar to the core 
of the penicillins (Fig 1.^) although at the concentrations 
achievable in vivo using current therapy it has little if 
any direct antimicrobial action; at much higher concen­
trations it does exhibit notable antimicrobial effect.
Its major importance is as a potent inhibitor of 
most bacterial 8-lactamases (Reading and Cole, 1977); 
thus the combination of clavulanic acid with a broad- 
spectrum penicillin results in the protection of the 
penicillin from the action of 8-lactamase thereby 
potentiating its activity. This occurs both in vitro 
and in vivo.
a) Mechanism of Action and Penicillin Potentiation
Destruction of the lactam ring in a penicillin by 
8-lactamase renderssthe antibiotic ineffective. 8-lactamase 
acts by cleavage of the penam ring, a nucleophilic attack 
on the lactam ring resulting in a penicilloyl-enzyme 
complex with hydrolysis to the penicilloic acid and 
regenerated enzyme (Virden, Bristow and Pain; 1973). 
Clavulanic acid undergoes the same nucleophilic attack, 
however the resultant enzyme/substrate complex does
CH, OH
rO
O N COOH
Clavulanic acid
FIGURE 1.4. Structure of clavulanic acid .
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not readily dissociate (Cherry and Newall, 1982), initially 
the reaction is readily reversible but later it tends to 
be irreversible or slowly reversible (Rolinson, 1980) .
Clavulanic acid was first reported by Howarth,
Brown and King, (1976) and was found to have significant 
penicillinase-inhibiting properties (Reading and Cole;
1977). The similarity in structure between the penam 
and clavam ring is immediately noticeable, and it was 
already known that potentiation of8-lactamase sensitive 
antibiotic could be achieved in the presence of a 
penicillinase resistant antibiotic (Hamilton-Miller,
Smith and Knox, 1964-; Sutherland and Batchelor, 1964-)
There are a number of different types of 8 -lactamase 
and these can occur simultaneously in the same organism 
(eg. see Sykes and Matthew, 1976). As summarised by Cherry 
and Newall (1982) some enzymes are irreversibly bound by 
clavulanic acid, some may slowly recover while others are 
not inhibited at all. The ratio of inhibitor to enzyme 
can vary markedly depending on the source of the enzyme; 
one mole of clavulanic acid inhibits one mole of S .Aureus 
penicillinase, while 115 moles of clavulanic acid are 
required to inactivate one mole of E. Coli RTEM-2 enzyme 
(Sykes and Bush, 1982). Of the 3-lactamases only chrom­
osomal cephalosporinase is readily resistant to the effects 
of clavulanic acid (Slocombe, 1980).
Clavulanic acid is therapeutically relevant only 
if used in conjunction with a 8-lactamase-sensitive broad 
spectrum antibiotic. Clavulanate in combination with 
amoxycillin has been succesfully launched, and early
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reports of the combinations efficacy were published (Ninane, 
et al, 1978; Symposium , 1980).
b ) Pharmacokinetics and Toxicology
Clavulanic acid can be administered orally or 
intravenously, the choice of route depending on the acid 
stability of its co-penicillin. It is poorly protein 
bound and is rapidly excreted mainly by renal elimination 
and is found unchanged in the urine (Oackson et al 1980), 
These authors also reported no significant toxicological 
problems, although Leigh et al (1980) found 8% of their 
patients suffered diarrhoea.
1.4. FOLATE ANTAGONISTS
1.4.1. Sulphonamides
Soon after the identification of sulphanilamide 
as the active component of Prontosil, a second sulph­
onamide, sulphapyridine, was introduced into clinical 
practice. It had a broader spectrum of activity and was 
effective against Streptococcus pneumoniae.
The early sulphonamides were poorly water soluble 
and their acetylated metabolites even less so which led 
to deposition of crystals within the urinary tract 
causing renal failure; the more modern sulphonamides do 
not commonly cause significant renal damage,
a )Mechanism of Action
Sulphonamides are anti-metabolites which act by 
inhibiting bacterial folate synthesis,for unlike eukaryotic 
cells bacteria cannot utilise exogenous folate (Fig 1.5), 
the reduction in available folate causes a failure of DNA 
synthesis; (Woods, 1940; Fildes, 1940). Sulphonamides
H2I
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act by competitively inhibiting the conversion of para- 
amino-benzoic acid (PABA) to dihydrofolic acid. However 
the affinity of dihydropteroate synthetase (DHPS) for 
PABA is one thousand times that for sulphonamide and thus 
high doses of sulphonamides are required to inhibit 
enzyme activity. There is a delay between the onset of 
therapy and the appearance of evidence of inhibition 
which results from the utilisation of the intracellular 
folate pool (Struller, 1968). Only when this has been 
depleted does the antimicrobial effect of the drug become 
apparent.
More recently evidence has been accumulating that 
sulphonamides may also inhibit dihydrofolate reductase 
(Poe, 1976; Golde, Bersch and Quan, 1978; Lacey, 1979; 
Lacey, 1982), Golde et al (1978) found there was inhibition 
of haemopoiesis in humans, such a finding is only of 
clinical significance in folate deficient individuals 
since pre-existing folate stores and the low affinity of 
the human enzyme usually protect against these effects 
during sulphonamide therapy,
b ) Spectrum of Activity
Sulphonamides exhibit a broad spectrum of activity 
although the development of resistance has limited their 
application. The site of infection determines whether 
one chooses highly soluble compounds for use in acidic 
urine to avoid renal precipitation eg. sulphafurazole 
or poorly absorbed compounds for use against gut flora 
eg. succinylsulphathiazole. A wide choice of halflives
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is available eg. sulphamethoxazole with a moderately long 
half-life requires to be given twice per day, sulphadi- 
methoxime with a longer half-life requires only one dose 
per day and others with very long half lives require 
dosing only weekly eg. sulphametopyrazine.
For best compliance dosing frequency should be 
kept to a minimum, the longer half-life drug requiring 
to be taken less frequently.
The sulphonamides with the best antimicrobial 
activity are sulphadiazine, sulphafurazole and sulph­
amethoxazole (Garrod et al, 1973) the last is of particular 
note as it is available in combination with trimethoprim 
as is sulphadiazine; other sulphonamides have been considered 
on the basis of their activity and pharmacokinetics for 
combination with trimethoprim (Ortengren, Fellner and Bergan, 1979a).
c) Microbial Resistance
Although there are a great variety of sulphonamides, 
organisms resistant to one are resistant in some degree 
to all others i.e. cross-resistance. As the sulphonamides 
have been in continual clinical use for nearly fifty years 
it is perhaps not surprising that resistance, although 
usually slow in developing, is widespread. The intro­
duction of the antibiotics superceded the use of sulph­
onamides in some instances and some previously resistant 
microbes, eg. gonococci, are sensitive once again.
Resistance may arise from modification of the 
active site of the enzyme with consequent reduced affinity 
for the sulphonamide, or by increased uptake of endogenous 
PABA, thereby diminishing the competitive effect. These
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result from chromosomal mutation whereas much of this 
resistance is specified by plasmids which encode an 
enzyme (DHPS) which has virtually zero affinity for the 
sulphonamides.
d ) Pharmacokinetics
Most sulphonamides. are well absorbed following 
an oral dose. Protein binding is variable within the 
class and there are a range of pKa's (Struller, 1968), the 
distribution within the body is variable. The routes of 
metabolism of all sulphonamides include acetylation and 
oxidation; the metabolites are inactive and in the case of 
the acetylsulphonamides, are less soluble in urine than the 
parent drug. The acetylator phenotype for some sulphonamides 
eg. sulphadimidine is bimodal (Van Outdshoorn and Pbtgieter, 
1971) and the percentage of fast to slow acetylators has 
been shown to vary between races (Curry 1980a: Utrecht and
Woosley, 1981). Renal clearance of sulphonamides is 
significant; filtration plays a major part with varying 
influences of secretion and reabsorption: it is possible 
to model these changes (Hori, Sunayashiki and Kamiya, 1976).
As the different sulphonamides undergo different 
rates of metabolism, renal secretion and reabsorption the 
excretion of the unchanged, active sulphonamides also 
varies. The effectiveness of the drug is related to the 
concentrations achieved at the site of action, the 
intrinsic potency of the sulphonamide and the susceptibility 
of the organism.
e ) Toxicity and Adverse Reactions
There are many side effects of sulphonamides, the
most serious of which may be fatal.
Of the haematological reactions, the most common 
is an acute haemolytic anaemia in subjects with glucose- 
6- phosphate dehydrogenase deficiency i.e.favism. The 
most severe haemolytic episodes are rare but may have a 
fatal outcome.
Although the modern sulphonamides are more water 
soluble than those used originally, there is still some 
risk from crystallisation.in the renal tubules; Buchanan 
(1978) reported several patients with renal failure 
following treatment with co-trimoxazole (sulphamethoxazole 
and trimethoprim) although such reactions may arise due 
to hypersensitivity.
Anorexia, nausea and vomiting are most common and 
occur in 1-2% of subjects, (Weistein, 1975b), these 
effects are reversed on withdrawal.
Stevens - Tohnson syndrome may be a rare and 
occasionally fatal complication.
1.4.2. Trimethoprim
The antimetabolite action of the sulphonamides 
may be improved by combined blockade of the bacterial 
folate pathway with the agent trimethoprim. It was the 
dramatic in vitro synergy claimed by Bushby and Hitchings 
(1968) that led to the great interest in this combination 
of drugs.
a) Mechanism of Action and Potentiation
Trimethoprim (TMP) was first synthesised in 1961 
by Hitchings and Bushby; TMP was found to inhibit the
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enzyme dihydrofolate reductase (DHFR) which is responsible 
for the production of tetrahydrofolate from dihydrofolate, 
whereas the sulphonamides inhibit the formation of dihydro 
folate (Fig 1.6 )aIthough i t h a s  been suggested that 
sulphonamides may inhibit both sites (Poe, 1976). The 
concept of combining TMP with a sulphonamide was clearly 
attractive and TMP was found to be a potent potentiator 
of sulphonamide action (Bushby and Hitchings, 1968). From 
pharmacokinetic considerations it was evident that the 
particular sulphonamide chosen should have a similar rate 
of elimination to TMP. Sulphamethoxazole (5MZ) w a s  chosen 
and the combination of TMP/SMZ, known as co-trimoxazole, 
was marketed as Septrin by Burroughs Wellcome, the 
manufacturers of trimethoprim and, Bactrim by Roche, the 
manufacturers of sulphamethoxazole.
The opportunity to market TMP alone was not taken 
despite the evidence in Bushby and Hitchings work (1968) 
of the much greater potency of TMP. This approach 
was not changed until 1979, although experience in Finland, 
where TMP alone was available from 1973 for the treatment 
of urinary tract infection,indicated that TMP alone was 
at least as effective, as well as being less expensive 
and less toxic than the combination (Kasanen et al 1978).
b) Pharmacokinetics
Trimethoprim is well absorbed after oral adminis­
tration. It has a volume of distribution (Vd) of the order of 
11/kg which is about six times the Vd of SMZ, and taking 
into account the relative potency and ideal ratios for
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FIGURE 1.6. Structure and mode of action of 
trimethoprim by inhibition of 
bacterial folate synthesis.
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synergy, a dosing ratio of 5:1, SMZ/TMP, is used. 
Elimination of TMP is partly through metabolism to 
hydroxylated/conjugated inactive metabolites and partly 
by renal excretion of unchanged drug; the latter accounts 
for approximately half of the drug eliminated (Kasanen 
et al 1978) although the rate of renal elimination of TMP 
is very sensitive to changes in urinary pH (Sharpstone,
1969).
c)Toxicity and Adverse Reactions
As TMP is a folate antagonist it is reasonable 
to expect that in depleted individuals there will be 
cases of acute folate deficiency. However TMP has an 
affinity 50,000 times less for mammalian DHFR than the 
bacterial enzyme (Burchall and Hitchings, 1965) and 
severe toxicity is rare. Surveys of co-trimoxazole 
therapy have shown that the commonest adverse reactions 
are skin rashes and nausea with an incidence rate of 
about 3.5% (Lawson and 3ick, 1978), the majority of side 
effects noted in a double-blind trial of TMP and co- 
trimoxazole could be attributed to the sulphonamide 
component (Lacey et al 1980).
1.5. FIXED DOSE COMBINATION OF ANTIMICROBIAL AGENTS
The activity of antimicrobial agents in combination 
may be: a) antagonistic, for example when a bacterio­
static and bacteriocidal drug are used together.
b)additive, as in the combination of two bacteriostatic 
agents or c) synergistic when two bacteriocidal agents, 
usually with different modes of action are.combined
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(Oawetz et al, 1931; Dawetz and Gunnison, 1952).
The simultaneous administration of two or more 
antimicrobial agents was suggested by Weinstein (1958) 
as being useful on four circumstances: 1) In the treatment 
of mixed bacterial infections, 2) to delay the emergence 
of bacterial resistance, 3) to enhance therapeutic 
activity and 4) In treatment of severe infections where 
the cause is not yet established.
In mixed infection it is uncommon that one drug 
has optimal therapy against two (or more) organisms, and 
therefore two (or more) antibiotics with high specific 
activity against one of the organisms is used; a similar 
argument holds for k above where a combination of drugs 
covers the wide spectrum required most appropriately.
Delay in emergence of resistance and enhanced activity are 
essentially different facets of synergy. Comprehensive 
coverage such as is required in the treatment of bacterial 
endocarditis where it is essential to kill all infecting 
organisms in a poorly vascularised site is a further facet. 
Triple therapy in the treatment of tuberculosis is an; 
example of the efficacy of combined therapy.
There are a number of disadvantages to combination 
therapy (Cohen, 1975), the most significant of which are: 
adverse drug reactions, superinfection and cost.
1.6. TECHNIQUES
1.6.1. Methods of Assay
Traditionally assay of antimicrobial agents has 
been performed microbiologically using an indicator 
organism. With care the precision and accuracy of these
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assays can be good and they are useful for the processing 
of large numbers of samples.
The confirmation of achievement of inhibitory or 
bacteriocidal concentration in vivo during therapy or 
monitoring of compliance should prove more rapid using 
chemical assay.
Chemical assays, including chromatography can also 
be accurate and precise; in the work described herein 
only chemical assays have been used and this allows a 
comparison to be made with the pharmacokinetics obtained 
by other workers using microbiological assay.
L 1.6.2. Pharmacokinetics
From knowledge of the disposition of antimicrobial 
agents it is possible to assess their therapeutic effect 
and determine appropriate dosages. In fixed dose combin­
ations the assumption is inherent that an individual will 
handle the drugs in combination in a predictable fashion 
allowing the benefits of the combined product to be 
effected. Examination of the pharmacokinetics of ’fixed- 
dose’ combinations is necessary to ascertain how 
efficiently the rationale applies in practice and this 
will be considered in this thesis.
In addition the methods and effectiveness of 
pharmacokinetic prediction techniques will be considered.
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1.7. AIMS and 0B3ECTIVES
The intention of this thesis is to describe:
1. The development and validation of chemical methods 
of assay for the antimicrobial agents under study in 
serum, urine and other biological fluids. The drugs 
are: trimethoprim, the sulphonamides sulphamethoxazole
and sulphamoxole, ticarcillin and clavulanic acid.
2. To examine the kinetics of the following:
a) the fixed dose combinations co-trimoxazole 
(trimethoprim and sulphamethoxazole) and co-trifamole 
(trimethoprim and sulphamoxole) in normal volunteers.
b) two preparations of trimethoprim alone in normal 
volunteers.
c) the fixed dose combination of ticarcillin and 
clavulanic acid in individuals with varying degrees 
of renal failure, during haemodialysis and during 
continuous ambulatory peritoneal dialysis.
The implications for therapy from the results of'these 
disposition studies for the above antimicrobial agents 
will be considered.
3. To examine the penetration of trimethoprim in chronic 
obstructive airways disease.
4. To consider the validity of pharmacokinetic predictions 
for trimethoprim using:
a ) Salivary data
b) Minimal individual data and population kinetics 
with Bayesian estimates.
I pass with relief from the tossing sea of Cause 
and Theory to the firm ground of Result and Fact.
Winston S. Churchill 1874-1964
The Story of the Malakand Field Force 1898
CH A PTER 2
ASSAY OF SULPHONAMIDES AND 
TRIMETHOPRIM IN BIOLOGICAL FLUIDS
I N T R O D U C T I O N  ^
2.1. SULPHONAMIDES
Sulphanilamide was the first effective sulphonamide
(Fuller, 1937) however the early sulphonamides were poorly 
soluble in water and metabolism by acetylation rendered 
them both bacteriologically inert and even less soluble; 
high rates of urine flow were necessary to avoid precip­
itation of both drug and metabolite in the renal tubules 
(Struller, 1968 ) .
2 .1.1 .Spectrophotometric Assays
Investigation and control of these phenomena was 
facilitated by the development of a simple colorimetric 
procedure for sulphonamides by Bratton and Marshall (1939).
All sulphonamide drugs are derivatives of sulph­
anilamide (p-aminosulphonamide); the p-amino group is
essential for antibacterial action. Acetylation occurs 
Zj.
at the N -amino group; this group is also diazotised in 
the assay of Bratton and Marshall (1939) with subsequent 
coupling with N (1-napthyl)ethylenediamine dihydrochloride ; 
the reaction is outlined in Fig 2.1.
It was originally believed that the acetyl derivative 
was the only metabolite, thus assay of an acid-hydrolysed 
sample gave ’total' sulphonamide whereas assay of an 
untreated sample provided an estimate of 'active' sulph­
onamide; the amount of acetyl metabolite was then obtained 
by difference.
There have been a great number of modifications to
NaN02 + HCI — ► HN02 + NaCI
h 2n -<( j V s o 2n h - r + h n o 2
N=N+- ^ ^ S 0 2NH-R+2H20
diazosulphonamide
N E N +
h n o 2+ h 2n s o 3h ► H2S04+H 20 + N 2
NH2-(CH2)2-NH2
s o 2n h - r + [OTO
coupling reagent
NH2(CH2)2NH2
r o T o :
N= N^ g ^ S Q 2NH-R 
azo products
FIGURE 2.1. The Bratton-Marshall reaction:
diazotisation of sulphonamide and 
coupling to naphthyletheylenediamine .
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the original assay,most of which relate to the reagent
composition. The assay quoted by Varley, Gowenlock and
Bell (1976) is fairly typical.
It is now known that sulphonamides undergo
N*acetylation,.N*glucuronidation, ring-N-glucuronidation
4
and to a lesser extent N-N -diacetyl formation and
3-hydroxylation.
4
The N glucuronide is unstable under the acid
conditions required for diazotisation, thus all of the
4.
above metabolites with a free N primary amine react in 
the Bratton-Marshall reaction.
The non-specificity of the Bratton-Marshall reaction 
is particularly important because it results in an 
overestimate of the apparent 'active' sulphonamide. 
Apparently effective concentrations could in reality be 
sub-therapeutic with respect to the active drug and thus 
select for resistance. The probability of misinter­
pretation is greater in the urine than serum as inactive 
metabolites predominate.
It was originally shown by Koechlin , Kern and 
Engelberg (1959) that solvent extraction could improve 
the assay specificity as the metabolites are not extracted. 
Subsequently Rieder (1972) described an assay with an 
ethyl acetate extraction following which a Bratton- 
Marshall reaction was performed in the organic solvent.
Thus the polar, conjugated, acetylated metabolites were 
excluded.
The assay is much more specific than the procedures
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previously in use and is claimed to give a good estimate 
of the bacteriologically active fraction in urine. With 
the addition of an acid hydrolysis step, the 'total* 
sulphonamide can also be measured.
Although this procedure is much more complex and 
time consuming than the simpler aqueous assays it has 
been claimed to have a precision of better than 5% and 
to be suitable for routine analysis.
Other reagents that react with the primary amine 
group can be used e.g. o-phthalaldehyde with fluorimetry 
of the final product (Amano and Mizukami 1965) .
The pairing of SMZ with TMP post-dated most of this 
work; subsequently a spectrophotometric assay for the 
simultaneous measurement of both TMP and SMZ in 
pharmaceutical preparation has been described (Ghanem, 
Meshali and Foda, 1979). A spectrophotofluorimetric 
procedure for serum TMP and SMZ levels (Lichtenwalner, 
et al, 1979) employs differential extraction of TMP 
and SMZ at alkaline and acid pH's into chloroform and 
n-butyl chloride respectively followed by separate 
measurements of each fraction.
The assay has limited accuracy and there was 
significant, although predictable, interference from 
salicylate. Despite this a precision of better than 
5% was claimed for the assay of both components, however 
the complexity and lack of adequate characterisation of 
the method make it unsuitable for routine use.
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? . l Microbiological Assays
Although the usual method for the routine deter-.: 
mination of sulphonamides in biological fluids is by the 
diazo-coupling reaction discussed above, quantitative 
determination can be performed microbiologically.
There are a number of options including agar 
diffusion, dilution and turbidimetric assays; of these 
only the first is sufficiently flexible to be routinely 
used in the determination of antimicrobial agents in 
serum and plasma.
In agar diffusion analyses an indicator organism 
is incorporated into the agar, wells are cut into the 
agar and calibrators, controls and test samples are placed 
in the wells.
The degree of inhibition of growth following inc-
the
ubation is proportional to concentration of antibiotic in 
the well. To perform these determinations succesfully 
a trained, experienced analyst is required. The indicator 
organism should ideally be sensitive only to the antibiotic 
of interest, although this specificity may be achieved, 
it is usually dependent on the concentration of the 
potentially interfering antibiotic.
Manoeuvres to destroy or inactivate interfering 
substances, including antagonism ■ enzymic removal or 
chromatographic purification may be used (Holt and Reeves,
1978), electrophoretic separation followed by microbio­
logical determination has been claimed to improve 
specificity ( Dornbusch, 1974).
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In view of the potential difficulties inherent in 
the technique it is not surprising that national quality 
control surveys, for gentamicin, have indicated significant 
error rates (Reeves and Bywater, 1975)
As sulphonamides, particularly SMZ, are used in 
combination with TMP the indicator strain must be 
susceptible only to the component of interest (Dornbusch, 
1974-). The available microbiological plate assay may 
prove to have problems of interference that may be 
insoluble. (Reeves, Bywater and Holt, 1978).
2 .1.3.Chromatographic Assays
Thin layer chromatography has been used to separate 
sulphonamides and their metabolites (Sigel et al, 1974-); 
following separation the absorbance of the SMZ zone was 
determined by reflectance densitometry.
Gas-liquid chromatography with electron capture 
detection has been used (Gyllenhaal and Ehrsson, 1975) 
but was not applied to biological samples. However HPLC 
separation of a mixture of sulphonamides was reported as 
early as 1972 by Kram.
Cobb and Hill (1976) using normal phase chromatography 
reported on the chromatographic behaviour of a number of 
sulphonamides and a more sophisticated study involving 
the use of normal phase ion-pairing and counter-ions was 
reported by Su, Hartkopf and Karger (1976). The deter­
mination of sulfamethazine in' bovine tissue was reported 
in 197 5 (Dohnson, Deter and Claiborne,'197 51 and SMZ and
4
its N acetyl metabolite were measured in blood by Harzer, 
(1978).
39
Most investigations of SMZ and other sulphonamides 
used in combination with IMP have reported the simultaneous 
analysis of both drugs. Helboe and Thomson (1977) reported 
an assay for pharmaceutical preparations but did not obtain 
the sensitivity necessary for biological fluids. A reverse- 
phase procedure allowing simultaneous determination of SMZ,
i\.
N acetyl SMZ and TMP in serum and urine with a simple 
dilution and protein precipitation procedure was described 
(Vree et al, 1978) and a similar type of method was reported 
by Bury and Mashford (1979).
Gochin, Kanfer and Haigh (1981) reported a: 
technique which gave excellent resolution, however a small 
peak attributed to caffeine co~eluted-with SMZ. As caffeine 
is widely available in drinks and proprietary medicines 
the method is not suitable for routine use. In addition 
the extraction procedure, although simple was lengthy.
The above procedures used reverse phase chromatography, 
Ascalone (1981) used normal phase chromatography for the
Ll
separation of TMP and sulfadiazine and its N acetyl 
metabolite and the procedure may be used for the assay of 
TMP and SMZ and its N acetyl metabolite. The analysis is 
simple, precise and sensitive, however no information is given 
on accuracy. The eluant used is a mixture of a halo- 
hydrocarbon, alcohol and base and is very similar to that 
used for the determination of tricyclic structured drugs 
by normal phase chromatography (Watson and Stewart, 1977a, 
1977b). Drugs of this type, particularly the phenothiazines
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have numerous metabolites and since such solvents have been 
noted as being suitable for the retention of basic compounds 
(Watson, 1979; Watson et al 1983), it is unlikely that the 
procedure would be interference-free when used for 
specimens from hospital patients, particularly as only 
a single stage extraction is used.
Due to the simplicity of the Bratton-Marshall assay 
either in its aqueous form or as modified by Rieder (1972) 
there has been no great incentive for the introduction of 
chromatographic procedures for sulphonamides.
2.2. TRIMETHOPRIM
2.2.1. Photometric Assays
TMP has been measured by UV spectrophotometry (Bushby 
and Hitchings, 1968) but this technique lacks the 
sensitivity needed for the determination of plasma concen­
trations although it is suitable for pharmaceutical
preparations (Ghanem et al 1979). Sensitive measurement
14of TMP in plasma can be attained using C TMP (Schwartz 
and Zeigler, 1969) with detection by scintillation 
spectrophotometry but this technique is of limited 
application.
The first succesful reported ’routine1 assay for 
TMP was the spectrofluorimetric method of Schwartz,
Koechlin and Weinfeld, (1969), the principle of which was 
the extraction of TMP at a basic pH into chloroform, 
back extraction into acid, oxidation to trimethoxy-benzoic 
acid by potassium permanganate, removal of excess perman­
ganate, extraction of trimethoxy-benzoic acid into 
chloroform and measurement of the fluorescence.
*fl
The wavelengths for excitation and emission were 275nm and 
350nm respectively. It is a fairly demanding technique 
although a precision of 6.2% was claimed, the throughput 
was low and a skilled analyst was necessary ; TMP-N-oxide 
can interfere (Rieder, 1973) but the other known metab­
olites do not. An alternative procedure was reported 
which used a single stage extraction for TMP and a second 
for SMZ (Lichtenwalner, et al 1979), although good 
comparability was claimed with the technique of Schwartz 
et al, (1969) on the basis of a regression line, the 
accuracy of the assay was not fully investigated and 
lacked sensitivity, allowing the detection only of 
concentrations greater than 0.5 mg/1.
2.2.2. Microbiological Assays 
The principle outlined earlier for sulphonamides 
may be applied to the determination of TMP. The first 
microbiological assay was described by Bushby and Hitchings 
(1968), other authors have modified the procedure 
(Dornbusch ,'197*0 . . Separation from SMZ followed by diffusion 
testing can be used (Dornbusch ,197*0 • A microbiological 
assay was compared to the spectrofluorimetric method of 
Schwartz et al (1969) and found to compare well (Kasanen 
et al, 1978); however after showing this the authors 
then chose to use the fluorimetric procedure in their 
kinetic studies. The microbiological method for TMP
is prone to interference problems (Allan and Nimmo-Smith, 
1978).
2.2.3. Chromatographic Assays.
In an attempt to improve the specificity of the
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TMP assay and also quantitate the metabolites, a fluor- 
imetric thin layer chromatographic procedure was developed 
(Sigel and Grace, 1973 ) , however the unidentified fluor­
escent product was produced only after exposure to light 
for 24 hours or more which is a limitation ; absorbance 
appeared to be as sensitive and immediately measurable 
(Sigel, et al, 1974). More recently a procedure that 
requires a single stage extraction followed by detection 
of a fluorescent derivative produced by heating the plate 
has been described (Schlobe and Thijssen, 1982 ). This 
method appears to be rapid, sensitive and precise.
Gas chromatography with a nitrogen-phosphorus . 
detector has been used for TMP analysis (Land, Dean and 
Bye, 1978); although very sensitive, the use of a 
brominated analogue which is not readily available as an 
internal standard, must be considered an important 
limitation. The authors found the use of an internal 
standard necessary to compensate for analytical losses.
There are a number of liquid chromatographic assays 
for TMP, either alone or in combination with a sulphonamide, 
usually SMZ. The analysis of Helboe and Thomsen (1977) 
for sulphonamides and TMP in pharmaceutical preparations 
lacked the required sensitivity and did not yield 
chromatographically efficient peaks for TMP (Watson et al,
1980). Vree et al (1978) claimed to have an assay with 
sufficient sensitivity for the determination of plasma 
TMP levels. Unfortunately two levels of sensitivity were 
quoted, 0.1 mg/1, and 0.73 mg/1 (equivalent to on column
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weights of 1.8 ng and 13.6 ng respectively) the former 
figure is unlikely with the UV detectors then available, 
the latter limit is probably correct, however such a 
concentration is too high for satisfactory pharmacokinetic 
profiles to be obtained. Bury and Mashford (1979) 
described an LC procedure for TMP but the peak was poorly 
resolved from early eluting material. The reverse phase 
method of Gochin et al, (1981) had satisfactory performance 
characteristics for TMP, but suffered from a lengthy 
extraction procedure. Reverse-phase ion-pair chromat ography 
has been used succesfully (Watson et al, 1980).
All of the above authors employed reverse:phase 
chromatography. Two assays for TMP using normal phase 
chromatography have also been described. The procedure 
of Weinfeld and Macasieb (1979) required a large serum 
sample (2 ml) but used a relatively straightforward 
extraction procedure. The performance of the method was 
not reported. The eluant consisted of a mixture of 
chloroform, methanol, water and ammonium hydroxide. Another 
technique had a similar solvent composition (Ascalone,
1981) using dichloromethane in place of chloroform; 
a different extraction procedure was used and again there 
was no check on accuracy. As noted earlier these eluants 
are similar to those used for tricyclic structured drugs 
(Watson, 1979) although at the wavelength used (280 nm)
their response would be attenuated.
Although TMP has been determined by differential
pulse polarography (Brooks, de Silva and D'Arconte, 1973)
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and lacked effective sensitivity, there is potential for 
the use of this technique as an HPLC detector; recently 
an electrochemical procedure for TMP has been described 
(Nordholm and Dalgaard, 1984), however the reported 
sensitivity of the electrochemical detector, was no better 
than a UV detector under the conditions used.
2.2.4.Assays for TMP in Other Biological Fluids 
TMP has been analysed in cerebrospinal fluid 
(Lichtenwalner et al, 1979), saliva (Eatman et al,1979; 
Sardi et al 1981) and in sputum ( Hansen et al, 1973a,b; McIntosh 
et al 1983). Assay of the first two named fluids is 
simple as neither has any significant protein content and 
is not viscous, however sputum is viscous and is difficult 
to manipulate if too thick and liquefaction is necessary 
in order to improve its handling (Li, Lee and Baker, 
1980; McIntosh et al -1983).
2.3. SIMULTANEOUS ASSAY OF SULPHONAMIDES AND TMP
Simultaneous determination of SMZ and TMP in 
biological fluids can only be succesfully achieved using 
chromatography, the spectrophotofluorimetric technique 
of Lichtenwalner et al (1979) is a two stage extraction 
of a single sample but requires further validation. The 
liquid chromatographic procedures for sulphonamides and 
TMP are all suitable for SMZ and TMP (Ascalone, 1981;
Gochin et al , 1981; Weber et al>1983) to date there has 
been no report of a liquid chromatographic assay for SDMO 
with or without TMP.
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MATERIALS AND METHODS
2.4. SULPHONAMIDE
'"2 • 4 • 1 • Bratton-Marshall Assay.
i ) Materials
The procedure used was based on that given by Varley 
et al (1976) .
The following reagents were prepared in deionised 
water from Analar grade reagents. (British Drug Houses, 
Poole, Dorset, U.K.).
(a) Trichloroacetic acid (200 g/1)
(b) Sodium nitrite (1 g/1)
(c) Ammonium sulphamate (5 g/I)
(d) N (1-naphthy1)ethylenediamine dihydrochloride 
(0.5 g/1)
The sodium nitrite and ammonium sulphamate W e r e  
prepared weekly and t'he N (1-naphthyl )ethylenediamine 
dihydrochloride was freshly prepared prior to each assay.
ii) Equipment
A Pye Unicam 1800 spectrophotometer (Pye Unicam, 
Cambridge, England) w i t h  1 cm glass cuvettes was used.
2.4-.2. Rieder (1972) Assay.
i ) Materials
The following reagents were prepared as described 
below:
(a) Mcllvain buffer (pH 5.5)
0.2 M citric acid and 0.4 M disodium hydrogen 
phosphate were prepared in deionised water from Analar 
grade reagents (BDH). One litre of buffer was prepared 
by mixing 430 ml of 0.2 M citric acid with 570 ml of
46
0.4 M disodium hydrogen phosphate and adjusted to pH 5.5 
if necessary.
(b) 8 M hydrochloric acid
The following reagents were prepared prior to each 
assay as described below
(c) 2 M acetonic hydrochloric acid: 1 volume of
aqueous 8 M hydrochloric acid was mixed with 3 volumes 
of acetone.
(d) Sodium nitrite (1 g/1) in acetone:water (3:1)
(e) Sulphamic acid (50 g/1) in acetone:water (3:1)
(f) N (1-naphthyl)ethvlenediamine hydrochloride (1 g/1) 
in acetone:water (3:1)
Calibrators for both procedures were prepared from
a stock solution of 2 g/1 SMZ or SDMO in 0.5 M hydrochloric
acid. SMZ was supplied by Wellcome Medical Division,
Crewe Hall, Crewe, Cheshire) and SDMO W a s  supplied by Berk 
Pharmaceuticals Limited, (St. Leonards Road, Eastbourne, 
Sussex). Calibrators covering the range 0-100 mg/1 were 
prepared in Horse Serum No. 5 (Wellcome, Northwich,
England) and urine calibrators over the range 0-750 mg/1 
were prepared in pooled drug-free human urine.
Quality control materials were independently prepared
in the same matrix at concentrations of 50 mg/1 and
150 mg/1 SMZ for serum and urine respectively. All calib­
rators and quality control material were stored at -20°C 
and thawed immediately prior to analysis.
ii)Sample handling
Serum was separated by centrifugation, and stored
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at -20°C prior to analysis. Urine volumes were noted and 
10ml aliquots were stored at -20°C prior to analysis 
2 .4.3. Procedures
i ) Bratton-Marshall assay.
To 3 ml of deionised water in a Z10 glass tube 
(Brunswick, Ballymoney, Northern Ireland) was added
0.1 ml of sample. Proteins were precipitated by addition 
of 0.9 ml of 200 g/1 trichloroacetic acid, the tubes were 
mixed and centrifuged at 2000'rpm for 5 minutes. Two 
ml of the supernatant solution were transferred to a 
fresh tube and the sulphonamide diazotised with Q.2 ml of 
1 g/1 sodium nitrite, the tubes were mixed and allowed 
to stand for 3 minutes. Excess acid was eliminated by 
the addition of 0.2 ml of 5 g/1 ammonium sulphamate, 
the tubes were mixed and allowed to stand for a further 
3 mins. Then 0.2 ml of 0.5 g/1 N(1-naphthyl)ethylene- 
diamine dihydrochloride was added, the tubes were mixed 
and allowed to stand for 10 minutes.
The optical densities were read on an SP 1800 
spectrophotometer (Pye Unicam) at 540 nm.
For urine,0.1 ml of sample was added to 1.5ml of 
water and 0.5 ml trichloroacetic acid to which was then 
added sodium nitrite, ammonium sulphamate and N(l-napthyl) 
ethylenediamine dihydrochloride as described for serum; 
on completion of the reaction 5 ml of water was added 
and the optical density read at 540 nm.
ii) Rieder assay
To 0.2 ml sample diluted in 1 ml of Mcllvain buffer 
in an MF 24/1/5 Q arid Q tube (Corning Ltd., Staffs.)
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was added 5 ml ethyl acetate. The tubes were stoppered 
and shaken for 10 minutes on a lateral shaker.and then 
centrifuged for 5 minutes at 2000 rpm. 3 ml of the 
organic extract was transferred to a second tube and 
0.5 ml of acetonic 2 M hydrochloric acid added; the tubes 
were mixed and 0.5 ml of 0.1% acetonic sodium nitrite 
added and the contents again mixed and left for 6 minutes
0.5 ml of 5% acetonic sulphamic acid was added and after 
mixing and the release of the gas bubbles produced, the 
tubes were left for 3 minutes and 0.5 ml of 0.1% acetonic 
N(l-napthyl)ethylenediamine dihydrochloride added; due 
to phase separation, 0.5 ml of methanol was added as 
co-solvent and the tubes mixed until the contents were 
homogeneous. The tubes were stoppered and incubated at 
room temperature for 30 minutes.
The absorbances were read on a Pye Unicam 1800 
instrument against distilled water at 545 nm and corrected 
for serum blank.
Urine was diluted 0.1 ml to 1 ml in Mcllvain buffer 
and extracted with 5 ml ethyl acetate and then the 
prodedure for serum was followed.
2.4.4. Experimental Design
i ) Accuracy
The assay of Rieder (1972) is claimed to have 
higher specificity than procedures based on the method of 
Bratton and Marshall (1939). All urine and serum samples 
for SMZ and SDMO were therefore analysed by both assays 
and the results compared.
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ii) Linearity
The linearity of the method was established using 
standards prepared as described earlier over the range 
0-250 mg/1 for serum and 0-1000 mg/1 for urine. Serum 
and aqueous calibrators were prepared of both SMZ and 
SDMO and the results compared to establish if there were 
any differences in the intensity of the absorbance at 
540 nm.
iii) Precision
The Rieder assay is an established assay and precision 
was confirmed using 12 serum samples with an added concen­
tration of 50 mg/1 and 30 urines randomly selected and 
re-assayed. The precision of the modified Bratton- 
Marshall assay was checked by re-assaying a randomly 
selected 30% of serum and urine samples.
iv) Sensitivity
Sensitivity was taken as twice the absorbance for 
the serum blank when read against a reagent blank.
2.5. ACETYLATOR PHENOTYPING
Subjects participating in the co-trifamole/co- 
trimoxazole study had their acetylator phenotype determined 
by a modification of the procedure of Schroder (1972)
2.5.1. Procedure
Subjects were given 10 mg/kg sulphadimidine by 
mouth and urine passed between the 5th and 6th hours 
post-dose was collected.
2.5.2. Assay
To 10 ul of urine was added 1 ml of 6 M hydrochloric 
acid and this was heated for 5 minutes at 90°C (Test A).
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To 50 ul of urine was added 1 ml of 6 M hydrochloric 
acid (Test B).
Test A is for total sulphadimidine and test B for 
non-N acetylsulphadimidine.
To both tests 1 ml of 0.1% sodium nitrite was added 
and after 2 minutes, this was followed by 1 ml of 0.5% 
ammonium sulphamate, left for 1 minute and then 1 ml of 
freshly prepared 0.05% N (1-naphthyl)ethylenediamine 
dihydrochloride was added. After 5 minutes at room 
temperature the tests were read at 5^0 nm versus a water 
blank.
The percent sulphadimidine was calculated as:
(1-B/A.5)100 = % acetylated Equation 2.1.
Fast acetylators are defined as those with >80% 
acetylation and slow acetylators those with <70% acetylation. 
Those falling between 70-80% were equivocal.
In view of the suspect accuracy of non-extracted 
Bratton-Marshall procedures a study of ten individuals 
was performed using the procedure above and a procedure 
based on the Rieder technique as detailed below.
2.5.3. Extracted Procedure
10 ul urine was heated with 1 ml of 6 M hydrochloric 
acid for 5 minutes at 90°C then cooled (Test A).
50 ul urine had 1 ml of 6 M hydrochloric acid added 
(Test B).
Sufficient -.5 M sodium hydroxide (approximately 1.2 ml) 
was added to obtain a pH of 5.5. To both tests was added
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1 ml of pH 5.5 Mcllvain buffer and 5 ml ethyl acetate. 
These were shaken for 10 minutes and centrifuged at 1500 
rpm for 5 minutes. 3 ml of supernatant were transferred 
and 0.5 ml of 'acetone;8M hydrochloric acid (3:1) added, 
mixed and 0.5 ml 0.1% sodium nitrite in acetone:water 
(3:1)was added, mixed, the tubes were left for 6 minutes 
and then 0.5 ml 5% sulphamic acid in acetone:water (3:1) 
was added, mixed and following the release of all the gas 
bubbles, left for 3 minutes; 0.5 ml 0.05% N (1-naphthyl) 
ethylenediamine dihydrochloride in acetone:water (3:1) 
was added and 0.5 ml of methanol mixed in until the ; 
solution was homogeneous the tubes were stoppered and : 
incubated for 45 minutes at room temperature and read 
at 545 nm versus a water blank.
The percentage acetylated was calculated using 
equation 2.1.
2.6. TRIMETHOPRIM
This was an LC assay.
2.6.1. Materials
The eluant initially used was methanol:sodium lauryl 
sulphate 6 g/1 in 0.05M phosphoric acid (70:30) this was 
subsequently modified by the substitution of hexane 
sulphonic acid (Fison.'s Loughborough, England) for 
the sodium lauryl sulphate. When TMP was assayed 
using an autosampler and a Varian 8500 pump it was 
necessary to decrease retention by the addition of sodium 
nitrate; in these circumstances the eluant was methanol: 
hexane sulphonic acid 1 g/1 in 0.05M phosphoric acid 
and 2 g/1 sodium nitrate (30:70). 2M sodium hydroxide
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was prepared in deionised water. Diazepam 250 ug/1, (Roche 
Products Ltd., Welwyn Garden City, Herts, U.K.) or m-amino 
acetaphenone 300 ug/1 (Aldrich Chemical Co. Ltd. Gillingham, 
Dorset U.K.) were prepared in dichloromethane and used as 
an internal standard for the serum assays only. All 
reagents were Analar grade from British Drug Houses, Poole, 
Dorset, England) unless otherwise stated.
Serum calibrators were prepared by weighing TMP 
(Berk Pharmaceuticals, Eastbourne, England) into horse 
serum No. 5 (Wellcome Reagents L t d ., Beckenham, England) 
over the concentration range 0-6 mg/1; urine calibrators 
were aqueous based and were prepared over the range 0-600 
mg/1. Quality control materials were produced independently 
of the calibrators in horse serum No. 5 (Wellcome) and 
urine from a drug-free subject at levels of 1.5 mg/1 for 
serum and 100 mg/1 for urine.
Calibrators and QC material were stored at -20°C 
until required and proved stable for at least one year.
2.6.2. Equipment
Assays for TMP were performed over an extended 
period of time and a number of items of equipment were 
used for liquid chromatography. In chronological order : 
the following HPLC systems were used:
1. A Varian 8500 pump (Varian Associates Ltd.,
Walton on Thames, England) with a Varian stop-flow slide 
injector or latterly a Rheodyne 7120 loop injector 
(Rheodyne, Berkeley, California, U.S.A.) with a Varichrom 
(Varian) variable wavelength UV detector latterly
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temperature controlled with a circulating water bath at 
25°C to improve stability and a Chessel (Worthing, Sussex, 
England) single pen flat-bed recorder.
The stop flow injector originally used allowed 
purging of the pump, this is not possible with a Rheodyne 
injection valve and a 13 way-2 to pressure’ valve was fitted 
for this purpose. One of the ports is a high pressure 
inlet, there is a high pressure outlet to the column and 
a low pressure outlet to waste. Pump flow had to be 
stopped prior to purging to avoid ’spurting' of eluant 
from the drain port.
Initially a 25 cm x 4.6 mm internal diameter Partisil 
10/0DS-2 column (Whatman Ltd ., Maidstone, England), a lOu 
column was used, but this was soon replaced with a 5u 
column of the same dimensions,an S50DS column (Hi-Chrom 
Woodley, Berks, England).
2. The second configuration consisted of the above 
equipment with the addition of a Varian 8050 liquid 
autosampler and an Infotronies 304-40 integrator (LDC,
Co. Clare, Eire) and the replacement of the above columns 
with 10 cm x 5 mmid columns packed in the laboratory with 
Hypersil 5u 0DS (Shandon Southern Ltd., Runcorn, Cheshire 
England) using a balanced density slurry technique in an 
upward packing mode.
Initially a line from a Varian 8500 pump was fitted 
with a Whitey high pressure needle valve (Whitey Forge Co., 
London). Columns with Shandon fittings were attached to 
a slurry reservoir (Shandon Southern, Runcorn) and packed 
in the downward mode at 8500 psi using 1% sodium acetate
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in 50% methanol as the balanced density solvent with 
methanol as follower solvent. Subsequently a Shandon 
column packer was used and packing in the upward mode 
at 10,000 psi was adopted as a standard technique, the 
balanced density solvent was changed to propan-2-ol with 
methanol as the follower solvent.
Column performance was checked using a test mix 
of 1 mg/1 of phenol, o-cresol and acetone in water, the 
eluant was methanol:water (50:50) at a flow rate of 
1 ml/min with detection at 254 nm. Efficiency in theory 
etical plates and peak asymmetry at 10% peak height were 
calculated; columns with efficiencies of less than 6500 
plates (h=>3.0) for o-cresol (the longest retained peak) 
and asymmetry outwith the range 0.9-1.3 were rejected.
In use column performance could deteriorate and 
removal of the top 5 mm-1 cm of packing material and 
replacement with fresh, methanol-damped, material and 
tamping into place restored column performance.
3. The last configuration consisted of the items 
noted in 2^ above with the following: A Pye Unicam LCX5
pump (Pye Unicam, Cambridge, England), a Rheodyne 7125 
loop injector (Rheodyne) for manual injections, a Pye 
Unicam LC-UV variable wavelength UV detector and a Philips 
8501 single pen recorder.
In addition other items that were required were a 
Pye Unicam 1800 spectrophotometer, a Pye Unicam 8000 
scanning spectrophotometer and an Astrup pH meter ' 
(Radiometer, Copenhagen, Denmark) for the measurement of
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salivary p H .
2.7. DEVELOPMENT OF A LIQUID CHROMATOGRAPHIC ASSAY FOR 
TRIMETHOPRIM IN SERUM AND URINE
The original intent was to develop a reverse phase 
LC assay for SMZ, SDMO and TMP. Due to the limitations of the 
procedures of Bury and Mashford (1979) and Vree et al 
(1978) for TMP, the procedure of Helboe and Thomsen (1977) 
appeared the most amenable to modification; when it proved 
impossible to reproduce their chromatography it was 
decided to develop a new method, as the assay of Weinfeld 
and Macasieb (1979)W a s  the only other alternative and 
normal phase LC is more difficult to operate reliably for 
any extended period,. The development of the procedure had 
two aspects: i) optimisation of the chromatography and
ii) optimisation of the extraction.
Therefore systematic changes in methanol/water ratios 
were investigated followed by investigation of the effect 
of alkali or acid as a controller of TMP ionisation.
Finally an anionic ion pairing agent was examined.
The sample preparation approach chosen was liquid/ 
liquid extraction. Initial examination of the solvents: 
diethyl ether, chloroform, hexane, dichloromethane, 
ethyl acetate and toluene was performed using 1 M sodium 
hydroxide for extraction of aqueous 100 mg/1 TMP standard. 
Ionisation control was examined by using 1 ml of 100 mg/1 
TMP standard and 5 ml dichloromethane plus one of: 100 ul
ammonia solution (rel. dens 0.88), 100 ul of 1 M hydro­
chloric acid, 1 ml 0.1 M borate buffer pH 9.0, 1 ml of
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0.3 M sodium carbonate, 1 ml of 1 M sodium hydroxide,
1 ml sodium bicarbonate; in addition ion pair extraction 
was attempted using sodium lauryl sulphate (0.1%) plus 
100 ul 0.1 M HC1. The extract residues were examined 
spectroscopically by scanning from 210 nm-290 nm at 
10 nm/sec.
Once the final solvent and alkali were chosen 
further experiments on recovery etc. were performed using 
LC and are explained in more detail below.
2.7.1.Linearity
To determine linearity as a function of on-column 
sample weight, 10 ul injection of aqueous TMP solutions 
over the concentration range 0-1000 mg/1 (0-10 pg on 
column weight) were used.
2.7.2 .Recovery
Serum trimethoprim standards covering the range 
0-6 mg/1 were analysed; the difference in detector response 
between these and directly injected aqueous standards 
represented the absolute percentage loss. Relative 
analytical recovery was assessed from the ratio of directly 
injected TMP/internal standard solution to comparable 
assayed serum standards at 0.5 mg/1 and 1.25 mg/1 with 
diazepam or 1 mg/1 with m-aminoacetophenone as internal 
standard. Urine recovery is absolute, no internal standard 
is required.
2.7.3 .Precision •
The within-batch precision was assessed from alternate 
analyses of trimethoprim controls at two concentrations: 
serum at 0.4-5 and 1.25 mg/1 with diazepam as internal
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standard and 1 mg/1 with m-aminoacetophenone as internal 
standard and for urine 100 and 200 mg/1; the values were 
assigned on the basis of preparation from a stock solution 
of TMP at 1 i g /1 (weighed in value) and prepared by 
dilution.
2.7.4. Accuracy
Accuracy may. be judged from the results of the 
recovery studies. Potential interference was examined 
for a number of drugs in aqueous solution at 1 mg/ml 
(10 ug on column): acepifycline,, amitriptyline, amylo-
barbital, butriptyline, carbamazepine, chlordiazepoxide, 
clomipramine, chlormethiazole, chlorpromazine, clonazepam
dapsone, desipramine, dextropropoxyphine, dothiepin,
a
doxepin, fluphenazine, gentamicin, imipramine, lorazepam, 
nialamide, medazepam, methotrexate, nitrazepam, nortrip­
tyline, oxyphenbutazone, paracetamol, penicillin, peri- 
cyazine, phenobarbita'l, prazepam, primaquine, primidone, 
promazine, promethazine, prothiaden, proxiphylline, 
salicylate, sulphadiazine, SMZ, SDM0, temazepam and 
trimipramine.
Thirdly the relative error for both serum and urine 
procedures were estimated using the formula:
observed expected , .. ,v
. . .  concentration ” concentrationrelative ^ _   . _____________
error standard error
Equation 2.2.
and applied to the 0.45 mg/1 serum standard and the 100 mg/1 
urine standard .
In addition a number of drug free samples were run.
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2.7.5. Quantitation
Serum: Once linearity was established and foundjto
be reproducible unknown serum concentrations were calculated 
as follows
r t .s
T = :  Equation 2.3.
. . . . . .  Rg _____
where T = TMP concentration of unknown
S = TMP concentration of calibrator
^ TMP peak height _____ .
internal standard peak height
for calibrator (S) and test (T) respectively 
(sub-script).
Urine: External standardisation was used; concent
trations ranged from 20-400 mg/1; to allow for any within 
batch chromatographic variation a 100 mg/1 calibrator 
was injected after every fourth sample; the values obtained 
from this calibrator were referred to the value of the 
100 mg/1 standard in the calibration line, this was the 
’target1 value. Any variation in a drift standard was 
corrected and the correction applied to the two unknowns 
on either side of that calibrator.
2.7.6. Optimised Procedure
i ) Serum
To 1 ml of serum for less) in a Quickfit MF 24/1/5 
tube (Corning Ltd.,Stone, Staffs) was added 1 ml of 2 M 
sodium hydroxide and 5 ml of internal standard solution.
The tubes were tightly stoppered and shaken for 5 minutes
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on a lateral shaker (Gallenkamp, London) then centrifuged 
at 3000 rpm for 5 minutes; the organic layer was transferred 
to a conical tube and the solvent evaporated in a water 
bath at 40°C under a stream of air. The residue was 
dissolved in 25 ul LC eluant and 10 ul injected via the : 
sampling loop.
i i ) Urine
A 10 ul sampling loop was used and 25 ul of sample
or calibrator was injected.
2.7.7. Chromatographic Conditions
The eluant in the developed assay was pumped at 
2 ml/min and detection performed at 230 nm at 0.2 AUFS for
serum extracts and 1.0 AUFS for urine extracts.
2.7.8. Modified TMP Assay
Hexane sulphonic acid could be desorbed from the 
C^gphase using acetone, sodium lauryl sulphate could not; 
the 5 u Hypersil columns were shorter and the eluant flow 
rate was decreased to 1 ml/min. The selectivity of the 
Hypersil columns was very different from Spherisorb 
and retention was tooigreat. Sodium nitrate was therefore 
added as counter-ion. The eluant for the modified assay 
was a 70:30 mixture of methanol and 0.05 M phosphoric 
acid containing 0.1% hexanesulphonic acid and 0.2% sodium 
nitrate. Detection was at 235 nm.
The substitution of hexane sulphonic acid for sodium 
dodecyl sulphate in the eluant and the addition of sodium 
nitrate quite clearly could be anticipated as having an 
effect on analytical performance. In addition Hypersil 
5 u 0DS is a more completely end-capped material.
For these reasons it was necessary to re-evaluate 
certain aspects of the assay performance; in particular 
accuracy, precision and sensitivity.
2.7.9. Modification of the Varian 8050 Autosampler 
A Varian 8050 sampler operates under gas pressure
which is used to force the analyte from the sample vial 
to the automatic loop, the sample also being used to 
flush the line (Fig 2.2) resulting in a minimum sample 
volume requirement of the order of 150 ul for a 10 ul loop 
(i.e.. 7.5% loaded) . In pharmacokinetic studies it is useful 
to maintain as good a sensitivity limit as possible, the 
operation was therefore modified.
The recommended inlet gas pressure to conform to the 
above sampling volumes is 20 psi; by placing a pressure 
gauge in the inlet line and continually monitoring the 
pressure to ensure that an inlet pressure of 7 psi is 
maintained it became possible to inject 10 ul from 70 ul
i.e. 14-. 3% of available analyte.
To assess whether there was an adverse effect on 
high to low sample carryover sera containing 250 ug/1 and 
2.5 mg/1 were assayed in consecutive pairs with a water 
wash vial between each sample, there were ten such pairs 
of each serum* Low to high sample carryover was also ; 
checked.
2.7.10. Accuracy, Precision and Sensitivity 
Precision,accuracy and sensitivity were assessed
as described previously.
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2.8. ASSAY FOR TMP IN-SALIVA AND SPUTUM
2.8.1. Saliva 
j)Sample Handling
Saliva flow was stimulated by mastication of a 
washed elastic band, the mixed saliva produced over the 
first two minutes was discarded and then saliva was 1 
collected into pre-weighed vials for five minutes or until 
5 ml had been produced and the time noted, whichever was 
the shorter. The vials were weighed and the weight of 
saliva noted; The specific gravity of saliva is virtually 
1.0 (Documenta Geigy, 1975). Immediately the collection 
was completed the saliva pH was measured using an Astrup 
micro pH meter (V.A.Howe, London) and the value recorded.
Samples were stored at -20°C prior to analysis. 
Freezing prior to analysis also served to clarify the 
saliva and decreased its viscocity by precipitation of 
the mucopolysaccharides which facilitated subsequent c. 
handling.
2.8.2. Sputum
Sputum is a thick mucoid product secreted in response 
to bronchial irritation and is continuously produced in 
COAD and alters during exacerbations 
i)Sample Collection
Expectorated sputum samples were collected in vials. 
These were labelled with time of collection and then split, 
one half being sent for bacteriological study, the other 
for assay of TMP. Following receipt, samples were stored 
frozen at - 20°C prior to analysis.
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. jjpSample Handling
The high viscocity of sputum requires that liquefaction 
be performed prior to analysis. The technique, developed 
in conjunction with Dr, D. Platt, Dept. Bacteriology,
Glasgow Royal Infirmary was as follows: to a volume of
sputum (1-5 ml) was added 2,3 dithiothreitol (diluted 1:10 
in water) in the ratio 10:1. This was then incubated for 
30-4-5 minutes at 60°C with occasional shaking. The 
viscosity was assessed by inspection and if the treatment 
was inadequate the lysis was repeated until a satisfactory 
result was achieved. This procedure also served to 
•pasteurise’ the specimen thereby excluding the possible 
dissemination of T B . Analysis was then as for serum,
iii)Analysis of Saliva and Sputum Samples
The modified TMP assay described above with the 
modified autosampler were used.
*v ) Precision and Recovery
Pools of drug free saliva and sputum were obtained 
and spiked at TMP concentrations of 1.5 mg/1 and 1 mg/1 
respectively
v ) Calibration 
Calibrators over the range 0-10 mg/1 were prepared 
in pooled saliva and sputum respectively.
2.8.3..Ultrafiltration of Serum
To enable comparison of 'free' TMP and saliva? ultra­
filtration of serum was performed using AMICON Centriflo 
CF25 membranes centrifuged at 3000 rpm for 30 minutes 
at 4°C. The ultrafiltrate was collected and stored at 
-20°C prior to assay.
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RESULTS
2.9. SULPHONAMIDE ASSAYS
2.9.1. Linearity
The colour produced by both the modified Bratton- 
Marshall procedure and that of Reider was shown to obey i 
Beer's Law from 0-250 mg/1 in serum and 0-1000 mg/1 for 
urine.
The relationship between concentration and absorbance 
for SDM0 calibrators and from SMX calibrators were 
superimposable.
2.9.2. Sensitivity
The sensitivity of the assays was better than 5 mg/1 
but variation in the blank reading and poor discrimination 
of absorbance at this level made precise' determination 
impossible. In use concentrations of less than 10 mg/1 
were not quantified.
2.9.3. Precision
The precision of the Bratton-Marshall procedure was 
1.4% (n=114) and 4.6% (n=41) for serum and urine respec­
tively and for the Reider procedure were 3.2% (n=12) and 
7.6% (n=30) respectively.
2.9.4. Accuracy
i ) Serum
There were no authenticated metabolites of either 
SDM0 or SMZ available to allow assessment of their inter­
ference in the assays. The correlation of serum SDM0 
and SMZ levels assayed by both the modified Bratton- 
Marshall and Reider procedures is shown in Fig. 2.3 
(r=0.984, gradient 1.04, intercept +3.55, n=61). In
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2.3. Association of serum sulphonamide using 
extracted (Rieder) versus unextracted 
(Varley) assays.
\_
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practical terms there is no difference in serum sulphonamide 
levels measured by either assay,
i i ) Urine
Comparison of urine sulphonamide concentrations 
from subjects taking SDMO and SMZ showed statistical 
association (r=0.78, gradient 1.62, intercept 152 .7 , n = l18). 
The gradient (Fig.2.4-) shows quite clearly that there is a 
large overestimate^ of sulphonamide by the Bratton-Marshall 
technique and that the procedure of Rieder is more specific.
2.9.5. Acetylator Phenotyping Accuracy 
Ten individuals 5 male and 5 female of between 18 and 
30 years of age participated; none had any detectable 
physical, or biochemical abnormality. The phenotyping 
is given in Table 2.1. The procedure using the Reider 
adaptation was more clearcut in the group studied however 
it is interesting how for two subjects the percentage acetylated 
has risen significantly ; both subjects KR and DD could have 
fallen into the equivocal category.
2.to . TRIMETHOPRIM
2.10.1. Original Assay 
i ) Development of the chromatography
There was no retention of TMP using the solvent of 
Helboe and Thomsen (1977); methanol/water gradients were 
used but were chromatographically inefficient. As TMP has 
a pKa of 7.3 and the packing material is only stable to 
a pH of 7.5 it was not possible to ensure that TMP could 
be kept in the free base form; by addition of acid to a pH 
of 5 or less the amino groups will be protonated.
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extracted .(Rieder) versus unextracted 
(Varley) assays.
TABLE 2.1
Comparison of sulphadimidine phenotyping by extracted and non- 
extracted Bratton-Marshall p r o c e d u r e s . _____________
Subject Sex
NOH-EXTRACTED EXTRACTED
% Acetylated Phenotype % Acetylated Phenotype
K.C. -F 90 Fast 92 Fast
C.C. F 89 Fast 88 Fast
K.R. F 4-8 Slow 68 Slow
A.McL. F •55 Slow 56 Slow
I.H. F 89 Fast 85 Fast
D.D M 54 Slow 70 Slow
I.S M 89 Fast 88 Fast
• G.H. M 53 Slow 46 Slow
D.McM. M 90 Fast 91 Fast
R.S. M 78 Equivocal 58 Slow
>80% Fast, ,<70% Slow, 70-80% Equivocal
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The chromatography obtained using methanol:water (90:10) 
is shown in Fig. 2.5.
At an acid pH the cationic state of TMP can be 
utilised to form ion-pairs with an anionic surfactant 
resulting in ion-pair chromatography. Various acetonitrile: 
0.05 M phosphoric acid: sodium lauryl sulphate eluants 
were tried, a typical chromatogram with eluant ratios of 
60:40:0.1(v/v/w) is shown in Fig2.6, a very similar pattern 
but with better resolution was seen with methanol:0.05 M 
phosphoric acid:sodium lauryl sulphate (15 : 85 :0. 2 ) (v / v/w) . 
(Fig. 2.7).
Typically the k* of the sulphonamides was <1 and oi 
for SDM0 and SMZ tended to 1. The primary interest 
therefore was in the development of an assay for TMP. 
Although useable peaks were obtained in neutral, basic 
and acidic solvents the best chromatographic efficiency 
was obtained with ion-pairing; a comparison of this and 
other parameters is given in Table 2.2. Neutral and basic 
solvents were the least efficient; controlling the pH and 
chromatographing TMP in its protonated form doubled the 
efficiency but retention was poor with minimal resolution 
from the sulphonamides. The addition of an anionic ion 
pair improved efficiency by a further threefold (sixfold 
in all), improved retention and hence resolution from the 
sulphonamidesfand is clearly the eluant of choice.
Development of the extraction
The results of single stage basic extraction into a 
variety of solvents is summarised in table 2.3; the 
chlorinated solvents gave.best recoveries but recovery
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TABLE 2.3
Solvent extraction of TMP : 1M sodium hydroxide as base and various 
solvents (ranked in order of increasing polarity) from Snyder and 
Kirkland (1974-)
Approximate 
* * r Absolute
Solvent ______ .  .   A_____B Recovery (%)
Hexane 7.3 0 0 o
Diethyl ether 7 A 2.0 0 20
Ethyl acetate 8.6 2.0 0. 55
Toluene 8.9 0.5 0 0
Chloroform 9.1 0.5 3.0 80
Dichloromethane 9.6 0.5 0 80
Dichloromethane/Isopropanol(98:2) 9.7 0.6 0.1 80
6 Hildebrand solubility parameter 
<5^  proton-acceptor parameter 
6 proton-donot parameter
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did not seem related to the proton donor effects of the 
solvents used. The use of alcohol to reduce adsorption 
or the use of silanisation both resulted in recoveries 
of around 80%.
Spectrophotometry of the aqueous phase confirmed 
that approximately 20% of TMP was still present.
As TMP is a base,a basic extract into the organic 
solvent should be effective. A number of choices were 
investigated including ion-pairing from acid conditions. 
The results are summarised in table 2.*f. Sodium hydroxide 
solution gave the best recovery. The ion-pairing result 
indicates the potential of this technique.
As suggested by the results in tables 2.3 and 2.4 
a dichloromethane extract with 1 M sodium hydroxide was 
chosen for further investigation. The absolute recovery 
for TMP in this system was around 80%. Initially diazepam 
was used as internal standard, but latterly m-amino- 
acetophenone was also used, both gave absolute recoveries 
of around 80%.
Using manual extraction,recovery of TMP had been 
variable and usually significantly lower than the figures 
quoted above. However it had been realised early on that 
the use of a mechanical shaker improved recovery and 
reproducibility, and this was used in all the work 
reported here.
The assay was then investigated with regard to its 
applicability to serum. Direct injection of urine did not 
result in any significant p e aks.in the region of TMP and
TABLE 2.4-
Solvent extraction of TMP : dichloromethane as solvent and 
various reagents for pH control (ranked in order of decreasing
PH) ___________ ;_____________ ;_______________ ;____________
Approx pH Approximate
of Aqueous Phase Absolute
R e a g e n t __________ After Addition Recovery(%)
Sodium Hydroxide 12.9 75
Sodium Carbonate 11.5 35
Ammonia Water 11.3 20
Borate Buffer 9.0 ' 10
Sodium Bicarbonate 8.3 50
Hydrochloric Acid 1.0 0
Hydrochloric Acid +
Sodium Lauryl Sulphate 1.0 4-0
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thus direct injection was pursued for urine analysis of 
IMP. The performance characteristics of the serum 
extraction and urine injection methods are described 
below.
iii )Linearity
Linearity was demonstrable as a function of on- 
column weight over the range 0-6 ug. As the assay was 
originally constituted this represented a linear concen­
tration range of 0-18 mg/1 for serum and 0-600 mg/1 
for urine.
iv) Recovery
a ) serum
Absolute recovery was dependent on extraction - 
efficiency and the amount of solvent transferred, this 
was found to be 80-10%. Recovery relative to diazepam 
as internal standard at two concentrations 0.5 mg/1 and 
1.25 mg/1 was 97.5^9.6% and 98^9.2% respectively.
With respect to m-aminoacetophenone at 1 mg/1 recovery 
was 101.6*7.7%. Each mean above is the result of thirty 
determinations.
b ) urine
Absolute recovery was 100-1.0% (n=10).
v ) Sensitivity
Serum and Urine
Sensitivity, defined as twice the signal to noise 
ratio, was 8 ng on-column weight using 5u 0DS material and 
30 ng on-column weight for lOu material. These were 
equivalent to 25 ug/1 and 90 ug/1 respectively for serum
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and 800 ug/1 and 3 mg/1 for urine,
vi ) Precision 
a ) serum
With diazepam as internal standard the mean value 
for the 0.4-5 mg/1 material was 0.442 mg/1 (CV=6.1%) and 
for the 1.25 mg/1 the mean was 1.229 mg/1 (CV=4.6%) for 
within-batch precision the equivalent data for m-amino- 
acetophenone for 1.0 mg/1 was a mean of 1.022 mg/1 (CV=7.9%). 
The corresponding between batch data for the 0.45 
and 1.25 mg/1 samples were: mean 0.443 mg/1 (CV=6.6%)
1.229 mg/1 (CV=6.3%) and for m-aminoacetophenone at 1.0mg/l 
1.01 mg 11 (CV = 9 .0%).
Each mean quoted above was based on .30 determinations. 
In addition to the above, one-third of all serum and urine 
analyses in the co-trifomole study were repeated on 
randomly selected samples. The precision found for serum 
and urine assays were 4.8% (n=121) and 4.6% (n=40) 
respectively. The precision of the m-aminoacetophenone 
internal standard was less satisfactory and diazepam was 
routinely used as internal standard,
b ) urine
The within-batch precision for the urine assay at 
100 and 200 mg/1 was 98.3 mg/1 (CV=3.3%) and 205.2 mg/1 
(CV=1.5%)(n=30 in both cases). A further thirty injections 
at each level for between batch precision gave means of 
98.9 mg/1 (CV = 3.6) and 205.0 mg/1 (CV = 2.0%) respectivley. 
vii )Accuracy
Of the drugs chromatographed, the sulphonamides 
were poorly extracted, but some basic drugs were extracted,
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only carbamazepine had a k' near that of TMP on the lOu 
ODS column (k'TMP=2.7, carbamazepine 2.1 - Rs=0.8). With 
a more efficient 5u ODS column these were separated. If 
m-aminacetophenone is used as an internal standard, it 
was found that even on a 5u ODS column neither lorazepam 
nor nitrazepam were completely resolved. (Rs= 1.0). No 
interference was noted from endogenous components in the 
serum assay. In the urine assay a small endogenous peak 
equivalent to 5 mg/1 could not be resolved from TMP using 
lOu ODS (Rs=0.3, h=20), however resolution was obtained 
using 5u ODS (Rs=1.25, h=5). Several hundred assays have 
been performed with no interference noted.
The calculated relative error for a serum concen­
tration of 0.4-5 mg/1 and a urine concentration of 100 mg/1 
gave t values of.Ii4 and 1.65 respectively, these were not 
significant at the 5% level.
viii)Separation
A chromatogram obtained from an extract of serum 
from a subject taking trimethoprim, with diazepam as 
internal standard is shown in Fig 2.8a; an extract from 
a subject prior to medication is shown in Fig 2.8b; the 
differences in internal standard peak height are due to 
differences in injected volume (a, lOul; b, 20ul). A 
chromatogram of a serum TMP extract with m-aminoacetophenone 
is shown in Fig 2.9.
The chromatogram obtained from the urine of a 
subject taking TMP is shown in Fig 2.10a and the chromatogram 
obtained prior to dosing is shown in Fig 2.10b.
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FIGURE 2.8a. LC of serum extract from subject dosed with TMP. 
Diazepam as internal standard
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FIGURE 2.8b. LC of serum extract from subject prior to dosing 
with TMP. Diazepam as internal standard.
CL
0.01 AUFS
Tr T 1 /
FIGURE 2.9. LC of serum extract from subject dosed with TMP. 
m-aminoacetophenone as internal standard.
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FIGURE 2.10a. LC of direct injection of urine from subject dosed 
with TMP. ?M = ? metabolite
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FIGURE 2.10b. LC of direct injection of urine from subject prior 
to dosing with TMP.
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2*10.2 Modified TMP Assay
i ) Separation
The change to 10 cm x 5 mm id 5u Hypersil ODS 
columns and the substitution of 0.1% hexane sulphonic 
acid for 0.2% sodium lauryl sulphate resulted in increased 
retention (TMPk'=5.7, diazepam k'=9.7) with a total 
chromatogram time of 17 minutes (Fig 2.11). Addition of 
0.2% sodium nitrate decreased retention (TMPk'=1.9, 
diazepam k ’=3.6) with a total chromatogram time of 7 minutes 
(Fig 2.12).
i i ) Accuracy
The accuracy of the assay was evaluated in the same 
manner as described above, carbamazepine did not interfere 
with the estimation of TMP and the endogenous peak did not 
interfere with TMP. Diazepam was the internal standard 
of choice and interference with m-aminoacetophenone was 
not checked. No new interferences were noted.
iii)Linearity and Sensitivity
The linearity and sensitivity as a function of 
on-column weight remained unchanged, however when the 
modified assay was used in conjunction with the autosampler 
the concentration range of linearity for serum and urine 
was 0-50 mg/1 and 0-600 mg/1 respectivley. r
The sensitivity limits for serum and urine cal­
culated from the percent of analyte presented are 85 ug/1 
and 800 ug/1 respectively; however if nitrate is used as 
counter-ion it absorbs at 230 nm. Offsetting to 235 nm 
decreases the signal to noise ratio but is. still larger 
than that previously noted and the measured sensitivity
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FIGURE 2.11. Modified LC eluant for TMP, containing hexanesulphonic 
acid in place of sodium lauryl sulphate. Column 
packing material changed to 5p Hypersii ODS, flow 
rate also reduced.
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T 1Tr i
FIGURE 2.12. Conditions as for FIG 2.11 but eluant includes sodium 
nitrate as a counter-ion.
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limits are 200 ug/1 and2.0 mg/1 respectively for serum 
and urine. By reverting to the manual injection procedure, 
but with nitrate in the eluant the detection limits were 
70 ug/1 and 2 mg/1 i.e. a decrease in sensitivity of 
approximately 2.5 for both assays. These limits are well 
below those that were expected to be encountered, 
iv) Precision
The precision was checked initially and was 2.9% 
(n=17) at 2 mg/1 TMP further validation is given in the 
assay for saliva and sputum.
2.10.3 Autosampler Modification
As the autosampler used the injected sample to 
flush the system of the previous sample there is a need 
for an intermediate wash vial. Reducing the pressure 
decreases the flush volume and can therefore lead to 
increased carryover. Sampling a serum of 250 ug/1 
followed by a water wash vial and then by a serum of 
- 2.5 mg/1 there was no observable decrement in the observed 
concentration of the second vial i.e. carryover is 0%
(n=10 pairs) i.e. there is no 'negative carryover’.
Sampling a serum of 2.5 mg/1 followed by a water wash 
vial and then a serum of 250 ug/1 led to an increment 
in the observed concentration of the second vial of 2%
(n=10 pairs) i.e. equivalent to 5 ug/1. There is therefore 
'positive carryover1 but this is insignificant.
2.10.4. Assay for TMP in Saliva and Sputum
i ) Recovery
Absolute recovery of TMP added to saliva and 
sputum was 91 + 8% (n = 10 ) and S^ + 9% (n = 10); recovery
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relative to the internal standard was 100=0% and 104±4-% 
respectively.
i i ) Precision
The precision for TMP saliva analysis was 10.9% 
(n=21) for saliva samples assayed in duplicate. For 
sputum the precision was found to be 5.6% (n=16) for 
samples run in series. There was no apparent reason for 
the differences in precision.
iii) Accuracy
The components of 2,3 dithiothreitol eluted prior 
to TMP. No interferences other than those previously 
noted were found.
iv) Separation
Chromatograms from saliva and sputum containing 
TMP are shown in Figs. 2.13 and 2 . H  respectively.
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FIGURE 2.14-. Conditions as for 2.12:. LC of liquefied/pasteurised 
sputum extract from subject dosed with TMP. 
Sputolysin is the liquefying agent.
DISCUSSION
2.11 SULPHONAMIDE ASSAY
The assay of Rieder (1972) for sulphonamides is 
well established as the procedure of choice in pharmaco­
kinetic studies (Bergan and Brodwall, 1972; Wilfert, 1973; 
Nolte and Buttner, 1974; Liedtke and Haase, 1979;
Broughall et al, 1979; Ortengnen, et al 1979a;
Trottier, Bergeron and Lessard, 1980; Singlas et al, 1982) 
and despite the amount of manual manipulation, acceptable 
precision was obtained. As this assay gave lower levels 
for serum sulphonamide than the standard non-extracted 
assay this implies greater specificity although in 
practical terms there is minimal difference. With 
extracted serum sulphonamides there is minimal return for 
the extra effort and the non-extracted assay tends to be 
more convenient.
The marked differences seen for the urine sulph­
onamide concentrations supports the contention of Rieder 
(1972) that the extraction step yields a more specific 
assay and there is no evidence to indicate that any 
significant interference occurs from metabolites in this 
method. Rieder did not perform a comparison as described 
here and it is surprising that there is an apparent 
absence of reports in the literature. In addition to 
its accuracy the procedure had good linearity, sensitivity 
and precision and is amenable to batch analysis.
In view of the large number of pharmacokinetic 
papers that have used the method of Rieder for sulph­
onamide analysis it is remarkable that the technique has
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not been applied to the determination of acetylator 
phenotyping using sulphadimidine, . A number of analytical 
approaches have been adopted ranging from qualitative 
assessment (Schroder 1972) to fairly sophisticated models 
(Lee and Lee 1982).
Of the individuals assessed in the phenotyping 
experiment none of them changed classification although 
an equivocal typing using the Bratton-Marshall procedure 
was typed as a slow acetylator with the extracted procedure. 
The percent acetylated differed markedly in three individuals 
one of which was the previously equivocal phenotyping.
For subject K.R. there was an increase of 20% and for 
subject D.D. an increase of 16% using the modified assay; 
as the percent acetylated is calculated by difference then 
overestimation of the unmetabolised sulphonamide will lead 
to underestimation of the percent acetylated. These 
individuals must apparently have a reactive metabolite 
~ eg. N^acetylsulphadimidine which is not estimated using the 
extraction procedure. In both of these caseslclear ; 1 slow 1 
metabolisers have come very close to the ’equivocal1 
range and it is probable that this range would no longer 
be applicable. The distribution of fast/and slow 
metabolisers are consistent with the distribution to be
expected in a Caucasian population ( C u r r y , 1980).
. A
2.12 TRIMETHOPRIM ASSAY
The lack of retention using the eluant of Helboe 
and Thomsen (1977) may be attributable to different column 
selectivity, although the columns initially used were
' 75
not notable for being well end-capped. In the investigation 
of methanol/water eluants there was minimal retention of 
SDMO and SMZ, both co-eluted with a k ! of <0.5; the TMP 
peak was asymmetric (As=l.8). It had been suggested by 
Helboe and Thomsen (1977) that the addition of alkali 
would increase the k', this appeared to have no notable 
effect although the peak shape improved (As=l.5), such an 
effect would suggest that the mechanism was normal phase 
chromatography and would tend to be confirmed by the 
use of ammonia in normal phase assays for TMP (Weinfeld 
and Macasieb, 1979; Ascalone 1981). All reverse phase 
assays for TMP use an acidic eluant with a pH <5.0 i.e. 
at least two pH units below the pKa of TMP (7.3), the 
change from neutral and alkaline eluants was associated 
with an improvement in peak shape, it has been suggested 
that strong acids should be used to effect this improve­
ment (Helboe and Thomsen, 1977).
In all the assays described to date (Helboe and 
Thomsen, 1977, Vree et al 1978, Weinfeld and Macasieb,
1979; Bury and Masfford, 1979; Ascalone, 1981; and Gochin 
et al 1981) the order of elution is TMP followed by SMZ 
despite the fact that the procedures of Weinfeld and 
Macasieb (1979) and Ascalone (1981) were normal phase 
procedures whilst the others are reverse phase assays.
In all conditions observed in this work including the 
solvent of Helboe and Thomsen (1977) on a variety of 
columns, SDMO andSMX eluted before TMP. There are two 
possible explanations either the .column selectivity used 
in this work is different or the solvent selectivity is
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different. The former possibility seems unlikely as Bury 
and Mashford (1979) also used a Spherisorb ODS column, 
and the second explanation appears equally unlikely as 
Gochin et al (1981) used a methanol:acetic acid eluant.
0.05 M phosphoric acid has a pH of 2.2, the 
dissociation will be attenuated by organic solvent as 
will the dissociation of the drugs, SMZ having a pKa of 
5.6 and SDMO of 7.4. Thus at pH2.2 the primary amino 
groups on TMP, SMZ and SDMO will be protonated; the c. 
addition of an anionic ion-pair resulted in an.increase 
in retention of TMP but not the sulphonamides, the k' of 
which remained at -0.3 thus any protonation of the 
sulphonamide primary amino group is not utilisable due 
to the inductive acidity of the substituted sulphonic 
acid.
In normal phase chromatography when ammonia is 
used in the eluant this serves to reduce the apparent 
acidity of the silanol groups which behavesas an ion-pair 
to anionic species and as a counter-ion to cationic 
species. The presence of alcohol in the eluant in addition 
to acting as a co-solvent and liquid layer to 'protect1 
the silica will act as a partition phase for hydrophilic 
compounds. A fuller account of the mechanisms is given 
elsewhere (Watson, 1977 ; Watson, 1979). If the above 
is true then anionic species should have increased 
retention and cationic species decreased retention i.e.
TMP should elute before SMZ. In a reverse phase system 
that is totally free of normal phase effects then to 
achieve such an order of elution a lipophilic cation
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should be used. It would be predicted therefore that a 
lipophilic anion will decrease SMZ k' and increase 
TMP k' which is what is observed. This does not explain 
the finding of this elution order prior to the addition 
of the ion-pairing agent.
From simple partition theory in normal phase 
chromatography the least polar compound should elute first 
followed by thosewith increasing polarity, such elution 
orders may not be those intuitively expected, but can 
be predicted (Watson and Stewart 1977a and b), in reverse 
phase systems the reverse is true i.e. the most polar 
compound is eluted first and this is followed by those 
with decreasing polarity. TMP is weakly basic whereas SMZ 
is more strongly acidic; TMP is less polar than SMZ, 
therefore in normal phase systems TMP should elute before 
SMZ and in the reverse order in reverse phase systems 
unless the eluant so modified one or other of the molecules, 
eg. acetate ion-paired to the primary amine group in the 
separation of Bury and Mashford (1979) and Gochin et al (1981) 
this would increase the apparent polarity of TMP, but 
not SMZ and cause earlier elution. The incomparability 
of the k !,s obtained in this work and that of Helboe 
and Thomsen (1977) cannot be explained by this last mechanism 
as their eluant was acetonitrile/phosphoric acid. As the 
only difference was the column, and the results obtained 
in this work accord with theory, it is possible that 
what they observed was a mixed normal/reverse phase 
partition with the selectivity of the former dominating.
As additional support for this contention Cobb and Hill
78
(1976) using normal-phase chromatography, report the 
elution order of the sulphonamides as SMZ followed by 
SDMO, implying that SDMO is more polar than SMZ, although 
it may be sterically hindered. If the former explanation 
is correct then the elution oorder on reverse phase 
should be SDMO followed by SMZ; in the early stages of 
the TMP assay development, this was the oorder observed, 
it therefore is most probable that reverse phase chromat­
ography predominated in this assay.
In the assay described here a lipophilic long chain 
( C ^ )  anion was used to ion-pair the protonated TMP.
The advantages of this technique have been known for some 
time (eg. Knox and Ourand,,1976) and the expected improv- 
ment in efficiency and selectivity was found. It seems 
probable that the predominant mechanisms operating in 
this separation are: ion-pair retention of cations,
solute counter-ion elution of anionic solutes and reverse 
phase partition.
Preliminary studies had shown that with a lOu ODS 
column with a limit of^sensitivity of 35 ng on-column 
weight, reproducible quantitation was possible at twice 
this level. If 100 ul each of serum and protein 
precipitant with injection of 50 ul of the supernatant 
were performed this would give a sensitivity limit of 
around 275 ug/1. Bury and Mashford (1979) used a 20:1 
ratio ofsample:precipitant and 100 ul injection and a 
sensitivity limit of around 200 ug/1. To improve assay 
specificity,sensitivity and minimise the column deterior­
ation frequently found with such protein precipitation
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techniques, liquid/liquid extraction was used.
Partition of analytes into the organic phase is 
most readily achieved when the analyte is in its most 
lipophilic i.e. unionised form, for TMP this means a 
pH >9.3; and this lipophilic form must be soluble in the 
solvent, essentially reflecting its polarity. The most 
suitable solvent was chosen from a range of medium to 
non-polar solvents, the chlorohydrocarbons investigated 
were found to give the best recoveries. Dichloromethane 
was chosen as it has a much lower boiling point than 
chloroform,thus facilitating the evaporation stage, and 
was also less toxic. Recovery was not consistently 
related to any solvent solubility parameter.
Generally the more basic the aqueous phase the 
better the absolute recovery with sodium hydroxide 
yielding the best result, the recoveries using sodium 
carbonate or ammonia water seem somewhat low. At a pH 
of 1.0 a recovery of 0% would be expected as protonated 
TMP is hydrophilic, however the addition of an anionic 
ion-pair reagent to the organic phase gave a recovery 
of 4-0%. The anionic ion-pair was the same as that used 
in the chromatography and the mechanism of partition is 
the same i . e . the ion-pairing agent enhances the lipophilicity 
of TMP increasing its partition into the organic phase.
Absolute recoveries in the dichloromethane/sodium 
hydroxide system tended to be of the order of 80%, 
spectrophotometry of the aqueous phase suggested that 
10-20% of TMP remained in this phase following the first
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extraction although there was some loss of organic phase 
during the removal of aqueous phase; absolute recovery 
could have been enhanced by a second extraction step 
which would have improved absolute recovery up to 96%, 
however the extra complexity involved was unnecessary 
as recovery was fairly consistent and, more importantly, 
variations were compensated for using on internal standard. 
Internal standards should exhibit physicochemical properties 
very similar to the analyte, thus they should partition 
to the same extent on extraction, have the same stability 
and separate from the analyte on chromatography without 
interfering with the analysis or resulting in excessive 
assay times. The ideal internal standard is an analogue 
of the analyte, unfortunately these can prove very 
difficult to obtain and thus some other compound must 
be chosen.
Initially diazepam wts chosen as an internal 
standard which extracted and chromatographed well, in 
the studies in which the assay to be used other medication, 
including diazepam were excluded. If the assay were to 
be of use in a more general population the Common use of 
diazepam could cause inaccuracy therefore an alternative 
internal standard was sought; m-aminoacetophenone chrom­
atographed before TMP and thereby helped to cut assay 
times -bu-t w 3s -i-es5 precise , m- ainihbacetophenone has a 
boiling point of 298°C but some losses, presumably due 
to decomposition occurred and care in controlling the 
temperature was required; when using this internal 
standard an evaporation temperature of 35°C was more reliable.
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The above highlights some of the difficulties of 
choosing an internal standard, particularly in the case 
of m-aminoacetophenone in which instance there was 
imprecision introduced into the assay due to the incon­
sistent performance of the internal standard.This type 
of behaviour has been reported before (Curry and Whelpton, 
1978). With care this problem could be avoided but 
resulted in a technically more demanding procedure. The 
potential for underestimating TMP with the diazepam 
internal standard is there, however the extent of the 
underestimation is difficult to judge, on the therapeutic 
doses which most individuals take typical peak levels are 
200 ug/1 with trough levels of around-100 ug/1; as 1250 ng 
of diazepam is added as internal standard then an error 
of around 10-20% could be expected, this is entirely 
unsatisfactory therefore both diazepam and m-aminoaceto­
phenone were latterly included in a composite internal 
standard.
As a matter of course quality control procedures 
were performed on all assays and this served to check on 
analytical credibility, and particularly of m-amino­
acetophenone performance.
The limits of linearity and sensitivity were 
adequate for the performance of meaningful pharmaco­
kinetic studies, the precision figures were acceptable.
No interferences have ever been noted in the assay either 
during volunteer studies or during the analysis of 
samples from the general population. The assay proved
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robust and reliable during operation and was technically
s i m p l e .
The performance characteristics of the modified 
assay may appear to be slightly worse than the original 
assay, due to the lower amount of substance presented by 
the autosampler and the use of nitrate causing a larger 
noise signal. The assay times were shorter and compat- 
ability between the autosampler's capacity and the 
limited solvent supply of the Varian 8500 pump was 
achieved (this pump is of the syringe-limited reservoir 
type). The lack of sensitivity resulting from the lower 
column loading by the autosampler was improved by reverting 
to manual injection, removal of nitrate and use of less 
ion-pairing agent could recover all the original sensit­
ivity. As sensitivity was not a problem time was not 
invested in such optimisation.
The classical procedure for the liquifaction of 
sputum is homogenisation but this could lead to problems 
of carryover and equipment sterility. It has been shown 
that N-acetylcysteine is a satisfactory liquefactant 
(Li, et al, 1980), however we chose to use 2,3 dithio- 
threitol (McIntosh, et al, 1983) which has the same net 
effect, the conditions we chose are also suitable for 
pasteurisation which would remove any danger from 
tuberculosis which is still fairly prevalent in the 
West of Scotland (SHHD Annual Report, 1983). The assays 
for both saliva and sputum have been found to perform 
satisfactorily.
2.13. CONCLUSION
In conclusion all the assays used in this study 
have been validated and found to perform well with the 
exception of the unextracted Bratton-Marshall procedure 
for urinary sulphonamides.
The great tragedy of Science - the slaying of a 
beautiful hypothesis by an ugly fact.
Thomas H. Huxley 1825-1895
CHAPTER 3
COMPARATIVE PHARMACOKINETICS OF CO-TRIFAMOLE AND 
CO-TRIMOXAZOLE TO ’STEADY-STATE’ IN NORMAL SUB3ECTS
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INTRODUCTION
3.1. TRIMETHOPRIM/SULPHONAMIDE SYNERGY
As sulphonamides and TMP both blockade the pathway 
of bacterial folate synthesis it was anticipated that 
the emergence of bacterial resistance would be significantly 
diminished by the use of a combination product.
To ensure the success of such a combination it 
would be desirable to maintain an inhibitory concentration 
of both drugs. Sulphamethoxazole (SMZ) had an elimination 
half-life that closely matched THP and was more potent 
than other similar sulphonamides. Thus these two compounds 
were formulated as co-trimoxazole. It has been shown 
that the synergy between TMP and SMZ is significant 
(Bushby and Hitchings, 1968), that it is maximal at a 
ratio of around 1:20 for most organisms (Bushby, 1973) 
and probably extends to the range 1:10 to 1:4-0 for SMZ 
and other sulphonamides (Brumfitt, Hamilton-Miller and 
Kosmidis, 1973; Ekstrom et al, 1979); the ratio reflects 
the relative potency of the drugs. As the apparent 
volume of distribution of TMP is of the order of 1 1/kg 
and that of SMZ approximately 0.2 1/kg (Schwartz and 
Rieder, 1970), to achieve the optimum ratio (i.e. 1:20) 
in serum a fixed dose combination in the ratio 1:5 
(TMP/sulphonamide) is required.
3.2. CLINICAL USE OF CO-TRIMOXAZOLE
Co-trimoxazole has been used succesfully in the
treatment of a wide variety of infections principally 
urinary tract infection (Reeves et al, 1969; Brumfitt
et al, 1969; Brumfitt and Hamilton-^Miller, 1979; 
Trimethoprim Study Group, 1981),and respiratory tract 
infections (Hughes et al 1969; Sordan et al, 1975). It 
has also been reported as effective against a number of 
other infections eg. typhoid (Snyder et al, 1973; Butler 
et al 1977); some protozoal infections, for instance 
those caused by Pneumocystis carnii. (Winston et al, 
1980); otitis media (3apan Co-operative Bacteriological Study 
Group for Co-trimoxazole, 1973) and gonorrhoea (Csonka, 
1969; Lawrence, Phillips and Nicol, 1973).
3.2.1. Alternative Sulphonamide/Trimethoprim 
Combinations
If it is assumed that the effectiveness in vivo of 
the combination is due to the synergy between TMP and 
SMZ then other sulphonamides should be acceptable 
substitutes for SMZ provided that they are equipotent 
with SMZ and their pharmacokinetics are similar.
On the basis of published half-lives Ekstrom et al
(1979) compiled a list of seventeen sulphonamides with 
elimination half lives ranging from 7-27 hours that 
would be suitable for pairing with TMP. From the known 
kinetics and potency this group examined the following 
sulphonamides in a multiple cross-over study: sulpha-
chloropyridazine, sulphadiazine, sulphaisodimidine, 
sulphamerazine and sulphamethoxazole (Ortengren 
et^al, 1979a ); from consideration of elimination
half-life and serum non-protein bound fraction sulpha­
diazine compared well with sulphamethoxazole with a
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longer half-life (10.214.1 hours as against 7.011.7 hours, 
n=7). Due to the higher concentrations achieved in urine, 
these authors have suggested that sulphadiazine would 
be a more suitable partner for TMP than SMZ in urinary 
tract infections which they confirmed subsequently in 
a comparative pharmacokinetic study .. (Ortengren , Magni 
and Bergan, 1979). These findings confirm the work of 
Andreason et al, (1978). Considering that sulphadiazine 
was introduced some twenty years prior to SMZ (Struller, 
1969) it is perhaps surprising that SMZ was originally 
chosen in preference although Reeves and Wilkinson (1979) 
suggest this may have been due to a misunderstanding of 
sulphadiazine kinetics leading to an inappropriately 
high dosage regimen.
Although Ortengren et al (1979a) dismiss sulphamoxole 
(SDMO) as having too low an intrinsic activity to be of 
interest and Struller (1968) states that SDMO is five 
times less active than SMZ, Seydel (1980) determined 
that there was significant synergy between TMP and SDMO 
in vitro and that such levels were obtainable in viv o .
Bohni (1976) found the in vitro action of SDMO/TMP to 
be sub-bacteriostatic and that organism regrowth could 
occur, however the experiments of Kuhne et al (1976) 
and Broughall et al (1979) on the inhibitory effect of 
urine from subjects taking the combination support.the 
view that bacteriocidal action will occur; on the basis 
of pharmacokinetic arguments Gladtke- (1980) suggests 
this action is due to synergy; however Reeves et al
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(1980a)found that SDMO had a shorter elimination half-life 
than SMZ and would not compare favourably with the half- 
life of TMP.
3.3. DOSING SCHEDULES FOR TMP/SULPHONAMIDE COMBINATIONS
The manufacturers’ recommended daily dose of the
TMP/sulphonamide combinations currently available 
is as follows: TMP/SMZ (co-trimoxazole), two tablets
twice daily i.e. TMP 320 mg/SMZ 1600 mg per day; TMP/ 
sulphadiazine (co-trimazine), one tablet twice daily 
i.e. TMP 180 mg/sulphadiazine 820 mg per day and TMP/
SDMO (co-trifamole) 2 tablet loading dose with one :v 
tablet twice daily thereafter i.e. the maintenance 
dose is TMP 160 mg/SDMO 800 mg per day. The lower doses 
decrease the risk of dose related side effects from 
either component. The fact that co-trifamole is given 
with a loading dose ensures rapid achievement of steady- 
state conditions. With co-trimoxazole therapy the larger 
doses used soon swamp any differences in SDMO kinetics, 
but the plasma and urine concentrations obtained using 
co-trimazine would not be expected to compare favourably 
with those of co-trifamole for at least the first 2 days.
3.4. CO-TRIFAMOLE
3.4.1. Clinical Use
Co-trifamole has been claimed to be effective 
in a variety of infections including those of the urinary 
tract (Eckstein, Etzel and Wesenberg, 1976; Peters,
Nuri and Po pa , 1977; Kaldeway, 1978; Leonetti, Crimi and 
Russo, 1980); the respiratory tract (Etzel, Neuhof and
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Wesenberg, 1976; Knothe et al 1978; Burkhardt and 
Undeutsh, 1978; Wettengel et al 1980) and the gastro­
intestinal tract (Etzel et al, 1976b).
One of the arguments advanced for the dosing 
regimen for co-trifamole was the prospect of a decrease 
in side-effects. In a study of 1371 subjects- taking. 
co-trifamole, 4.1% exhibited side effects (Etzel and 
Wesenberg, 1976) , whereas in a survey of 649 patients 
taking co-trimoxazole a rate of 8 , 0 1  was found (Lawson 
and 3ick, 1978). These figures support the regimen 
adopted for co-trifamole.
3.4.2. Pharmacokinetics
There is a paucity of data concerning SDMO kinetics, 
in the pharmacokinetic studies performed on co-trifamole. 
Kuhne et al (1976) did not calculate any parameters,
Seydel (1980) quoted a half life of 11±3 hours and Reeves 
et al (1980a) found a range of 7.2-9.8 hours. On the 
basis of pKa and consequently lipid solubility, Seydel
(1980) anticipated that SDMO would exhibit better 
penetration than SMZ and have a larger apparent volume 
of distribution than that of SMZ which has been found 
to be approximately 12 1 (Schwartz and Rieder, 1970: 
Welling et al, 1973). Reeves and Wilkinson (1979) 
subsequently quoted a value of 21 1 for the Vd of SDMO.
A comparative pharmacokinetic study of co-trifamole 
and co-trimoxazole was undertaken to investigate the 
implications for therapy of the disposition of the
components of the combinations and to determine the 
pharmacokinetic parameters for SDMO.
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3.5 CLINICAL
3.5.1. Subjects
Five male and five non-pregnant female subjects 
aged 18-25 years and of acceptable body weight (mean 
66.2 kg, range 58-80 k g ) part.icipated in a two-way 
crossover study of co-trimoxazole and co-trifamole. All 
were normotensive; and their haematological (full 
blood count, haemoglobin and packed'cell volumes) and 
biochemical (urea and electrolytes and liver function 
tests) profiles were within normal limits. Informed 
consent and ethical approval were obtained.
3.5.2. Study Design
The co-trimoxazole dosage regimen used was the 
standard treatment suggested by the manufacturers i.e. 
two tablets (each containing 80 mg TMP and 400 mg SMZ) 
orally and for a further nine doses every 12 hours , 
Co-trifamole was also administered according to the 
manufacturers recommended protocol i.e. a loading dose 
of two tablets (each containing 80 mg TMP and 400 mg 
SDMO ) followed by a maintenance dose of one tablet every 
twelve hours for nine doses.
This was a two-way crossover study with a three 
week washout period between study legs; the order of 
administration of regimens was randomized and balanced.
Nc concomitant medication was allowed one week 
prior to and during the study, although the minor 
analgesics aspirin and paracetamol were permitted up to
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48 hours prior to commencement. Alcohol was not permitted
4-8 hours prior to or during the dosing period. The subjects 
were required tc fast for 12 hours prior to each part of 
the study and for 4 hours following; the initial doses 
were taken with 100 ml of water, and volunteers were 
requested to restrict fluids (to water or fruit juices) 
for 12 hours prior to each leg.
3.5.3. Serum Collection
On the first day only,indwelling venous catheters 
were inserted into the cephalic vein and 10 ml blood 
samples drawn prior to the initial dose and thereafter 
at 0.5, 1, 2, 3, 4, 8 and 12 hours. Subsequently blood 
was obtained by venepuncture immediately prior to the 
morning dose and 2 hours after that dose for the remaining
days of the study. The blood was allowed to clot and was
centrifuged for 10 minutes at 2000 rpm. The serum was
removed and stored in two 1.5 ml aliquots at -20°C for
subsequent analysis.
3.5.4. Urine Collections
The bladder was emptied prior to medication and a 
50 ml aliquot kept at -20°C. After dosing, urine was 
collected between 0-12 hr and 12-24 hr on the first day 
and 24 hourly on subsequent days;' the volumes of the 
collections were noted and two 25 ml aliquots taken and 
stored at -20°C for subsequent analysis. The creatinine 
concentrations were measured in order to detect major 
errors in urine collection.
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3.6. ANALYTICAL
3.6.1. Assays
TMP and sulphonamide analysis were performed as 
described in section 2.7.6.i and 2.4.3.ii. A manual 
injection procedure was used. Sodium lauryl sulphate 
was added as ion-pairing agent as detailed in section 
2 .10.1. i .
3.6.2. Acetylator Status
The acetylator status of each subject was determined 
using the procedures described in section 2.5.1.
3.6.3. Pharmacokinetics
Over the initial period (0-12 hours) the observed 
serum concentrations and corresponding times to peak 
were taken as representing peak serum concentration and 
time to peak respectively. The area under the serum 
concentration time curve (AUC) was calculated from the 
12 hour data, extrapolating to the sensitivity of the 
assay (70 yg/1) using the trapezoidal rule.
The derived pharmacokinetic parameters were 
obtained by least squares linear regression analysis of 
the logarithm of serum concentrations against time 
from peak levels to 12 hours after the first dose, 
extrapolated to the sensitivity of the assay. First 
order one-compartment kinetics and complete absorption 
were assumed. The absorption rate constant was obtained 
by the method of residuals. The following equations 
were used to calculate serum pharmacokinetic parameters:
4-i0 0.693 ' . . _ 't£$ =  _____  Equation 3.1
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Vd   Equation 3.2
AUC.k . 
el
D
Cl =    Equation 3.3
AUC
where t-|3 = elimination half-life (h)
= elimination rate constant (h~^)
Vd = apparent volume of distribution (1)
D = dose (mg)
AUC = total area under the serum drug
concentration time curve (mg.hour/1)
Cls = total clearance of drug from
serum (1/h )
The mean achieved serum concentrations were compared
with those predicted using equations 3.4-3.7 and assumptions 
noted below.
k .F.D. a , * , , .
r - 3 , -k ,.t — k •t %
PRED ~ ________ -_ (e el - e a )
V<ka-'W
Equation 3.^.
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F.D
C MAX DDIrn ss PRED
m
V(l-e'ke l ’T )
Equa t ion 3.5 .
C s s AVEPRED
1.44.F.D .ti
m
Vt Equation 3.6.
C HINDDrn = C HAXDOCn.e‘kerTss PRED ss PRED Equation 3.7
where ka 
F
D . 
t 
V 
D
m
T =
absorption rate constant 
fraction of dose absorbed 
dose
time following dose 
volume of distribution 
maintenance dose 
dosage interval
(h-1 )
(mg) 
(h) 
(1) 
(mg) 
(h)
assuming: complete absorption for TMP, SMZ, and SDMO.
Following multiple dosing the time to 'steady 
state was taken as the time at which the average of 
the 'peak' and 'trough' serum values for a 24 hour 
period were within 10% of the average for one or more 
subsequent 2b hour periods (using levels at 2b and 26, 
48 and 50, 72 and 74 and 96 and 98 hours).
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RESULTS
3.7. SERUM
3.7.1. Serum Drugs Concentrations
The predicted and mean observed serum concentrations 
for TMP and SDMO following co-trimoxazole are given in 
tables 3.1 and 3.2 and for TMP and SMZ following 
co-trimoxazole given in tables 3.3 and 3.4.
3.7.2. Initial Dose
For the initial dose the predicted concentrations 
for all drugs are consistently higher, but within 1 sd , 
of the observed concentrations; the mean concentrations 
for both preparations are graphed in Fig. 3.1
3.7.3. Steady State •
The mean steady-state nadir levels compare well 
for TMP but the predicted peak levels are higher than the 
observed for SDMO, SMZ and TMP following co-trifamole.
Although the predicted levels following a single 
dose compare well with the observed for both SDMO, SMZ 
and TMP at steady state these were underestimates, but 
were within 2 sd of the observed levels.
The MIC for TMP and sulphonamides acting indepen­
dently are 1.5-2.5 mg/1 and 45-55 mg/1 (Reeves and 
Wilkinson, 1979)
Steady state conditions were achieved for both; 
components of co-trifamole earlier than for co-tri­
moxazole ,median 24 hours and 48 hours respectively' 
individual times are noted in appendix A. As would be 
predicted from the dosing regimens,the peak serum TMP
TABLE 3.1.
Observed (mean)and predicted TMP concentrations following
co-trifamole therapy ( n = 1 0 ) ________ ____________________
CONCENTRATION (mg/1)
range
Time mean sd low high predicted
0 0 0 0 0 0
0.5 0.97 0.69 0.08 2.15 1.43
1 1.48 0.50 0.61 2.33 1.79
2 , 1.57 0.24 1.25 1.90 1.82
3 1.58 0.29 1.16 1.98 1.71
4 1.35 0.30 0.79 1.68 1.59
8 1.12 0.20 0.77 1.40 1.21
12 0.86 0.12 0.65 1.02 0.91
24 0.91 0.20 0.60 1.J9
26 1.73 0.34 0.99 2.00 C MIN = 0 . 7 8  ss
48 0.85 0.18 0.51 ■1.11 C AVE = 1.29 ss
50 1.50 0.27 1.10 1.80 C MAX = 1.81 
ss
72 0.83 0.26 0.44 1.26
74 1.51 0.39 0.71 1.91
96 0.81 0.24 0.46 1.03
98 1.40 0.39 0.78 2.02
'
TABLE 3.2.
Observed (mean) and predicted SDMO concentrations
following co-trifamole therapy (n=1 0).
CONCENTRATION (mg/1)
range
Time (h) mean sd low high predicted
0 0 0 0 0 0
0. 5 46 27 2 97 57
1 69 26 17 105 72
2 80 26 38 132 72
3 72 15 48 88 66
4 67 13 43 82 60
8 49 12 28 57 40
12 34 13 18 449 27
24 38 17 16 71
2 6 76 24 27 111 C MIN = 18 ss
48 42 19 18 SO C AVE = 4 1  ss
50 75 27 3 a • 134 C MAX = 6 1  ss
72 42 21 15 77
74 75 31 29 136
96 41 20 16 ; 82
98 72 24 34 119
TABLE 3.3.
Observed (mean) and predicted serum TMP concentrations
following co-trimoxazole therapy _________  _____ _____
CONCENTRATION (mg/1)
range
Time (h) mean sd low high predicted
0 0 0 0 .0 0
0.5 1.07 0.33 0.64 1.80 1.57
1 1.55 0.35 0.95 2.33 1.97
2 1.76 0.25 1.10 2.14 2.00
3 1.64 0.26 1.13 2.03 1.88
4 1.52 0.29 1.02 1.98 1.75
8 1.21 0.24 0.93 1.60 1.33
12 0.90 0.2] 0.69 1.20 1.00
24 1.37 0.41 0.83 2.05
26 3.34 0.76 1.77 4.05 C MIN = 1.71 
ss
48 1.93 0.45 1.42 2.85 C AVE = 2.97 
ss
50 3.58 0.49 2.53 4.23 C MAX = 3.97 
ss
72 2.05 0.65 1.10 3.12
74 3.83 0.95 2.10 5.23
96 2.05 0.49 1.13 2.95
98 3.66 0.94 2.00 5.55
TABLE 3.4.
Observed (mean) and predicted serum SMZ concentrations
following co-trimoxazole therapy ( n = 1 0 ) ______________
CONCENTRATION (mg/i)
. range
T ime (h) mean sd low high predicted
0 0 0 0 0 0
0 .5 23 12 9 45 33
1 45 12 26 59 48
2 65 13 43 91 56
3 62 10 42 72 55
4 58 8 46 68 31
8 43 4 37 49 37
12 31 7 44 27
24 48 7 37 56
26 79 21 52 102 C MIN = 4 1  ss
48 65 12 39 81 C AVE = 72 ss
50 104 20 71 110 C MAX =108 ss
72 70 16 39 97
74 113 26 71 143
96 70 13 39 86
98 110 29 66 140
FIGURE
10
JL
0 
co
0
5 80 <
E
0
§ 6 0 .
r
a
3 40<
CO
E 20<
Du
0
CO
12
T im e (hr)
.1. Time v serum concentration curves following co-trifamole 
and co-trimoxazole for SDMO, SMZ and TMP.
• = co-trimoxazole
o = co-trifamole
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and sulphonamide concentrations obtained from 24 h onwards 
during multiple dosing with co-trifamole were significantly 
lower than for co-trimoxazole (p<0.05, t test) except 
at 24 h and 26 h .
3.7.4. Serum Concentration Ratios
Using the mean data and the predicted values 
the serum ratios for co-trifamole and co-trimoxazole 
have been calculated and are presented in tables 3.5 and 
3.6. .
Assuming the synergistic range to be 1:10 to 1:40, 
the predicted ratios for co-trifamole are initially at 
the extremes, however the mean observed ratios are 
consistently greater than40:l with a great deal of scatter 
over the observed range, the scatter is inter-individual 
rather than intra-individual. For co-trimoxazole the 
predicted and observed ratios tend to fall within the 
synergistic range and there is much less variation, 
this situation continued throughout the period of the 
study.
Statistically significant differences between 
treatments were noted at 26, 50, 74 and 98 hours (p<0.05, 
t test) .
3.7.5. Kinetics (Single Oral Dose)
Due to the small number of observations obtained
the absorption rate constant was calculated from averaged
data; the k of TMP was found to be 2,5 h” (for both a
preparations) and the for SDMO and SMZ to be 2.3 and 1.4 h“* 
respectively The mean (-sd) data on the serum pharmaco-
TABLE 3.5.
Serum ratio of SDM0:TMP following co-trifamole therapy
Time (h) mean sd
RATIO
range predicted
0 .5 84.3 138.2 25-477 40
1 47.7 17.1 27-85 40
2 51.0 14.9 28-82 40
3 46.2 10.4 29-68 39
4 52.1 19.5 37-104 38
8 44.4 13.9 31-78 33
12 39.7 14.1 18-63 30
24 41.7 20.1 27-92
26 43.] 9.3 27-56' a t C  MIN ss 23
48 49.5 20.9 17-96 at C AVE ss 32
5° 51.3 23.6 36-116 at C MAX ss
34
72 53.6 28.9 12-113
74 50.9 22.1 27-104
96 49.9 14.5 22-80
98 52.6 15.9 29-91
TABLE 3.6.
Serum ratio of'..SMZ: TMP following co-trimoxazole 
therapy _____ ________________ ______ '
RATIO
Time (h)- mean sd range predicted
0 .5 , 22.4 12.6 9-45 2!
1 31.3 13.5 17-60 24
2 38.1 9.4 23-51 28
3 38.3 6.3 27-51 29
4 38.8 5.3 28-49 29
8 35.9 4 .4 28-41 28
12 34.9 7.1 25-47 27
24 36.7 8.8 23-54
26 24.3 5.7 17-30 at C MIN ss 24
48 35.1 9.6 21-50 at C AVE ss
24
5° 29.2 4.6 20-36 at C MAX ss 27
72 37.2 13.2 19-64
74 30.6 6.9 17-41
96 35.6 10.9 20-58
98 30.7 7.2 19-41
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kinetics are reported in table 3.7, the individual data 
for each subject are reported in appendix A.
The area under the serum drug concentration-time 
curve was greater for SDMO than SMZ (p<0.05) There was 
no significant difference in the AUC for TMP using the 
two formulations although there were individual instances 
where this general observation did not hold true. In 
particular there were larger differences than anticipated 
between formulations for TMP in subjects 1, 3, 7 and 9 
and for sulphonamides in subject 3. The observed mean 
peak serum concentrations reflect the differences found 
for AUC between SDMO and SMZ and the similarities for 
TMP. There was no difference in time to peak between 
individuals.
The mean elimination half-life for SDMO is shorter 
than SMZ and is at the level of significance (0.1>p>0.05, 
t test), there was no statistically significant difference 
between the TMP elimination half lives although there 
was intra-individual variation. This and other estimates 
of elimination are noted in table 3.7.
There was no statistically significant difference 
between the serum clearance of TMP following the two 
preparations neither was there any difference between
the clearance of SDMO and SMZ.
The apparent volume of distribution for SDMO was 
less than for SMZ (p<0.05, t test); in two subjects 
(5 and 9) V d ’s were comparable. There was no statis­
tically significant difference between the V d 's for
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IMP between the two formulations; the inter-individual 
variation was more marked than the intra-individual / 
variation.
, / -3.7.6. Acetylator Phenotypinq
Using sulphadimidine, four of the nine subjects 
were found to be fast acetylators and five were slow 
acetylators; the acetylator status of one individual 
could not be determined as the subject was no longer 
available. For the fast acetylator group the mean (range) 
half-life of SDMO and SMZ were 7.3hi(4-.9-13.2h) and 
8.7 h (^f.7-12.6 h) respectively and for the slow acetylator 
group 9.0 h (6.6-11.0 h) and 9.7 h (7.6-13.9 h) respectively. 
Thus there was no correlation between acetylator status 
and SDMO or SMZ half-life.
3.8 URINE
3.8.1. Urine Concentrations
Disregarding synergy, the M I C ’s for sulphonamide 
and trimethoprim in urine may be considered to be 200 mg/1 
(Brumfitt et al, 1973) and 8 mg/1 (Huovinen, Mantyjarvi 
and Toivanen, 1982) respectively; the mean ~ urinary data 
are given in table 3.8. However following co-trifamole 
therapy no individual had a urinary SDMO concentration 
that consistently exceeded 200 mg/1; with the higher 
doses used in co-trimoxazole therapy this level was 
achieved, but only one subject (subject 3) consistently 
exceeded this figure. The individual data are reported 
in appendix A.
In all urine collections the TMP concentration
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were in excess of 2 mg/1; the lowest concentration 
following co-trifamole therapy was 34 mg/1 and following 
co-trimoxazole therapy 30 mg/1.
Urinary TMP and sulphonamide concentrations achieved 
during the first 12 hours following the initial dose 
were not significantly different for the two preparations. 
However, TMP concentrations achieved during the 12 hour 
to 108 hour period were significantly lower following 
co-trifamole therapy,as was expected; similarly SDMO 
concentrations were lower than SMZ over the same period 
(p<0.05, t test).
3.8.2. Urine Concentration Ratios
The mean urinary sulphonamide:TMP ratios for the 
different collection periods during co-trimoxazole and 
co- trifamole therapy are given in table 3.9.
Urinary sulphonamide to TMP concentration ratios 
for both co-trimoxazole and co-trifamole were similar 
with mean ratios ranging from 1.2 to 2.4. The highest 
individual ratio was 4,1.
3.8.3. Cumulative Urinary Excretion
The mean cumulative excretion of the sulphonamides 
from 0-108 hours following co-trifamole and co-trimoxazole 
therapy were 791.5 mg (393.2-1296.2 mg) and 1046.9 mg 
(619.8-1545.0 mg) i.e. 18.0% (8.9-29.5%) and 13.1% 
(7.7-19.3%) respectively; the corresponding figures for 
TMP were 425.7 mg (305.7-504.4 mg) and 750.4 mg (579.9- 
944.1 mg) i.e. 48.4% (34.7-57.3%) and 46.9% (36.2-59.0%) 
respectively. The differences in amount excreted but not 
percentage excretion was statistically significant (p<0.05).
TABLE 3.9.
Urinary SDMO;TMP and SMZ:TMP ratios during therapy
Time(hrs) 0-12 12-24 24-48 48-72 72-96 96-108
SDMO:TMP 
mean 
sd 
range
2.4 
0.5 
1.4-3.1
1.5 
0.6 
0.5-2.4
1.6 
0.7 
0.7-3.1
2.0 
1.1 
0.7-3.7
2.0 
1.1 
0.8-3.9
2.0 
1.2 
0.8-4.1
1.6 1.8
0.9 0.9
0.6-3.8 1.0-3.5
SMZ:TMP
mean 2.2 1.3 1.5 1.2
sd 0.8 0.8 0.7 0.5
range 1.4-3.4 0.4-2.5 0.6-3.0 0.7-2.0
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DISCUSSION
3.9. SERUM
3.9.1. Serum Drug Concentrations
As would be anticipated there was good agreement 
of TMP concentrations following the initial dose.
SDMO levels were higher than, those of SMZ and may 
reflect differences in the completeness of absorption 
but mere probably the difference in volume of distribution.
3.9.2. Initial Dose
The predicted single dose concentrations for TMP 
are within one sd of those observed.
The predicted sulphonamide concentrations following 
the initial dose of co-trifamole or co-trimoxazole are 
lower following mean time to peak although always within 
one sd of those observed.
3.9.3. Steady State
The predicted CssMIN and ^ssMAX for TMP were
within 1 sd of those observed for TMP. The difference
in predicted TMP levels found during subsequent doses
is due to the use of the different mean V d ’s found
for each preparation, although the differences were
not statistically significant fcr both SMZ and SDMO.
C MAXnnrri was also within one sd of the observed mean, ss PRED 7
however C MINnDrn for both SDMO and SMZ are notably ss PRED J
lower than the mean trough levels although within two 
sd. Thus use of a one compartment open model with 
first order kinetics provides an adequate approximation 
for the observed data.
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The observed steady state SMZ peak and trough 
levels of 109 mg/1 and 70 mg/1 respectively compare 
with levels found by others using specific liquid 
chromatographic procedures having made appropriate 
adjustments for dosage as required with mean peak and 
trough levels of 110 mg/1 and 62 mg/1 (Vree et al, 1978; 
Siber et a l , 1982; Spicehandler, et al 1982). Ortengren 
et a l , (1979a,b ) , using the Rieder assay, found peak and 
trough levels of 106 mg/1 and 60 mg/1 W h i c h  again compare 
with the current study but are in marked contrast to 
the peak and trough levels of 84 mg/1 and 50 mg/1 
reported by Reeves et al (1980). One report (Nolte and 
Buttner, 1974) found SMZ trough leveTs ranging from 
30-50 mg/1 as did Reeves and Wilkinson, (1979) and Bergan 
and Brodwall (1972).
It is difficult to explain these differences as 
the assays used by all workers appear to be accurate 
with minimal interference. There may have been differ­
ences in the purity of material used in the preparation 
of calibrators but this supposition cannot be substantiated.
The differences noted above are important as the 
study of Reeves et al (1980a) is one of only two detailed 
papers on the comparative kinetics of SDMO and SMZ, the 
other report derives from this work (Watson et al, 1982).
The mean peak and trough SDMO levels reported herein 
were 75 mg/1 and 42 mg/1 and in the study of Reeves 
et al (1980a) 50 mg/1 and 23 mg/1 respectively. In 
Support of the higher levels reported here,, trough 
SDMO levels of 46 mg/1 were found by Kuhne et al (1976)
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If the MIC values of 1.5-2.5 mg/1 for TMP and 45-55 mg/1 
for sulphonamide(Reeves and Wilkinson, 1979) are relevant 
in serum then the trough levdls of SDMO found in this 
study are inadequate while the levels of TMP achieved 
throughout the period of co-trifamole therapy are also 
inadequate if the drugs were to act independently, indeed 
while the SMZ levels are acceptable, TMP levels following 
co-trimoxazole therapy are barely adequate; considering 
that such levels can easily be predicted it may seem 
surprising that the lower dose regimen of co-trifamole 
was considered. Consequently there is an increased 
reliance on synergy for adequate effect.
3.9.4. Serum Concentration Ratios
Co-trimoxazole is formulated in the ratio TMP:SMZ 
(1:5) To attain ratios between 1:10 and 1:40 in vivo, 
the limits of optimal synergy (Schwartz andRieder, 1970; 
Brumfitt et a l , 1973). This w a s  achieved in nearly all 
individuals for co-trimoxazole; however the greater relative 
"availability" of SDMO due to its poorer distribution 
means that higher concentrations are achieved during co- 
trifamole therapy and consequently the majority of subjects 
had ratios well in excess of the optimum for synergy, with 
considerable inter-individual scatter. The use of the 1:5 
formulation may seem inappropriate for co-trifamole 
however the percentages of free i.e. unbound TMP, SDMO 
and SMZ in serum are 55, 10 and 20% respectively (Seydel, 
1980), therefore for co-trifamole and co-trimoxazole 
during treatment the respective mean serum ratios
achieved are between 7 and 15 which is the lower range 
for optimal synergy in vitro. Synergy in serum is not 
usually relevant to treatment of the infected site as 
the degree and rate of penetration from the plasma 
water for the drugs may well differ and is reflected 
in reported T M P :sulphonamide ratios for sputum of 
1:1.25 (Reeves and Wilkinson, 1979) and cerebrospinal 
fluid of 1:1.6 (Bach, Gold and Finland, 1973).
The anticipated dose-dependent differences in 
concentration are seen following multiple dosing. The 
expected rates of achievement of steady state for the 
two preparations were found.
3.9.5. Kinetics (Single Oral Dose)
i ) Absorption
Although there are a large number of studies 
on the pharmacokinetics of TMP and SMZ they contain 
minimal derived pharmacokinetic parameters, thus comparison 
with other studies can be difficult particularly if 
any discrepancy exists.
Due to the small number of data points on each 
individual,k could not be reliably calculated, however
a
the use of meaned values enabled estimates of k to be
a
made using the method of residuals. The k^ for SMZ 
was found to be 1.4 h  ^ which compares very well with 
the mean value obtained by Ortengren of 1.36 h"^ .
(Ortengren, et al, 1979a) and 1.29 h * (Ortengren, et al 
1979b). Reeves et al (1980a)obtained an "invasion rate" 
of 0.4 h, assuming that this phrase refers to the
104-
absorption half-life then a k of 1.7 h”  ^ is obtained.
a
The k^ for TMP of 2.5 h  ^ found in this work agrees
with the value of Kasanen et al (1978) of 2.54 h r a t h e r
than the value of 1.79 h”* found by Ortengren et al
(1979b). The k for SDMO.of 2.3 h  ^ is lower than thea
value of 3.5 h  ^ derived from the "invasion rate" of
Reeves et al (1980 a); thus absorption is rapid for all of
the drugs.
ii) Volume of distribution
The Vd obtained for SMZ of 12.012.3 1 compares
well with the .values of 12.3, 10.8, 12.5t2.1 and 15.4 ;
obtained by other workers (Schwartz and Rieder 1970;
Welling et al, 1973; Ortengren et al, 1979a and Ortengren
et a l , 1979b ) .
There are some discrepancies in the literature
as to the Vd of TMP; the mean values obtained in this
study were 71.3 and 77.8 1 which compares with V d ’s
of 71.7 + 4.9 1 found by Kasanen et al (1978) and y s ^ l ^  1
(derived) found by Ortengren et al (1979b). This is in
contrast to the higher values reported by other workers
of 94 1 (Schwartz and Rieder, 1970), 100 1 (Nolte and
Buttner,1973; Naber, Vergin and Weigard,1981), 126 1
1982
(Liedtke and Haase, 1979 and 143 1 (Singlas et al). The 
large Vd of TMP reflects its uptake into the tissue 
compartment and is affected by body weight. It is possible 
that some of these differences could be resolved by the 
use of normalised data. The lower estimates of Vd tend 
to have been determined on a larger number of individuals
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and thus a more statistically representative sample of
the general population is likely to be found. Wilkinson
and Reeves (1979) quote a range of 69-130 1.
The Vd of SDMO has been quoted as 21 1 (Wilkinson
and Reeves, 1979), although there is no evidence presented
for this. Using data from Reeves et al (1980a)the Vd
may be calculated as 11 1 which is much closer to the
value found in this study.
iii) Elimination
Elimination half-life for SMZ was found to
be 9.112.6 hours which compares with previous reports
of 9.0 (Schwartz and Rieder, 1970), 8.7 hours (Welling
et al, 1973) 9.5 hours (Kaplan et al, 1973), 9.6-11.2 hours
(Reeves et al, 1980a)and 7.7-10.7 hours (Ortengren, 1979b),
the report of Ortengren et al, (1979a) quotes a slightly
shorter half-life of 7.Oil.7 hours. Serum clearance of
1*0.2 lh”  ^ is similar to that of Ortengren et al (1979a;
1979b) of 1.13±0.3 and -I.33i0.45- respectively.
There: has been less consistency in the quoted
elimination half-life of TMP. The mean half-lives for
TMP in this study were 10.5 and 11.0 hours, this compares
with 8.8±0.8 hours (Kasanen et al, 1978), 8.6 hours 
(Schwartz and Rieder, 1970), 9.4.hours (Nolte and Buttner
1973) 9.6±2.7 hours (Ortengren, 1979b) and somewhat
higher, 14.5 hours (Kaplan et al, 1973). The serum
clearance of 5.Oil.7 lh~^ compares with 4.5 l h f o u n d
by Ortengren et al (1979b) and 5.76 lh  ^ found by
Kasanen et al (1978).
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A half-life of 11±3 hours for SDMO was given by 
Seydel, (1980) although the derivation of this not clear. 
In the current study an elimination half-life of 8±2.8 h 
was found and compares with the half-life of 7.2-9.8 h 
found by Reeves et al (1980a).As these elimination half- 
lives are lower than those commonly found for TMP, SDMO 
is thus no better a match than SMZ on "kinetic" grounds 
for combination therapy; in addition SDMO is five times 
less active than SMZ (Struller, 1968) and with a Vd 
similar to SMZ there is no advantage in the substitution 
of SDMO for SMZ.
3.9.6. Acetylator Phenotyping
Acetylator phenotyping was performed to ascertain 
if there was polymorphic metabolism of SDMO,as this 
had not previously been investigated. There was no 
evidence that polymorphism existed in this small group 
of subjects.
The time to steady state reflected the dosing 
regimens, as stated in the introduction the use of a 
loading dose is not necessary in co-trimoxazole therapy 
but as the levels attainable with the co-trifamole 
regimen are lower it is necessary to achieve steady 
state as soon as possible.
3.10. URINE
3.10.1. Cumulative Urinary Excretion
The mean fraction of SMZ excreted was 13.1% 
which compares with other reports (Ortengren et al, 1979b) 
although the TMP recovery of 48% was somewhat lower
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than the 58% found by the same author, Kasanen et al,
(1978) obtained 51-60% recovery. As TMP excretion in 
urine is pH dependant (Sharpstone, 1969) there may have
' ■  i  -
been some differences in the groups. There are no 
directly comparable data available for SDMO.
3.10.2. Urine Concentrations
There is little doubt that co-trimoxazole is 
effective in the treatment of urinary tract infection 
(Reeves et al, 1969; Acar et al, 1979; Ekstrom et al,
1979), co-trifamole has been found to be as effective 
as co-trimoxazole (Eckstein et al, 1976; Helwig et al,
1976; Peters, et al, 1977) and TMP has been found to 
be as effective as co-trimoxazole (Brumfitt and Pursell, 
1972; Kasanen et al, 1978; Lacey et al, 1980; Kasanen 
et al, 1983) or even better (Brumfitt et al, 1982). 
Obviously the efficacy may be considered as being compr 
arable.
The lower maintenance dose of co-trifamole inevitably 
results in lower concentrations of sulphonamide and 
trimethoprim in the urine. If synergy occurs in Urine 
then sensitive organisms should be eradicated,if there 
were no synergy then the organisms would be controlled 
by the independent actions of the component drugs.
Although the MIC in urine for sensitive organisms 
has been quoted as approximately 200 mg/1 for sulph- 
onamides and 2 mg/1 for TMP (Brumfitt et al, 1973, an MIC 
of 8 mg/1 has been suggested for TMP in urine by Huovinen 
et al, (1982). The urinary SDMO levels, and to lesser
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extent urinary SMZ levels, are intermittently below 
the MIC in all subjects, except subject 3 when on 
co-trimoxazole, whereas even the higher MIC for TMP is 
exceeded by all subjects by at least a factor of 4 and 
usually much more at all points. In addition to this 
must be considered the ratios of TMP/sulphonamide achieved.
3.10.3. Urine Concentration Ratios
In vitro the range of optimal synergy for TMP/SMZ 
is 1:10 to '1:40 (Ekstrom et al, 1979), although synergy 
may occur outwith this range it would be expected to be 
of a lesser order of magnitude as indeed was found by 
Bushby and Hitchings (1968). The highest ratio for co- 
trimoxazole was 1:3.8 and for co-tri’f amole 1:4.1, 
substantially below optimum synergy. In addition SDMO 
is intrinsically about five times less potent than SMZ 
although this effect is not maintained on in vitro 
testing in combination with TMP (Reeves, Bywater and 
Holt, 1980) which is in contrast to the results of 
Bohni (1976). Rieder et al (1974) after noting the 
attainment of sub-optimal ratios suggest that the high 
levels of TMP will compensate for this. A further 
factor that requires consideration is that although TMP/ 
SMZ was initially claimed to be bacteriocidal in urine, 
it has subsequently been shown to bacteriostatic (Lewis, 
Anderson and Lacey, 1974; Anderson, et al, 1974).
The reason for this anomaly may be that the sulphonamide 
component was either swamped by the action of 
TMP (Greenwood and O'Grady, 1976) or that 
the action of TMP was antagonised by the presence
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of SMZ in the urine (Anderson, Sellin and Lacey, 1973; 
Anderson et al, 1974) and indeed any bacteriocidal action 
was due to the TMP component (Lewis et, 1974). It is 
probable that antagonism is the cause of the result , 
reported by Kasanen et al (1983 ),that TMP alone had a 
higher cure rate than co-trimoxazole; they also noted 
fewer side effects for TMP alone which reflects the 
findings of Lacey et al (1980); and Brumfitt et al (1982).
It therefore seems reasonable to anticipate that 
the explanation of the comparable efficacy of co-trimoxazole, 
co-trifamole and TMP alone in urinary tract infection is 
due to the reliance of the combination products principally 
on the effect of TMP.
It is of interest to note that one of the first 
papers on co-trimoxazole therapy in urinary tract 
infection (Reeves et al, 1969) noted that effectiveness 
could be related to the organisms susceptibility to TMP.
3.11. CONCLUSION
The argument for TMP alone in urinary tract and 
other infections is very strong. There is agreement 
amongst a number of authors who have reached this 
conclusion on the basis of bacteriological findings 
in vitro (Anderson et al, 1973; Lewis et al, 1974) , 
clinical cure rates (Kasanen et al, 1978; Brumfitt and 
Hamilton-Miller, 1979; Lacey et al 1980; Brumfitt and 
Hamilton-Miller, 1980; Trimethoprim Study Group, 1981; 
Brumfitt and Hamilton-Miller, 1982; Brumfitt et al 1982; 
Kasanen et al, 1983) and on pharmacokinetic grounds.
(Reeves and Wilkinson, 1979; Wilkinson and Reeves, 1979 
Watson et al, 1981; Watson et al, 1982).
New things are made familiar, 
and familiar things are made new.
Samuel Johnson 1709-1784 
Lives of the English Poets
CHAPTER 4
THERAPY WITH TRIMETHOPRIM ALONE: 
PHARMACOKINETICS OF TRIMETHOPRIM 
AT TWO DOSAGE LEVELS
Ill
INTRODUCTION
4.1. THE CHANCING RATIONAL OF THERAPY WITH TMP AND ITS
RELATIONSHIP TO BACTERIAL RESISTANCE
4.1.1. Trimethoprim Resistance
When TMP was first marketed it was available only in 
combination with SMZ, as it was anticipated that the 
mechanism of sequential blockade would afford protection 
against the emergence of resistance, particularly to TMP 
(Darrell, Garrod and Waterworth, 1968)
Sequential blockade is however unlikely to be syner­
gistic (Lacey, 1979; Lacey, 1982), the synergism observed 
is more probably attributable to the simultaneous blockade 
of dihydrofolate reductase by both TMP and sulphonamides 
(Poe, 1976), thus sulphonamides would have two modes of 
action and may not therefore protect against the emergence 
of TMP resistance in vivo (Lacey, 1982).
TMP resistance is R factor mediated (Fleming, Datta 
and Gruneberg, 1972) and is a high level resistance.
The antibacterial action of TMP is due to thymineless 
death (Then and Angehrn, 1973; Then and Angehrn, 1974) , 
thus bacteria able to utilise thymine or other sources 
for the production of thymidylate, a cofactor in bio­
chemical reactions, will be resistant to the action of 
TMP (and sulphonamides) (Then and Angehrn, 1974).
TMP resistance may also be due to insensitive dihydrofolate 
reductase (Then and Angehrn, 1979) presumably due to 
deviations from the normal conformational state; pteridine 
dihydrofolate reductase inhibitors had similar potency 
to TMP which is in keeping with the finding that dihydro­
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folate reductase bound TMP is very similar in conformation 
to dihydrofolate reductase bound methotrexate (Roberts 
et a l , 1981).
TMP sensitivity in general practice and hospital 
populations was virtually unchanged during the period 
1971-1978 (Grunberg, 1980), while TMP was available 
only in combination with a sulphonamide, about 5% of 
urinary E .Coli were found to be resistant. In Finland 
TMP alone was available for use from 1973, and initially 
there was a low incidence (<1%) of resistant strains 
(Kasanen et al 1978), however the level of resistance in 
another Finnish study was found to be 20.3% in outpatients 
and 39.8% from in-patients (Huovinen and Toivanen, 1980). 
The same authors found lower levels of resistance in two 
acute hospitals in the same city of 12.2% and 8.6%, 
(Huovinen, et a l , * 1982 ) . A comparative
study during 1977-1978 between resistance in long-stay 
hospitals in Finland of 49% and resistance in Sweden of 
3.6% (Dornbusch and Toivanen,1981) was said to reflect 
the level of usage of TMP alone in the Finnish hospital.
In 1973 TMP resistance in the U.K. was 11.5% 
(Hamilton-Miller, Gooding and Brumfitt, 1981) and in 
1979 was 12.4% (Brumfitt, Hamilton-Miller and Gooding,
1980) however in 1979 resistance in certain genera showed 
increases especially for E .Coli and Proteus. During 
this period TMP was only available with SMZ in the U.K. 
Covering a slightly later period an increase in high level 
plasmid or transposon mediated resistance was noted for 
E .Coli (Kraft, Platt and Timbury, 1984).
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Currently the extent of use of TMP alone is too low, 
and the period of its use in this was may be too short to 
allow clear conclusions to be drawn as to the probability 
of increased resistance to TMP alone; however in 1981 
the incidence of TMP resistance was levelling off 
(Brumfitt, Hamilton-Miller and Wood, 1983). The level 
of TMP resistance found during the period prior to its 
being available as a single drug formulation indicates 
that the sulphonamide component did not protect against 
the emergence of resistance to TMP, particularly as the 
incidence of sulphonamide resistance was higher during 
this period, of the order of 30% or higher depending on 
the strains (Huovinen and Toivenen, "1980; Gruneberg,
1980; Dornbusch and Toivanen, 1981), and thus the use of 
TMP alone may not be disadvantageous, restriction of its 
use only being necessary in certain clearly defined 
circumstances (Kasanen et al, 1983). Additionally 
Lacey et al (1980) concluded that TMP rarely selected 
for resistance, although epidermal staphylococci did 
show an increase in resistance.
4.1.2. Use of Trimethoprim Alone
Opinion is moving towards the use of TMP alone in 
certain circumstances (Reeves, 1982; Brumfitt and Hamilton 
Miller, 1982; Salter, 1982; Lacey, 1982) and its breadth 
of application and frequency of use is likely to increase. 
It is particularly appropriate in the treatment of 
uncomplicated urinary tract infection (Kasanen et al, 1978 
Lacey et al, 19S0, Trimethoprim Study Group, 1981 Neu, 1982)
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4.1.3. Pharmacokinetics
TMP as a single drug formulation was introduced in 
the U.K. in 1981 for use in urinary tract and other 
infections, but two different dosing schedules were available. 
Brumfitt and Hamilton-Miller (1980) have observed that 
detailed pharmacokinetic studies are necessary to decide 
upon appropriate dosage regimens for use of TMP alone and 
also to ensure that there was no variation between different 
brands, a problem previously encountered with nitrofurantoins 
(Di Santo et a l , 1976).
A study was therefore undertaken of serum and urinary 
TMP concentration in normal subjects taking two different 
TMP preparations according to the manufacturers recommended 
regimens (200 mg twice daily or 300 mg once daily); 
the pharmacokinetics and the relative bioavailability 
of the two preparations were examined.
MATERIALS AND METHODS •LX^
4.2. CLINICAL 
   4.2.1. Subjects
Volunteers were admitted to the study subject to being 
of acceptable weight (mean 72.1 kg) (within 25% of desirable 
weight for height, weight and sex), with normal blood 
pressure, normal haematological profile (differential 
white count, ESR and platelets) and normal biochemical 
profile (urea and electrolytes and liver function tests).
The individual sex, age and weights are given in appendix B.
4.2.2. Dosage Regimen
This was a two way crossover trial in which the order 
of administration of treatment was randomised and balanced. 
There was a four-week wash-out period between each leg 
of the trial.
Administration was of either 300 mg TMP every 24 hours 
for 5 doses or 200 mg TMP every 12 hours for 10 doses.
Mean doses were 5.95 and 4.47 mg/kg/day respectively.
No alcohol was permitted for 24 hours prior to, and 
during the administration of TMP, and no concomitant 
medication was allowed prior to or during the study period. 
Subjects were fasted for 12 hours prior to and 4 hours 
after the initial dose; no fluid was allowed 2 hours prior 
to the initial dose, thereafter there were no fluid or 
dietary restrictions. The medication was taken with 100ml 
of water on each occasion; following the initial dose 
100ml water was taken every hour for 4 hours to ensure 
adequate urinary production.
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4.2.3. Serum Collection
On the first day of each leg an indwelling catheter 
was inserted into the cephalic vein and 10 ml samples of 
blood drawn pre dose and at 0.5, 1, 2 , 4 ,  7, and 12 hours 
after the initial dose. Thereafter samples were obtained 
by venepuncture immediately prior to the morning dose 
(0900) and 2 hours afterwards. The blood was allowed to 
clot, centrifuged at 1500g for 10 minutes, the serum 
removed and stored in 1.5 ml aliquots at -20°C prior to 
subsequent analysis.
4.2.4. Urine collection
The bladder was emptied prior to the first dose and 
2x20 ml aliquots of urine collected. After the initial 
dose complete urine collections were made for the following 
times: 0-2, 2-4, 4-6, 6-8, 8-12, and 12-24 hours. Following 
completion of a collection period the urine volume was 
recorded, the pH measured and 2x20 ml aliquots retained and 
stored at -20°C for subsequent assay.
4.2.5. Adverse Reactions
Three subjects complained once each of headache 
during treatment with the 300 mg tablet.
4.3. ANALYTICAL
4.3.1. Trimethoprim Estimation
Concentrations of unmetabolised TMP were determined 
using the LC assay described in section 2.7.6; the 
instrumentation configuration was the grouping described 
in section 2.6.2. (2) and the assay calibrated and quality 
controlled as previously detailed (section 2.6.-1.).
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4- • 3 • 2 . Pharmacokinetic Parameters
i ) Serum
The criteria for peak serum concentration, time to 
peak, derived and predicted pharmcokinetic parameters following the 
initial dose and the criteria for achievement of steady 
state were as described section 3.6.3.
ii) Urine
The highest observed urinary TMP concentration and 
the time at which this occurred relative to dose are 
referred to as peak urinary concentration (C^MAX) and 
time to peak (T^MAX) respectively. The observed peak 
urinary TMP excretion rate is C^MAX.V.
Renal clearance (C1r ) for a given collection 
period was calculated from the following equation:
C .V u
Cl = *—r—  Equation 4.1.
r C
s
where Cu is the average urine concentration per collection
period, V is the average urine flow per collection period
and C the mid-point serum concentration, 
s
4.3.3. Statistical Analysis of Data
Appropriate parametric and non-parametric statistical 
tests were applied to the data as indicated in the method 
section. Where the results for the two preparations are 
compared, the correlation co-efficient, r, was calculated 
using a least squared regression programme. The limit 
of statistical significance was p<0.05.
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4.3.4. Clinically Effective Trimethoprim Levels 
TMP levels considered desirable i.e. in excess of 
the MIC of common sensitive pathogens were taken as 
2 and 8 mg/1 for serum and urine respectively.
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RESULTS
4 - . SERUM KINETICS
4.4.1. Single Dose Pharmacokinetics
i ) Predicted and observed concentration
The predicted and mean (± s.d.) and range of observed
serum concentrations for both preparations at the different 
sampling points are presented in t a b l e -4.1.■ Following 
the initial dose the predictions are higher than the 
observed mean serum concentrations although W i t h i n
one s.d. The s.d. on 200 mg b .d 0.5 hr and 300 mg o.d.
0.5, 1, and 2 hours are large and the observed mean 
values are notably lower than the predicted values.
Sub ject 5 had unusual absorption characteristics; omitting 
this subject from 300 mg o.d., (0.5, 1 and 2 hours) resulted 
in mean values of 2.0, 3.1, and 2.8 mg/1 respectively and 
omission of subjects 5 and 8 from 200 mg b .d . (0.5 hr) 
resulted in a mean concentration of 2.2 mg/1.
The predicted and observed mean trough serum 
concentrations agree well for both regimes; predicted 
CssMAX is higher than the observed concentrations 2 hours 
following dose at steady state.
ii) Absorption
The lag times of absorption for both preparations 
was the same at 0.2 hours, the k for each preparation was
a
calculated from mean serum concentration to minimise
error and were found to be 3.01 h”  ^ for the 200 mg b.d.
preparation and 2.77 h~^ for the 300 mg o.d. preparation.
The k for subject 5 following the 300 mg dose is notably 
a
TABLE 4.1
Mean, s.d. and range of serum TMP levels following 200 mg b.d. and 
300 mg o.d. (mq/1) . ____________     ■_____
Preparation 200ma b.d. 300ma o.d.
Time X s.d : range Predicted X
■
s.d range Predicted
0 0 0 0 0 0 0 0 0
0.5 1.2 0.7 <0.07-2.1 1.8 1.8 1.0 <0.07-2.9 2.7
1 2.1 0.6 0.8-2.6 2.3 2.9 1.1 0.9-4.6 3.4
2 2.1 0.4 1.4-2.8 2.1 2.6 0.8 1.0-3.3 3.4
4 1.8 0.3 1.3-2.4 2.0 2.6 0.5 1.7-3.1 3.0
7 1.4 0.3 1.0-1.9 1.6 2.1 0.3 1.5-2.4 2.4
10 1.2 0.3 0.9-1.7 1.3 1.8 0.4 1.3-2.2 2.0
12 1.0 0.2 0.8-1.3 1.1 1.5 0.4 0.9-1.9 1.7
24 1.5 0.3 1.0-1.8 - 0.8 0.3 0.5-1.3 0.7
26 3.4 0.8 2.2-4.6 3.3 1.0 1.6-4.5
48 2.1 0.6 1.1-3.2 1.1 0.3 0.8-1.7
50 3.8 1.0 2.3-5.3 4.0 1.0 2.6-5.5
72 2.2 0.6 1.4-3.1 1.0 0.4 0.1-1,3
74 4.0 0.9 2.3-4.9 3.8 0.8 2.3-4.8
96 2.1 0.7 1.1-2.9 1.3 0.6 0.5-2.3
98 4.0 0.8 2.7-5.1 3.8 0.6 2.4-4.4
C MIN ss - - - 2.0 - - 0.9
C AVE ss 3.1 0.7 - 3.3 2.5 0.5 - 2.5
C MAX ss - - - 4.5 - - - 4.7
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slower than this at 0.7 h~^; it was not possible to 
calculate the for this individual during the 200 mg b.d. 
regimen as was observed at 1 hour.
The mean serum pharmacokinetics are presented in 
table 4.2. The individual data are contained in appendix B. 
The median time to maximum concentration was identical 
and the ratio of means was 0.688, the expected ratio
is 0.67.
iii) AUC
As expected the AUC for the 300 mg o.d. dose is 
significantly different from that for the 200 mg b.d. 
dose (p<0.001, paired t test); the predicted AUC is 
higher than the mean in both cases as would be anticipated 
from the calculated values in table 4.1.
The AUC ratio for the 200:300 mg dose is 0.64 
showing equivalent bioavailability (predicted ratio is
0.67) .
iv) Volume of distribution
The mean volumes of distribution are comparable 
and are in agreement with the values obtained in Chapter 3. 
The inter-individual variation was greater than intra­
individual variation and this was confirmed on examination 
of normalised Vd, this approach minimised differences 
due to weight and indicated good agreement.
v ) Elimination
The elimination half-life, elimination rate constant 
and serum clearance are in good agreement with the mean 
values between the preparations and those previously
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reported in chapter 3. There was however marked inter 
and intra subject variation, particularly the elimination 
half life found for subject 4.
4.4.2. Steady State
There was no significant difference in time to
steady state and C peak between treatments (p<0.05),s s
there was a significant difference between treatments
for C trough (p<0.0001, t test), 
s s
Comparable bioequivalence was again confirmed as
the observed ratio for C MIN (200 mg b.d./300 mg o.d.)
s s
was 2.0 and the predicted ratio was 2.2.
Throughout the 300 mg b.d. treatment no subject
attained a Css trough of 2 mg/1, on 200 mg b.d. three
subjects (3, 4 and 3) did not exceed 2 mg/1.
The mean observed C AVE for 300 mg o.d. and 200 mg
s s
b . d . were 2 . 5±0 . 5 mg/T and 3.1*0.7 mg/1 respectively;
the predicted C AVE . levels., (table.'4.1) were 2,5 and 3.3mg/l
respectively.
4.5. URINE KINETICS
4.5.1. Cumulative Excretion
The mean cumulative excretion of TMP over 96 hours 
for the 200 mg preparation was 575 mg (range 491-640 mg)
i.e. 35.9% (30.7-40.0%) and 300 mg-was 497 mg (range 
402-581 mg) i.e. 41.4% (33.5-48.4%) of the dose.
4.5.2. Urinary Concentrations
The mean and range of observed urinary TMP for 
each collection period during the first 24 hours for 
both regimes (table 4.3) shows that for both preparations
co
d-
LlJ
_J
CD
<
H—
.
</>
-C
<Sr
CM LA CM
i d- CO 0\
O CM V0 CM d - i-H
v—' i i-H 1 i
CM <—t <h 00
•D i-H d- CM.
O
•H
U
0
Q.
O V0
C CM i-H I"-' ■
o r-H Ov •— 1 IA i-H
•H I d- i 00 1
■P 00 O CM
O . CM d*
0
•—I
i-J
o
o
IA O
jC O oo
o 00 00 i-H IA i-H
<0 1 . LA « 0v l
0 V0 IA o
ro vo
u
o
-<<- .
C0
c o 00
o vo d-.
*H vo 0\ i-H CM i— l
4-> 1 OO 1 i-H 1
r0 d- o i-H V0
U LTV 00
4->
c
0
o
c
o in d-
o in CM
d- CM i— 1 i-H
CL t 00 1 i
21 CM o vo
J— CM CM
>» ;
u — 1
r0
c o>
•H E O OU d- VO
u CM 0V i-H VO iH
1 IA 1 t"* i
<p tf) o O d
o c i-H ro
0
0 E
O •iH
c Ol
<o 0
Sh ■. -— -•
JZ
•o -C O) o>
' c P E  0 E  0
rO o 0 C Ol C Ol
-Q E O  ro C O  ro C
c •H O  0  ro O  0  ro
ro P H- CM E  U CO E  U
0 O
'JS1 P
122
a concentration of 8mg/l is exceeded in all subjects; as 
would be anticipated higher initial concentrations are 
achieved for the 300 mg preparation,these reached statis­
tical significance at 6-8 and 8-12 hr (p<0 .05). .The
lowest individual urine concentrations for each treatment 
were for 200 mg, 10 mg/1 (subject 4, 0-2hrs) and 300 mg ,
26 mg/1 (subject 8, 2-4 hrs) .
The urine concentrations achieved following multiple 
dosing reflect the dosing regimen (table 4. 4) . The lowest 
individual concentrations achieved after 24- hours were 
40 mg/1 for 200 mg b.d. (subject 8, 60-72 hours) and 24 mg/1 
for 300 mg o.d. (subject 3, 36-48 hours). The mean 
individual urinary concentrations achieved are noted in 
table 4.5 ^subject 4 had the lowest mean urine TMP levels.
Statistically significant differences between the 
preparations were found at 12-24 hours, 60-72 hours and 
72-84 hours only (p <0.05, t test).
4.5.3. Excretion Rates
For the 0-12 hour period the mean maximum excretion
rate for the 200 mg and 300 mg doses were 5.1± 1.4 mg/h
and 7.0±1.1 mg/h respectively; the corresponding rates 
over the total period of the study were 9.2±1.9 mg/h and
8.0±1.4 mg/h. The peak excretion rates were significantly 
different for the 0-12 hour period, but did not reach 
significance over the period of the study.
4.5.4. Relationship of Renal Clearance of 
Trimethoprim to Other Parameters
The associations between renal clearance at 8-12 hours 
(i.e. after absorption and distribution are complete) and
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serum clearance, urinary flow, urine pH and mid-point
serum TMP concentration were compared. The mean parameters
for both dosage regimens are listed in table 4.6, they
were not statistically significantly different between
treatments. There was no correlation between renal
clearance and either urinary, flow or mid-point serum TMP
concentration. There was statistically significant
negative association with urine pH r=-0.493 ( 200 d.f.)
(p<0.01) and also an association between renal and serum
clearance r=0.603, (15 d.f. p< 0 .01)
The fraction of drug excreted unchanged (fe) for
the 200 mg b.d. and 300 mg o.d. regimens respectively
was 0.29 and 0.33; k~ the renal elimination rate constante
wasthus 0.021 and 0.024h-  ^ respectively -(k =fe..-ke^ ) .
The estimated metabolic clearance was approximately 2.9 1/h 
for both preparations.
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DISCUSSION
4.6. SERUM KINETICS
4.6.1. Single Dose Pharmacokinetics
The absorption, elimination and distribution 
kinetics of the two TMP preparations were found to be 
similar; the principle area of difference being in the 
concentrations achieved , which was dose-related. As in 
chapter 3 the predicted serum TMP concentrations were in 
good agreement with those found following the initial 
dose although unusual individual absorption kinetics were 
noted.
4.6.2. Steady State Pharmacokinetics
predicted and observed C MIN and C AVE.. The predicted
ss ss K
C ^ M A X  was higher than the mean 2 hour post morning dose
point does not coincide with true C MAX, following
observed C ^ M I N  and C ^ A V E  were significantly different
between treatments however C MAX was not; but substit-
ss ’
uting mean CssMIN values (table 4.1) in the equation,
In steady-state there was good agreement between
samples which might be anticipated as this sampling
the initial dose median C hour
with V=75_l
F.D
+ C MIN Equation 4.2
V ss
then the predicted C cMAX values for the 200 mg b.d.
i> w
and 300 mg o.d, regimens are 4.9 mg/1 and 5.1 mg/1
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respectively; thus no difference at or near C MAX would
5 S
be anticipated.
4.6.3. Bioequivalence
Bioequivalence was demonstrated by the finding of 
the anticipated ratios for and AUC and the compar­
ability between the ratio anticipated for C ' 'MIN.;
4.6.4. Intraindividual Differences 
Although there was variation in the absorption
of TMP between individuals sometimes markedly so, the 
finding was not reproducible between study legs; assuming 
that the individual(s) concerned obeyed the manufacturers 
instructions as to dosage and timings, no explanation 
can be offered for the anomalies.
4.6.5. Effect of Sulphonamide on Trimethoprim
\
Kinetics
The pharmacokinetic parameters calculated for 
both dosage regimens are comparable with those calculated 
for TMP in chapter 3 for co-trimoxazole and co-trifamole; 
therefore the presence of sulphonamides has no detectable 
effect on the kinetics of TMP, a finding which confirms 
the work of others (Nolte and Buttner, 1973; Welling 
et al, 1973)
4.6.6. Half-life of Elimination and Dose 
Although there are no great differences in the TMP
dosages studied it is of interest to note that TMP exhibits 
linear disposition kinetics;' in a report of an overdose 
a half-life of 11.9 hours was found following an ingested 
dose of around 3.2 g (Hoppu ,Partanen and Koskela 1980)
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particularly as large single oral doses of co-trimoxazole 
have been used (Yoshikawa and Guze, 1976); it is possible 
that such an approach could be used for TMP alone.
4.6.7. Serum: Clinical Implications of the Dosage
Regimens
The MIC for species sensitive to TMP is 2 mg/1 (Brumfitt 
and Hamilton-Miller, 1980). The serum trough concentrations 
obtained using the 300 mg dose may therefore be regarded 
as unsatisfactory, and the level achieved in subject 3 
on 200 mg b.d. was also unsatisfactory. However TMP 
serum concentrations are not as relevant as the concen­
trations achieved at the site of the infection.
4.7. URINE KINETICS
4.7.1. Urine; Clinical Implications of the Dosage 
Regimens
At the time this work was performed the 300 mg o.d. 
preparation was intended only for treatment of urinary 
tract infections whereas the 200 mg b.d. regimen was also 
to be used in respiratory tract infection. In urine the 
MIC of TMP should be considered as 8 mg/1 (Huovinen and 
Toivanen, 1980; Huovinen et al, 1982); the lowest urinary 
TMP concentration on repeated dosing exceeded this value 
by a factor of 3 and usually more. Comparing mean urine 
TMP levels from the achievement of steady state on showed 
that the lowest mean TMP level exceeded the MIC by a 
factor of more than 7. Therefore from a pharmacokinetic 
standpoint either preparation would be acceptable for 
the treatment of urinary tract infection.
127
4.7.2. Relationship of Renal Clearance of :
Trimethoprim to Other Parameters
Renal clearance correlated with pH (negative
correlation) and serum clearance (positive correlation) ,
such findings are consistent with previous reports
(Sharpstone, 1969; Bergan and Brodwall, 1972) the mean
Cl /Cl ratio is of the order of 0.5, somewhat lower thanr s
the 0.68 reported by Andreason et al., (197-8). There was 
no association between renal clearance and urine flow, 
which is contrary to the findings of Andreason et al 
(1978), but in agreement with the findings of Sharpstone 
(1969).
The relationship between urinary pH and renal 
clearance is not surprising in view of the pKa of the 
drug and the physiological range of urinary pH, over 
this range TMP will to varying extents be protonated.
The evidence suggests that renal tubular reabsorption 
of TMP is pH dependant (Sharpstone, 1969, Friesen,
Hekster and Vree, 1981). Thus at the pH of blood,
.TMP is 50% ionised i.e. 50% of the non-protein bound 
fraction is unionised and able to passively diffuse 
across the renal tubular cells, TMP will also undergo 
filtration. As the hydrogen-ion concentration of the 
urine increases, TMP is increasingly protonated, as 
an ionised molecule it is difficult to back diffuse, 
hence the concentration of TMP is greater in situations 
where pH dependant accumulation can occur.
The renal clearance of TMP would be expected to be
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variable due to the influence of pH. The renal clearances 
from this study compare with values of 1.1-8.9 1/h 
(mean 3.3 1/h) (Sharpstone, 1969), 3.1-8.3 1/h (Bergan 
and Brodwall, 1972) and 1.5-9.5 1/h (Andreasen et al,
1978).
The excretion rates did not differ significantly 
in the steady-state portions of each part of the study, 
as this is a dose related parameter this might have 
been attributed to variations in individual pH, but 
no association was found. This finding may reflect the 
need for a larger number of subjects to be studied.
4.8. CONCLUSION
The comparability of the kinetics of the two 
preparations indicate that there is equivalent bio­
availability , the urinary concentrations achieved are 
adequate for use in urinary tract infection, however 
the 'steady-state1 serum concentrationsiin the 300 mg o.d. 
regimen were consistently below 2 mg/1, the MIC for 
sensitive organisms. Where serum concentrations are 
a guide to efficacy the kinetics suggest that a 300 mg o.d. 
regimen would be inappropriate for the treatment of 
infections where penetration to the site of infection is 
not subject to favourable pH gradients, indeed this 
could select for resistance, (Platt, Guthrie and Langan 
1983) although this is probably rare (Lacey, 1982 ) . Due 
to the higher dose and hence higher serum levels the 
200 mg b.d. preparation would be preferable.
Se no e vero ma e ben trovato.
( I t m a y  not be true but it is well contrived).
Giordano Bruno 1548-1600
CHAPTER 5
THE RELATIONSHIP BETWEEN 
SALIVA AND SERUM TMP CONCENTRATIONS
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INTRODUCTION
5.1. SALIVA AND DRUG MONITORING
Since saliva can be obtained non-invasively it has 
been advanced as an acceptable alternative to serum for 
investigating compliance, obtaining pharmacokinetic 
information or for therapeutic drug monitoring.
A strong case has been made for the use of saliva 
in the monitoring of anticonvulsants in paediatric patients 
(Knott and Reynolds, 1984) however in two recent reviews 
(Danhof and Breimer, 1978; Mucklow, 1982) it was agreed 
that the anticonvulsants phenytoin and carbamazepine 
could be monitored using saliva, but opinion differed for 
phenobarbitone and ethosuximide; it was agreed that for 
digoxin, theophylline, procainamide and a variety of 
other drugs a poor correlation was obtained between 
saliva and serum levels.
5.1.1. Sources of saliva
Saliva is secreted by the three major paired 
salivary glands, the parotid, submandibular and sublingual. 
In addition there are a number of smaller glands (labial, 
buccal and palatal); the composition of saliva from these 
glands varies considerably and the combined product is 
termed ’mixed’ saliva. The composition and flow rate 
of saliva changes rapidly following stimulation; mixed 
saliva contains the electrolytes potassium, sodium, 
chloride and bicarbonate each at concentrations of 
approximately 20 mmol/1 plus calcium and magnesium at 
10% and 1% respectively of these levels, the other main components
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are enzymes, the chief of which is amylase, and mucus, of 
which the main constituents are the sialomucins and the 
fucomucins which are sialic acid rich mucoproteins and 
fucose-rich mucopolysaccharides respectively ; the mucins 
are present at a concentration of 2.7 g/1 (Documenta 
Geigy, 1975). Although the nature of the stimulus to 
salivation does not affect the composition of the saliva 
produced, the proportions of parotid and sub-mandibular 
saliva can vary according to stimulus and as these 
glands give saliva of different composition, the mixed 
saliva produced will reflect these differences (Dawes 
and 3enkins, 1964). So far as the effect on drug concen­
trations is concerned the most impor-tant factor is the
hydrogen ion concentration of the saliva since this will
\
determine the extent of partition of ionised drugs.
Resting saliva, both parotid and submandibular, has a 
pH of 6.8-7.2 (Danhof and Breimer, 1978) whereas saliva 
secreted following stimulation may show a rise in 
pH of as much as two pH units. The extent of the pH 
changehas been reported as being related to flow rate " 
(Dawes and 3enkins, 1964).
5.1.2. Stimulation of Salivary Flow
Encouragement of saliva flow can be achieved either by 
mastication or by a gustative stimulus. A number of 
materials have been used for mastication-stimulated 
salivary flow including paraffin wax (Hoeprich and 
Warshauer , 1974), parafilm (Koup, 3usko and Goldfarb, 
1975), teflon (Boxenbaum et al, 1975) or a washed rubber
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band (Hallstrom, Lader and Curry, 1980). Parafilm suffers 
from the disadvantage that it is likely to ’extract' 
lipophilic drugs (Chang and Chiou, 1976; Taylor, Kaspi 
and Turner, 1978) and such a criticism is likely to apply 
also to paraffin wax. A relatively inert material such 
as teflon or a rubber band is to preferred provided that 
substances which may interfere in the assay are not 
leached from them.
A number of sapid stimuli were used by Dawes and 
Oenkins (1964) including citric acid, oxo and salt; 
citric acid is the most commonly used of these (Reynolds 
et al, 1976; Stephen and Speirs, 1976) .
5.1.3. Collection of Saliva
Following stimulation an adequate pool of mixed 
saliva is allowed to collect in the mouth and is smoothly 
expelled into a preweighed collecting tube, avoiding 
expectoration (Mucklow, 1982). The use of a preweighed 
vial and known collection time allows calculation of the 
salivary flow rate (Hallstrom et al, 1980). The salivary 
hydrogen ion concentration needs to be determined when 
measuring ionized drugs (Dvorchik and Vesell, 1976) .
Loss of bicarbonate will result in falsely elevated 
estimates of salivary hydrogen ion concentration at the 
point of secretion (Borzelleca and Putney, 1970; Mucklow, 
1982), although once saliva has been collected the pH 
has been found to be stable for 24 hours (Hallstrom 
et al , 1980).
A number of devices have been described for the
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sampling of individual glands (Lashley, 1916; Shannon 
and Chauncey, 1967; Stephen and Speirs, 1976) although 
these do not lend themselves readily to routine use.
5.1.4. Passage of Drugs into Saliva
It is generally accepted that the passage of drugs 
from the plasma, through the salivary gland cells to the 
salivary ducts is effected by passive diffusion; therefore 
the difference in concentration across the gradient will 
determine the rate of penetration from plasma to saliva.
In addition the physical properties of the drug will 
determine its ability to cross the membranes of the 
salivary gland cells, the more lipophilic a compound 
the better will be its diffusion across a lipid membrane; 
the degree of ionisation at physiological plasma pH will 
determine the extent of penetration -and its degree of 
ionisation at physiological saliva pH will affect its 
rate of back-diffusion. Prediction of plasma drug 
concentrations from saliva is best for drugs that are 
mainly un-ionised at physiological plasma pH (Mucklow, 
et al, 1978).
There appears to be little evidence of drug binding 
to the mucins , drug in saliva is usually considered
t'o be unbound (Mucklow, 1982).
A number of antimicrobial agents have been inves­
tigated to determine whether there is a relationship
between saliva and serum concentrations. Day and Houston
/
(1980) were able to establish acetylator phenotypes 
using salivary sulphapyrimidine and acetylsulphapyrimidine
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levels, although results using salivary dapsone gave 
conflicting results (Lammintausta, Kangas and Lammintausta, 
1979; Peters et al, 1981). Pyrimethamine appears to be 
a suitable candidate for salivary monitoring (Ahmad and 
Rogers, 1981)whereas there was no relationship between 
saliva and serum chloramphenicol levels (Koup et al, 1979).
It has been proposed that the ratio between saliva 
(S) and plasma (P) (or S/P ratio) can be predicted for 
ionised drugs as was successfully shown for tolbutamide 
by Matin, Wan and Karam, (1974).
Since TMP is a basic drug with a pKa of 7.3 and 
is substantially ionised at physiological plasma pH it 
is a useful probe for assessing the predictability of
the equation of Matin et al ('197 4).' The saliva and 
\ - 
serum concentrations of TMP have previously been inves­
tigated by several groups of workers in dogs (Granato,
Gross and Stamey, 1973) and in humans: (Quayle and Hailey, 
1973; Hansen, et al 1973a; Ko u p , et a 1
1975; Eatman et al 1977; Bernard et a l , 1978 ; Sardi, 
et al, 1981 and Kamme, Melander and Nilsson, J983).
Of these reports those of Koup et al (1975),
Eatman et al (1977) and Sardi et al (1981) have considered 
the predictability of the TMP S/P ratio using the equation 
of Matin et al (1974).
Significant correlation between serum and saliva 
TMP concentrations has been 'reported by Eatman et al
i
(1977) and Sardi et al (1981). Good agreement between 
observed and predicted S/P ratios is claimed by Koup et al
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(1975), Eatman et al (1977) and Sard! et al (1981).
Saliva and serum concentrations obtained during 
the study reported in Chapter 4 were used to assess the 
predictability of the equation of Matin et al (1974) for 
TMP. In addition the relationship between saliva and 
serum TMP concentrations and the influence of saliva 
hydrogen ion concentration and saliva flow rate on the 
observed TMP S/P ratio was examined. Two dosage forms 
(200 mg b.d. and 300 mg o.d.) were also studied since Sardi 
et al (1981) have suggested that saliva might be a useful 
medium for examining the relative disposition of different 
dosage forms of TMP.
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METHODS
5.2. CLINICAL
5.2.1. Study Design
Saliva samples were collected as described in
section 2.8.1 from the participants of the study described 
in section 4.2.2,. The samples were collected at the sane 
time as blood samples i.e. 2 and 10 hours after the 
initial dose and immediately prior to and 2 hours after 
the dose administered at 72 hours. These samples were 
analysed for TMP as described in Chapter 2 as were serum 
ultrafiltrates using the modified TMP assay and the 
second and latterly the third instrument configuration 
(section 2.6.2.(2) and 2.6.2.(3)).
5.3. MATHEMATICS
the relationship between degree of ionisation and pH.
The partition of TMP between plasma (or serum) and saliva 
is pH dependent.
The Henderson-Hasselbalch equation is given below:
5.3.1. Prediction of Saliva/Serum Ratio
The Henderson-Hasselbalch equation (5.1) describes
I A - I
pH = pKa + log
I HA |
Equation 5.1
This may be rewritten as
I A" | 10(pH-pl<a) Equation 5.2.
I HA |
13 6
B u t ,
[A ] + [HA] = [A"j Equation 3.3*
Combining equations 5.2 and 5.3 gives the following 
result:
[A] = 1 + 10 ^ pKa) Equation 5.4-.
Clearly the ratio of saliva and plasma (or serum)
concentrations is a ratio of equation 5.A- i.e.
[Aj saliva l+10^p^s~p^a ^
=  _____________   Equation 5.5.
[a] plasma l+10^p^p~p^a ^
Equation 5.5. applies to acids, equation 5.6. describes 
the predicted ratio for bases i.e.
[B] saliva 1+10(pKa-pHs\
 _________   = _ _ _ _____________  Equation 5.6.
[Bl plasma 1+10^P^a ~p^p \
A factor which allows for the proportion of the drug 
which is free (i.e. unbound) also needs to be included.
S [B] saliva l + 10(pKa-pHs ) f
__ = ___________ = ______________  . Equation 5.7.
P [b] plasma l+10^P^a ~P^p^ fg
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In these equations pKa is the pKa of TMP (7.3),.pH 
is the saliva pH (as measured or» collection), f is the 
fraction of unbound drug in plasma (0.6) (Schwartz and 
Zeigler, 1969). and. fg is the fraction of unbound drug in 
saliva (assumed to 1.0) (Mucklow, 1582).
Equation 5.7 corresponds to the equation given 
by Matin et al (1974) for bases and used by other workers 
for TMP.
Actual individual S/P ratios were determined from 
the measured serum and saliva TMP concentrations; these 
were compared with the calculated ratios.
5.4. STATISTICS
5.4.1. Calculation of 95th Percentile 
The 95th percentile line on Figs. 5.1 and Figs. 5.3 
was calculated from the following formula:
ca c /2 . -.2 * Equation 5.8.Sy = Sm7a^ +■ (x^-x)-------------- ---------------
where Sy is the standard error of y
2O' is the variance of x 
x
Sm is the standard error of the gradient of x to y
x ^ is the ith observation
* and x is the mean of x
5.4.2. Estimates of Precision and Bias 
In addition to the association comparison of 
observed TMP plasma level and calculated TMP plasma 
level, predictive evaluation was performed according to 
the recommendations of Sheiner and Beal (1981a) on
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calculated TMP levels from equation 5.7 and TMP levels 
calculated from the regression line of saliva TMP 
versus serum TMP (Fig 5.1) :
A measure of the precision of the prediction is 
given by the mean squared prediction error (mse)
w h e r e p e  (prediction error) is the difference between the 
predicted and observed value; root mse (rmse) is
and is a measure of precision in the original units of 
the original quantities.
Bias is obtained by calculating the mean prediction 
error (me) which is defined as
mse Equation 5.9
rmse = yf mse Equation 5.10
me Equation 5.11
Relative precision is calculated as the difference 
between two predictions i.e.
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Amse = mse mse 2 Equation 3.12
similarly relative bias is calculated by difference
i.e. Arne = me^-me^ Equation 3.13
A naive standard is an absolute predictive 
comparator, only predictions better than this standard 
are preferred for forecasting. The naive standard 
assumes that all predicted levels are equivalent to 
the mean of the observed data.
The confidence estimates aid comparison, essentially 
if the confidence interval does not include zero, the 
smaller mse is the most precise, if it does include 
zero the difference is not significant at the 0.05 
level (using a 2 tailed test) although the smaller mse 
is usually favoured (Sheiner and Beal, 1981a).
Amse and, Arne are measures of relative precision 
and bias, essentially the smaller the value the better 
they are, indeed a negative value favours that predictor 
as a better estimate than the predictor to which it 
has been compared.
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Confidence limits were calculated using the following 
equations :
x - t„ n. j n‘^ s e -  <x <x + t' 0-7c^n”1 ^se-
x t 0.975 x0.975
Equation 5.14
where:
se - 
x
n(n-l)
n
Z 
i = l
(x.-x)2 Equation 5.15
se
The Amse was calculated usinq:
se
Amse =
n(n-1) i = l
—*2
2 2 
^peli'"Pe2 i )" mse
Equation 5.16
and for se
Arne *
se n
Arne =  —  £
n(n-l) i=l
(peu -pe2 i )- me
Equation 5.17
h
|n
141
RESULTS
Only mean data are presented in this section,data 
from-.individuals are given in appendix C .
5.5. TMP PARTITION IN SALIVA
5.5.1. Comparison of Saliva and Serum Concentrations 
There was a statistically significant linear
correlation between observed saliva TMP and serum TMP, 
this relationship held for both dosage regimes and for 
all time points (p<0.01) (Fig 5.1.); 8.2% of points are 
outside the 95% confidence limits. Saliva and serum 
TMP concentrations closely paralleled each other for 
both dosage regimes (Fig 5.2.). Occasional saliva 
levels were notably greater than the serum level.
5.5.2. Observed S/P Ratios
The mean S/P ratio for all time points was 0.879 + 
0.22 for the 300 m g o . d .  r e g i m e n , 0.835 1 0.20 for the
200 mg b.d. regimen and 0.874 t 0.21 for both regimens.
The ratios for each time point are given in table 5.1.
There was no statistically significant difference
between times, treatments or individuals (t.test).
5.5.3. Effect of Saliva Flow Rate and Hydrogen 
Ion Concentration on Salivary TMP 
Concentration
The mean saliva flow rate was 1.386 ± 0.426 ml/min 
and the mean hydrogen ion concentration was 35.92 ± 24.2 
nmol/1. Using non-parametric statistics a significant 
(non-linear) correlation was found between salivary 
flow rate and hydrogen ion concentration (p<0.01,
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FIGURE 5.1* Association of observed plasma TMP versus observed 
saliva TMP. The regression line is bounded by 
68 and 95% confidence limits.
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TABLE 5.1
TMP S/P ratios at different time points for 200 mg and 
300 mg dosage regimens._______________    .
Time (hrs) 2 10 72 74
200 mg mean 0.90 0.75 0.94 0 . 84
regimen sd 0.30 0.17 0.24 0.11
300 mg mean 0.86 0.79 1.07 0.87
regimen sd 0.13 0.24 0.23 0.12
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Kendall rank correlation coefficient). Salivary flow 
rate appeared reasonably reproducible within an individual 
although there were insufficient data points to test 
this hypothesis statistically. Hydrogen ion concentration 
was less consistent within individuals between study 
legs.
There was no significant correlation between 
salivary TMP concentration and salivary hydrogen ion 
concentration, but there was a weak negative correlation 
with salivary flow rate (r=-0.288, p<0.05).
No correlation was found between observed S/P ratio 
and either salivary hydrogen ion concentration or 
salivary flow rate.
5.5.4. Predicted S/P Ratios
The predicted range of S/P ratios using equation 
5.7 and the assumptions previously noted, was 0.4-0.9.
This is similar to the observed range of 0.4-1.59 over 
an observed pH range of 6.5-8.2. However, there was 
no correlation between individual observed and predicted 
S/P data points using either parametric or non-parametric 
tests of association.
A comparison between predicted and observed TMP 
S/P ratios from this study and those reported by other 
workers is given in table 5.2.
5.5.5. Prediction and Measurement of fp
The free plasma concentration can be calculated 
using equation 5.7 by substituting observed S/P and 
pHs; the result of this manipulation are presented in
TABLE 5.2
Reported observed and predicted TMP S/P ratios
AUTHORS Observed TMP 
S/P ratio
Calculated TMP 
S/P ratio
Koup et .al (1975) 
..using data of 
Hansen et al 1973a
cr\• 
00 1 . 
o
 • 
rH 0.7-7 .6
Eatman et .al (1977) 1.26±0.345 1.27 (mean)
Sardi et al (1981) 0.839±0.171 0.64-0.73
This study 0.874±0.21 
(range 0 .4-1.59)
0
 
• -p 1 o •
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Fig 5.3, clearly prediction is poor with wide intra­
individual scatter.
TMP concentrations in serum ultrafiltrate were 
estimated at 2 and 72 hours during the 200 mg b.d. 
regimen, the mean value was 0.2 (± 0.08) and 0.54 (± 0.12) 
mg/1 respectively, representing 9.8% and 13.0% of the 
serum concentrations respectively.
5.5.6. Relative Predictive Performance 
From Fig 5.3. it is clear that fp cannot be predicted, 
there was however an association between the observed 
serum TMP concentration and that predicted from equation 
5.7, (Fig 5.4) although 14/60 (23%) of points are outwith 
the 95% confidence limits. .
As the regression obtained for observed saliva 
TMP concentration versus observed serum TMP concentration 
was better (Fig 5.1) than the performance of prediction 
using equation 5.7, a comparison of the predictive 
performance of these two approaches was required.
Sheiner and Beal (1981) have criticised the use of 
regression lines for predictive purposes and had developed 
an approach for the estimation of precision and bias 
of predictions using equations 5.9-5.17; these were 
applied' to assess the predictability of equation 5.7 and 
linear regression (Fig 5.1) for predicted values as 
compared to observed values for the 300 mg b.d. data 
(appendix C, table C.2), the results of this exercise 
are summarised in table 5.3. Linear regression performed 
best, equation 5.7 performed poorly, worse than the
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absolute (naive) standard and was a poor predictor.
5.6. BIOEQUIVALENCE: SERUM VERSUS SALIVA
5.6.1. TMP Concentrations in Saliva and Serum
Salivary and serum TMP concentrations were signif­
icantly different between treatments 2, 10 and 72 hours 
(p<0.01, t.test). There was no significant difference 
between dose regimens at 74 hours for either serum or 
saliva concentrations.
Calculation of : C' MA-X (Equation 3.5) predicts 
levels of 4.5 mg/1 and 4.7 mg/1 for the 200 mg b.d. and 
300 mg o.d. regimens (table 4.1) thus no difference would 
be expected.
5.6.2. Concentration Ratios between Regimens
Using the equations previously described (Equations
3.4 and 3.7) the anticipated serum level ratio (200mg/300mg) 
for the two regimens can be calculated at 10 and 72 hours; 
the results of this along with the mean serum ratios and 
mean saliva ratio are given in table 5.4. There was 
greater variation associated with the saliva results 
than with serum results, this was significant at 10 hours 
(p<0.05, F test) but not at 72 hours.
TABLE 5.4-.
Predicted mean serum and.mean saliva 
concentration ratios (200mg/300mg) at 
10 and 72 hours post initial dose.
Time (hrs) 10 72
Predicted
ratio
0.67 2.16
Serum x 0.68 2.13
ratio sd 0.11 0.4-5
Saliva x 0.76 2.0
ratio sd 0.51 0.51
DISCUSSION
5.7. TMP PARTITION IN SALIVA
5.7.1. Comparison of Saliva and Serum Concentrations
The highly significant correlation between saliva
and serum concentrations is in agreement with previous 
reports (Eatman et al, 1977; Bernard et al, 1978; Sardi 
et a l , 1981); calculation of the results reported by 
Hansen et a l , (1973a)also shows good correlation.
5.7.2. Observed S/P Ratios
The mean observed TMP S/P ratio compares well with 
that noted by Sardi et al,(1981) but is 30% lower than 
that quoted by Eatman et al (1977), however these 
authors measured TMP in blood rather than serum and on 
the basis of a blood/plasma concentration ratio determined 
by in vitro experimentation, adjusted all their observed 
blood levels by the mean of this result. The ratios 
found by Hansen et al (1973a)are much higher (up to 8.5) 
which would suggest some form of active secretion with 
the 'ion-trapping1 effect of a saliva pH which was 
lower than serum pH. The same authors noted reproducible 
S/P ratios at different times within one individual.
5.7.3. Effect of Saliva Flow Rate and Hydrogen 
Ioni Concentration on Salivary TMP 
Concentration
There is a non-linear relationship between salivary 
flow rate and hydrogen ion concentration (Dawes and 
denkins, 1964-) , this work confirms this finding. Since 
the scatter observed was large the only statement which
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can be made is the general one that increasing salivary 
flow rate results in a decrease in hydrogen ion concen­
tration .
TMP partition will be profoundly affected by minor 
fluctuations in salivary pH (and hence flow rate), a 
view supported by Mucklow et al (1978) and noted for 
lidocaine (Barchowsky et al, 1982) and for chloramphenicol 
(Koup et al, 1979).
The relationship between saliva TMP concentration 
and saliva pH is not discernable, and although there is 
a weak correlation between saliva TMP and flow rate, 
this only accounts for 8.3% of the variability and is of 
marginal significance.
5.7.4. Predicted S/P Ratios
Various authors have endeavoured to use the equation 
of Matin et al (1974-), the observed range of S/P ratios 
of 0.4--1.59 (mean 0.87) compares with the range calculated 
using equation 5.7 of 0.4--0.9 (saliva pH 7.1-8.2), 
superficially there seems to be agreement. Koup et al 
(1975) calculated TMP S/P ratios from the data of Hansen 
et al (1973a) and predicted a range of 0.7-7.6 which 
compared with an observed range of 1.0-8.3, this was 
despite the fact that Hansen et al (1973a) did not give 
pH values for their saliva samples. Koup et al (1975) 
used a saliva pH range of 6.3-8.0, using the equation 
they quoted (equivalent to equation 5.6) the calculated 
range is actually 0.7-6.1, presumably an error in 
calculation was made, in addition these authors neglected
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the fp component of equation 5.7 (Matin et al, 1974) 1 
incorporating this the calculated range of S/P ratios 
becomes 0.4-3.7.
Eatman et al (1977) claimed close agreement between 
an observed S/P ratio of 1.26 and a calculated ratio 
of 1.27, however they assumed that the carbon dioxide 
loss from collected saliva would result in a pH reduction 
of one unit and calculated their results at a pH of 6.5, 
despite the fact that in their study salivary flow was 
stimulated by mastication of a piece of teflon tape, this 
will result in a more alkaline saliva (Dawes and 3enkins, 
1964; Sardi et al, 1981). Their assumption as to the extent 
of carbon dioxide loss after collection is probably an 
overestimate, (Hallstrom et al, 1980; Mucklow, 1982 ) .
In the present study the pH of the collected saliva was 
determined immediately, and although there may be 
carbon dioxide loss between the instant of secretion and 
the moment of collection it is unlikely to be such a 
large change although evidence for collection loss has 
been reported (Borzelleca and Putney, 1970; Levy et al 
1980). Eatman et al (1977) considerably overestimated 
the TMP S/P ratio as 2.44 wheras without pH "correction" 
a value of about 0.7 would have been obtained. This 
would also have avoided the dubious manoeuvre of correcting 
their calculated TMP S/P ratio for "buccal mucosa 
partitioning" by 48% giving an S/P ratio of 1.27, this 
hypothesis was discounted by Sardi et al (1981).
Sardi et al (1981) assumed a decrease in saliva
1.48
pH between secretion and collection of 0.2-0.3 pH units
based on the findings of Dawes and Oenkins, (1964) and
Mucklow et al (1978), although the degree of loss is
speculative. Sardi and co-workers claim comparability
between the calculated and observed parameters although
the former are higher than the observed by 15-30%;
the comparability was not tested statistically.
Calculation of S/P ratio using equation 5.7
requires assumptions as to plasma pH, fg and f^. Most
authors assume plasma pH to be 7.4. The fraction
unbound in serum (f ) has been measured by Schwartz and
p
Zeigler (1969) and Sardi et al (1981) and found to be
0.58 and 0.51 * 0.02 for TMP; other authors have assumed 
a value of 0.5 or 0.6 for this variable; the latter 
assumption was made in this work. Eatman et al (1977) 
quote Devine et al (1969) as the source of this figure.
The fraction unbound in saliva is taken to be 1.0 
unless there is evidence to the contrary (Mucklow,
1982), this has also been the practice of other workers.
5.7.5. Prediction and Measurement of fp 
Calculation of the free serum fraction (fp) was 
wildly inaccurate and did not reflect previously reported 
values. As calculated fp is generally greater than 0.6 
(the observed fp) this suggests that fs was not overes­
timated as this would result in an underestimate of fp, 
however the extent of C0£ loss will affect predicted fp; 
it will be overestimated if there is a decrease in 
hydrogen ion concentration, no adjustments were made to
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the measured pHs in this study. In view of the over­
estimate found some adjustment would appear appropriate, 
however there was no consistency in the estimates for 
calculated S/P ratio or calculated fp. Although the plasma 
ultrafiltrate levels suggested binding of the order of 90% 
this does not agree with any. literature reports and is 
probably an artefact caused by binding of TMP to the 
ultrafiltration membrane.
The lack of consistency in any predictions attempted, 
there being no reproducible over or underestimate, indicate 
the inapplicability of the equation of Matin et al to 
drugs that are largely ionised at normal serum and saliva 
pH; this expands the caution expressed by Mucklow et al 
(1978).
5.7.6. Relative Predictive Performance
Using the criteria suggested by Sheiner and Beal 
(1981a) it is seen that predictions made from the linear 
regression line (Fig 5.1) of saliva TMP concentration 
versus serum TMP concentration gives estimates which 
are closer to those observed than values obtained using 
equation 5.7. The former estimates show better precision 
and less bias as measured by mse and me respectively 
and compare well with the absolute (naive) standard 
(Amse and Arne), the finding of a negative estimate 
between the two predictors confirms linear regression 
as being superior.
Since the relative precision of equation 5.7 is 
worse than the naive standard (positive Amse for A minus
naive) the relevance of this equation as an adequate 
mathematical description of partitioning between saliva 
and plasma (serum) is open to considerable doubt.
The theoretical advantages of using saliva rather 
than blood samples as a means of predicting the plasma 
concentration of TMP, which is significantly ionised at 
physiological pH, are not borne out by this work. The 
correlation observed between saliva and serum TMP 
concentrations allows an approximate estimate of the 
serum concentration to be made from analysis of saliva.
5.8. BIOEQUIVALENCErSERUM VERSUS SALIVA
As would be expected,observed saliva TMP data on 
both treatment regimens compared well with the data 
obtained from serum, however there was a larger variance, 
thus there would be an increased error in any parameters 
derived from saliva values; for bioequvalence studies 
saliva values would probably be adequate.
An aspect of salivary monitoring that is mentioned 
infrequently is the aesthetics of this approach to 
sampling; most volunteers found the mastication technique 
mildly unpleasant and the sample collection more so and 
expressed their views that a blood sample was easier and 
quicker to obtain and, for them at least, this was 
desirable.
5.9. CONCLUSION
In conclusion the use of saliva concentrations 
for studies on TMP are unsatisfactory due to the 
unpredictability of the relationship between serum and
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saliva TMP. If these findings are characteristic of all 
well ionised drugs saliva monitoring should probably be 
restricted to a few drugs (Danhof and Breimer, 1978) 
and then only in clearly defined circumstances (Mucklow, 
1982) .
Errors using inadequate data are much less than 
those using no data at all.
Charles Babbage 1792-1871
CHAPTER 6
THERAPY OF ACUTE EXACERBATIONS OF 
CHRONIC BRONCHITIS IN GENERAL PRACTICE 
WITH TRIMETHOPRIM ALONE: CURE RATES
AND TRIMETHOPRIM CONCENTRATIONS IN 
SPUTUM
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INTRODUCTION
6.1. ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS
Acute exacerbations of chronic bronchitis are :
significant because of their contribution to morbidity, 
leading to more severe respiratory problems, possibly 
culminating in eventual! respiratory failure.
The role of antimicrobials has been established
in exacerbations with a bacterial aetiology, however in 
a number of exacerbations either no bacteriological cause 
can be found or the suspected pathogen is not eradicated 
and yet there is an apparent clinical cure. Although 
the situation is very complex the former has been 
ascribed to H. Influenzae (Hughes et al, 1969), and the 
latter to a further infection or incomplete eradication 
following initial therapy (Chodosh et al, 1982).
6.1.1. Trimethoprim in Therapy 
Co-trimoxazole has been used in a number of 
comparative studies in the treatment of exacerbations of 
chronic bronchitis in which it was as effective or better 
than the following antibiotics: ampicillin (Hughes,
1969; Chodosh et al, 1982) ,. tetracycline ■ (Lai ■ and Bhalla, 
1969) dimethylchlortetracycline (Beumer, 1972), doxycycline 
(General Practitioner Research Group, 1972; Pandy, 1979) ampiclox 
(Kaplan and Stegman, 1972), amoxycillin (Carroll et al, 
1977; Pines et al, 1977) and cephalexin
(Cooper and McGillion, 1978)-. Efficacy equivalent to 
that found for co-trimoxazole has been demonstrated for 
co-trifamole (Knothe et al, 1978) and co-trimazine 
(sulphadiazine and trimethoprim), (Leone et al, 1984).
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Trimethoprim alone has been compared with co-trimoxazole 
in respiratory infections (including chronic bronchitis) 
and been shown to be as effective as co-trimoxazole 
(Lacey et al, 1980; Ashford and Downey, 1982) with fewer 
side-effects (Lacey et a l , 1980); therefore TMP alone 
would seem preferable in the treatment of chronic 
bronchitis rather than co-trimoxazole.
6.1.2. Trimethoprim in Sputum
Trimethoprim has been shown to accumulate in lung 
tissue (Hansen et al, 1973a, b; Wieser, Haiderer and 
Takacs, 1981), and to a greater extent when the tissue 
is inflamed (Hansen et a l , 1973b), TMP levels in sputum 
have been shown to be of the same order as lung tissue 
levels (Hansen et al 1973a). It is probable therefore 
that levels of TMP in the sputum of chronic bronchiti.cs-'. 
in exacerbation will be sufficiently high to ensure 
eradication of the common causative organisms.
TMP sputum levels were measured as part of a study 
performed in domiciliary practice to determine the 
comparative efficacy of TMP and ampicillin . in the treat­
ment of acute exacerbations of chronic bronchitis. It 
was the intention to determine whether either bacterio­
logical or 'clinical' cure were related to achievement 
of concentrations of TMP in sputum which were greater 
than the MIC for the pathogen isolated.
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METHODS
6.2. CLINICAL
This was a two phase study with clinical and bacterio­
logical assessment of patients and was performed in 
conjunction with Dr. C.E. Langan (Baillieston Health 
Centre, Glasgow) who co-ordinated the clinical aspects 
of the trial and Dr. D.3.Platt (Dept. Bacteriology,
Glasgow Royal Infirmary) who performed the associated 
bacteriology.
6.2.1. Patient Selection
i ) Admissions
- . Patients that satisfied all of the following 
criteria were admitted:
a) A history of recurrent lower respiratory 
tract infection (LRTI) associated with a productive
cough (for 2 years or longer). Clinical and bacteriological 
assessment of the patients were performed between 
exacerbations i.e. baseline assessment.
b) An acute exacerbation associated with a 
macroscopically purulent sputum having previously 
undergone baseline assessment.
c) The respiratory tract pathogens present in 
sputum were sensitive to both TMP and ampicillin: these 
drugs were administered under double-blind conditions
in doses of 200 mg b.d. and 500 q.i.d. respectively for 
10 days.
The patients were allowed to receive concomitant 
bronchodilator therapy and other treatment e.g. steroids
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for respiratory tract disease, other antimicrobial agents 
were not permitted. Presence of organic disease was not 
a criterion for exclusion.
ii) Exclusions
Patients with the following histories
were excluded:
a) Hypersensitivity to TMP or Blactams.
b) suspected, recent or unhealed tuberculosis.
c) Diagnosis pf pneumonia, carcinoma of the 
bronchus or empyema.
d) Severe renal, hepatic or cardiac impairment.
e ) Malabsorption.
' f) Blood dyscrasias, severe dermatitis or 
infectious mononucleosis.
g) Current use of oral contraceptive steroids.
h ) Pregnant or lactating .
i) Requiring parenteral chemotherapy.
j) Previous recent (14 days) exposure to 
preparations containing TMP or a penicillin.
6.2.2. Patient Assessments
Assessments were performed pre-treatment (baseline), 
on presentation with an exacerbation (day 0) and days 3,
11 (cessation of treatment) and 38 (4 weeks post treatment).
Clinical and bacteriological assessment of the 
volume and appearance of sputum were performed according 
to the MRC criteria (Medical Research Council, 1965). A full 
medical history, with particular reference to cough, breathlessness 
and sleeplessness, was obtained. The significance and
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sensitivity of the organisms isolated was determined.
6.3. ANALYTICAL
6.3.1. Sputum TMP Estimations
Sputum was analysed for TMP once steady state had 
been achieved. Samples were usually obtained at day 3 
or occasionally ■ ^^ other times.
Sputum TMP assay was performed as described in 
section 2.8.2, using the instrument conf iguration described 
in section 2.6.2.(3). Specimens ofsputum were obtained by 
expectoration and clotted blood by venepuncture on 
visiting the surgery. Where two samples of sputum were 
provided a clotted blood sample was taken as close as 
possible to the timing of the second sputum sample.
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RESULTS
6.4. BACTERIOLOGICAL AND CLINICAL CURE
The main aspects of the trial were clinical and 
bacteriological assessment of cure, the findings are 
summarised below. (The permission of Drs Langan and 
Platt is acknowledged).
6.4.1. Clinical
Highly significant improvements were found between 
day 0 and day 11 for many of the clinical variables.
The improvements in performance were statistically 
significant (p<0.005, paired t test) for both treatment 
groups; there was no difference in the extent of improv­
ement between groups. There were 118 initial entrants to the trial.
There was a difference between the GP's assessment 
of macroscopical sputum purulence and that of the
bacteriologist, but the degree of change found with
treatment corresponded well.
6.4.2. Bacteriological
Haemophilus influenzae and Streptococcus pneumoniae 
were considered to be primary pathogens and were isolated 
in 20 patients in the ampicillin group and 16 in the 
TMP group on day 0, but were eradicated in 15/20 ampicillin 
and 13/16 TMP cases by day 11. Although there was 
significant clinical improvement in 78/83 assessable 
patients only 17/83 had a complete cure i.e. at or 
better than baseline response, the remainder had not 
improved to this extent but were better by day 11 than
they had been at day 0.
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On comparison of all variables such as relapse 
rate, ventilatory capacity change, sputum appearance 
etc. there was no significant difference between groups 
at any stage. The only differences were: a higher
proportion of patients withdrawn due to lack of efficacy 
in the ampicillin group (TMP 0/41, ampicillin 5/42) and 
a higher side-effect rate in the TMP group (TMP 15/41, 
ampicillin 9/42).
6.5. TRIMETHOPRIM IN SPUTUM
Paired serum and sputum samples were required and 
some losses were experienced as is evident from table 6.1., 
there were no serum samples for several individuals, 
subjects for whom no sputum sample was received have 
been omitted from the table.
i . - .
6*5.1. Clinical and Bacteriological Aspects
The breakdown*of available data is as follows. Of 
the 118 entrants to the trial 35 were withdrawn for 
clinical reasons, 41 were allocated to TMP therapy 
(i.e. 41 TMP, 42 on ampicillin) bacteria were isolated 
in 33 of these; there were samples for sputum TMP 
analysis for 35/41, of these 29 had matching sputum and 
serum samples; there were pathogens detected at baseline 
in 14/33, none detected in 11/33,* and information not 
available in the remainder i.e. 8/33 (5/33 clinical 
withdrawals and 3/33 lost to follow-up) .
Of the group on whom sputum TMP levels were 
available, there were 19/25 clinical cures at day 11 
although 4 subsequently relapsed 4 were failures and
TABLE 6.1
Serum and sputum concentrations of TMP at steady-state
SUBJECT SERUM SPUTUM SPUTUM nVTTn
TMP mg/1 mg/1 SERUM K A 1 iU
1 4.7 8.7 1.9
2 8.2 9.4 1.2
6 0.2 0.2 1.0
. 8 0.2 0.1 0.5
12 0.5 3.0 6.0
14 4.4 13.0 3.0
•'18 6.5 2.5 0.4
24 4.2 7.2 1.7
25 5.3
30 1.7 7.7 4.5
32 3.6 1.5 0.4
35 4.0 <0.1
36 4.5 <0.1
37 2.0 5.3 2.7
38 5.4 5.1 0.9
40 2.8 3.2 1.1
41 6.5
42 2.8 4.7 1.7
45 5.8 17.5 3.0
56 0.1 0.4
66) (2.5
66) (2.3
TABLE 6.1 (cont.)
SUBJECT SERUM SPUTUM SPUTUM
TMP mg/l mg/1 SERUM KA,1U
71 13.3
72 6.6 4.9 0.7
76 4.3
78) j o  (18.7
78) ( 6.2 •
80 15.3
81) a n  (5*° i a
,81) *'°. (7.1 1,8
82 5.6 12.3 2.2
84) . 3 (4.2 . .
84) (4.8 1#1
88 1.1 7.8 7.1
90 3.6 6.2 1.7
93 1.6 2.3 1.4
95 1.6 ; 4.2 ; 2.6
104 3.5 6.5 1.9
114 2.6 3.6 1.4
x 3.48 5.97 2.04
sd 2.11 4.68 1.63
n 29 39 26
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2 were withdrawn for other reasons. Of the 14 with 
isolates on day 0, by day 11, 9 had been eradicated, 
in 2 the same organism was present, in 2 a different 
organism was found and one was lost to follow-up. Of 
the 9 bacteriological successes, all had sputum TMP 
concentrations of >2 mg/1, the mean was 6.2 mg/1 with 
a range of 2.5-12.3 mg/1.
6.5.2. Sputum Kinetics of Trimethoprim
In general sputum levels were greater than serum 
levels although there was considerable variation between 
individuals, the relationship of sampling to dose was 
not clear in many individuals.
Fig 6.1. shows consecutive sputum TMP levels in 
relation to dosing for those patients for whom this 
information is available.
There was no consistent change in sputum TMP 
concentration with time. In subject 95 a number of 
sputum samples were obtained, C^AX s 2.75 hours post 
dose which is within the limits found for serum TMP 
Cm a x * Approximately 4 hours post dose the sputum 
concentration is fairly steady; however the magnitude 
of concentration varies widely as did the direction of 
change, with subjects 45, 81 and 84 all showing increases 
during the 3 hours following dosing, subject 66 showing 
little change and subject 78 having a high TMP concen­
tration shortly after dosing with a rapid fall some 2 
hours later.
Subject 95 was the only patient willing to give
FIGURE
Sputum TMP 
mg/l
20
45
95b84
95a
66
+10 0 2 4 6 8 10 12 
Hours post doseDose
.1. Sputum TMP concentration versus time curves. The
numbers on each line relate to patient identification.
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samples on two consecutive days, following the initial 
dose (95^) there is some evidence of accumulation following' 
the second dose (95g), unfortunately this patient had to 
withdraw due to side-effects (vomiting) at day 3.
There was an association between serum TMP concen­
tration and sputum TMP concentration: slope = 1.32,
intercept 2.26, r = 0.4-59, '(n = 23), this association 
although not strong is statistically at the level of 
significance ( 0.01<p<0.05)
6.5.3. Bacteriological Cure and Sputum Trimethoprim 
Concentration 
Data on serum and sputum TMP levels were available 
in 25 subjects for whom there was also information on 
bacteriological outcome. The following terminology was 
used: "cure" was the eradication of the pathogen
which had been isolated on day 0, "no cure" was the 
failure to eradicate the pathogen and "negative" was 
the failure to identify the pathogen at day 0. The 
outcome is plotted in Fig 6.2 in relation to sputum and 
serum TMP. Cures were associated with sputum levels 
ranging from 0.1-13 mg/l, however those with no cure 
spanned the range 0.1-18.7 mg/l.
The clinical criteria used were more variable, but 
no association between sputum TMP levels and clinical 
improvement could be demonstrated. There were two 
individuals who developed a thymidine-requiring mutant 
of the same biotype as their original pathogen, these 
patients had sputum and serum TMP levels of <0.2 mg/l.
Sp
utu
m 
TM
Pm
g/
l
• cure
X
x no cure
□ no change
Serum TMPmg/l
FIGURE 6.2. Association between serum TMP and sputum TMP concentrations 
with an indication of outcome for each case.
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(Platt, Guthrie and Langan, 1983).
6.6. TRIMETHOPRIM AND RENAL FUNCTION
There was a slight but statistically significant increase
i
(p<0.05, t test) in creatinine level following treatment 
with TMP between day 0 and day 11.
DISCUSSION
6.7. BACTERIOLOGICAL AND CLINICAL CURE
6.7.1. Clinical
i " ■ - . .
This study confirms previous findings that TMP 
alone is effective in the treatment of LRTI (eg.Lacey 
et al, 1980, Hughes and Russell, 1982). The equivalence 
of efficacy of TMP alone with ampicillin has not previously 
been reported although there is equivalence between 
co-trimoxazole and ampicillin (Hughes, 1969; Chodosh 
et al, 1982). As in the report of Chodosh et al (1982) 
there is a notable improvement in symptomatic rating 
score and sputum appearance and volume from initiation 
of therapy to its conclusion. Treatment with either
antimicrobial has therefore been consistent with clinical
\
cure.
6.7.2. Bacteriological
-.Although'sputum' presentation and symptomology 
are objective measures of change, another appropriate 
indicator is the eradication of the pathogen involved, 
the isolation rate in this study was 67%, this compares 
with 54% isolated by Hughes et al (1969). The same 
author reported a clinical failure rate for co-trimoxazole 
of 6% and a bacteriological failure rate of 16%, in 
this study the corresponding rates were 0% and 19% 
respectively.
Interpretation of results can be complicated by 
patient compliance, non-compliance with therapy will 
present as a clinical failure but with a sensitive
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pathogen, if one were detected initially. During this 
study two patients (subjects 6 and 8) were both found 
to have thymidine requiring Haemophilus influenzae strains
\
in their sputum after TMP therapy; on biotyping these 
strains were found to be identical with those isolated 
at exacerbation. Reference to table 6;1 shows that on 
day 3 these subjects (6 and 8) both had low TMP 
levels in their serum and sputum, indicating non-compliance. 
These levels, which were at or below the organisms1 
MIC for TMP, selected for resistance, but the mutants were 
present only transiently suggesting they were poorly 
adapted to their environment (Platt et al, 1983).
6.8. TRIMETHOPRIM IN SPUTUM -
6.8.1. Sputum Sampling
\ '
There are some limitations related to the sputum
sampling procedure used here. Sputum was expectorated
therefore there is likely to be contamination with
saliva and possibly nasopharyngeal secretion, with or
without pus. Saliva has a slightly lower TMP concentration
than serum (Section 5.5.2.) and nasopharyngeal secretion
should have similar concentrations (Hoeprich, 1971),
thus expectorated sputum would be expected to show TMP
levels lower than the ’true' value. It is well known
in salivary drug monitoring that care is required to
ensure no tablet or capsule residue is in the mouth
leading to spuriously high levels (Mucklow, 1982 ).
Expectorated sputum may therefore have impaired sample
integrity. The only satisfactory procedure for sampling
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sputum is transtracheal aspiration, especially for pharm­
acokinetic studies, however such procedures are impractical 
in general practice.
6.8.2. Kinetic Aspects
The data shown in table 6.1 indicates that in 33 
of 39 samples the sputum TMP concentrations exceed the 
TMP MIC of 2 mg/l. It has been shown by Hansen et al 
(1973a, b) that TMP accumulates in the lung and that 
the concentration in lung tissue may be 1.5-3.5 times 
greater than the corresponding serum level with sputum 
attaining ratios of 0.5-4 times. This is a narrower range 
than found in this study.
The time to C ^ ^  in sputum for subject 95 was 
slightly later than that usually found in serum studies, 
suggesting delay in penetration, however as lung tissue 
is highly perfused the rate of delivery to lung cells 
will be rapid; although uptake and passage may well be 
impaired in lungs damaged by bronchitis.
6 . 8 . 3 .  T r im ethop r im  P e n e t r a t i o n  and P a t h o l o g i c a l  
Changes
Acute on chronic bronchitis is a complex situation 
and there will be a number of factors that will affect 
the rate of TMP penetration into lung tissue, including:
i i) Decreased hepatic blood flow secondary to 
increased hypoxia (Kirby, Cooke and Finley, 1976), 
resulting in decreased TMP metabolic clearance and 
higher plasma concentration which would be reflected in 
tissue levels.
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ii) Decreased pH due to CO^ retention may 
have two effects:
a) There will be an increase in ionisation 
of TMP from that found at normal (or fully compensated) 
blood pH from 44% at pH 7.4 to 56% at pH 7.2. Presuming 
penetration to be passive then there will be a decrease 
in the proportion of TMP available for diffusion.
b) There could be an increase in TMP fp 
as acidosis has been associated with decreased plasma 
protein binding, (Tillement, Lhoste. and Giudicelli, 1978)
iii) As in many other diseases chronic bronchitis 
is associated with hypoalbuminaemia, resulting in an 
increase in TMP fp.
iv) TMP penetration into lung cells will be 
enhanced in the presence of inflammation (Hansen et al, 
1973b).
6.8.4. Factors Affecting Trimethoprim Concentrations 
in Sputum
Once TMP has penetrated into the lung cell there 
is a tendency for it to accumulate (Hansen e t a l ,  1973a, b) 
subsequent secretion reflects these levels. Once sputum 
is in situ there are a number of factors which will 
affect the apparent TMP concentration, these include 
evaporation of the sputum resulting in concentration, 
expectoration in which part of the sputum (at least) 
is lost and a new sputum drug concentration would be 
established and, possible mixing with other sputum 
with different concentrations of TMP. The levels achieved
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will also depend on the rate of sputum formation and 
residence time, the general trend perceived in fig 6.1 
was for an increase in concentration following a dose of 
TMP. Patient 78 may have contaminated his initial 
sample with residual drug in the oral cavity causing a 
spuriously high level and an apparent subsequent fall.
There was a weak association between serum and 
sputum TMP concentrations, this is in contrast to a 
preliminary publication in which no association was 
reported (McIntosh et al, 1983). This was due to the 
larger numbers that have since been examined giving a 
more statistically meaningful sample.
6.8.5. Bacteriological Cure and Sputum Trimethoprim 
Concentration 
Association of cure rate, either clinical or 
bacteriological, with TMP sputum level is not proven, 
in Fig 6.2 although there were no cures at levels below 
the MIC, there was also failure at very high sputum 
levels. As described earlier measurement of TMP 
concentrations in serum and urine could prove non-comp­
liance and provide a rationale for the emergence of a 
thymidine requiring mutant.
Since the rate of resistance to ampicillin in 
British hospitals is 6.2% in H. influenzae isolates 
(Philpott-Howard and Williams, 1982) TMP has been looked 
to as a useful alternative, however the same authors 
have noted an increase in the rate of resistance to TMP 
from 0.2% to 1.4% from 1970-1977, the current rate is
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unknown.
6.9. TRIMETHOPRIM AND RENAL FUNCTION
The rise which was found in serum creatinine is 
marginal, but confirms the findings of other workers who 
have noted this in patients treated with co-trimoxazole, 
but have identified TMP as the causative agent (Kainer 
and Rosenberg, 1981; Dijkmans et al, 1981 ' Roy et al,
1982). The rise is reversible and may be associated 
with the free TMP concentration (Dijkmans et al, 1981).
It has been suggested that the cause is interference 
with creatinine secretion (Kainer and Rosenberg, 1981;
Roy et al, 1982), since total renal function as determined 
by ^Cr- E D T A  clearance is not impaired (Kainer and 
Rosenberg, 1981).
6.10. CONCLUSION
In conclusion,* this study has shown TMP levels well 
in excess of the MIC (2mg/l) for sensitive pathogens can 
be achieved in sputum. There was bacteriological success 
in a significant proportion of individuals and clinical 
improvement in numbers equivalent to those improved by 
the use of the ’reference* antibiotic. TMP used alone 
can ’cure' bacteriologically induced exacerbations of 
chronic bronchitis.
I have yet to see any problem, however complicated, 
which, when you looked at it the right way, did 
not become still more complicated.
Poul Anderson
New Scientist 25th Sept. 1969.
CHAPTER 7
INDIVIDUAL PLASMA CONCENTRATIONS AND PHARMACOKINETIC 
PARAMETERS: COMPARISON OF OBSERVED VALUES AND
ESTIMATES OBTAINED FROM OPT, A PROGRAMME USING 
BAYESIAN STATISTICS AND ESTIMATES OF MAXIMUM
LIKELIHOOD
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INTRODUCTION
7.1. STANDARD APPROACH TO OBTAINING 'POPULATION' KINETICS
Following administration of a standard dose to a 
number of matched individuals, carefully timed samples 
are withdrawn and analysed to determine the drug 
concentration. The number of exponential terms required 
to describe the serum drug concentration time curve 
indicate whether a one, two or three compartment model 
is appropriate for fitting the data. A monoexponential 
term requires a one compartment mode.1, a biexponential 
a two-compartment model and a triexponential a three- 
compartment model (Fig 7.1), the choice of appropriate 
model can however be complicated by considerations as to
the compartment in which elimination etc is occurring
' *
(Wagner, 1975). In many cases the simplest model,
the one-compartment model, provides an adequate description
allowing prediction of future Cp and dosage to be
performed relatively easily.
If a one-compartment model is chosen then the 
equations and procedures described in section 3.6.3. can 
be used to obtain estimates of the parameters: V d , Cl, 
ka etc. Taking the mean of the individual parameters 
will yield population parameters, however there may be 
errors in such estimates due to the variance of each 
Cp contributing to mispecification of the curve, this 
is particularly true if models of greater complexity 
than one-compartment are used. An approach which avoids
FIGURE 7.
(a) Single Compartment Model
Dose ka
C
► Vd -
k Elimination
(by excretion and metabolism)
(b) Two Compartment Model
Central Peripheral
Compartment Compartment
k a
M2
-► V d , V d -i «
i *21l k
Elimination
(by excretion and metabolism)
(c) Three Compartment Model
Central
Compartment ^
Dose
Elimination
* -  Vd
Compartment 2
Compartment 3
(by excretion and metabolism)
^ One, two and three compartment models. It.is assumed 
that absorption and elimination occur through the 
central compartment.
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this difficulty is to use time averaged concentrations 
i.e. at a particular time all the concentrations are 
averaged and the parameters determined, from the meaned 
data; this provides a good estimate of the population 
kinetic parameters but provides no information on the 
variance of the . parameters .
Parameters are usually calculated following a single 
dose but estimates may be obtained in steady-state 
(Benet and Massoud, 1984-).
7.2. BAYESIAN STATISTICS
Statistical methods are usually based on the 
frequency view of probability, however Bayes's Theorem, 
(named after an English clergyman, Thomas Bayes, 1702- 
1761) is appropriate in situations in which foreknowledge 
of the possibility of an event i.e. prior probability 
is used to judge the likelihood of the event; once an 
observation(s ) has been made then the probability of the 
event will be retrospectively modified i.e. posterior 
probability. By taking the most likely parameter it may 
be inferred that this is the best estimate of that 
parameter (Fig. 7.2.); this is the method of maximum 
likelihood. This may be expressed as: posterior 
probability is proportional to likelihood multiplied 
by prior probability.
With the combination of Bayesian statistics and 
estimates of maximum likelihood it is possible by 
entering minimal information to estimate parameters for
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which there is a previously obtained reference.
7.3. BAYESIAN ESTIMATION OF INDIVIDUAL KINETICS
The plasma drug concentration (Cp) after a known 
dose and time is a function of an individual's pharmco- 
kinetics; there will be variance associated with the Cp 
eg.analytical and pharmacokinetic, and there will be a 
distribution of likely estimates. In relation to this 
individual the population distribution of parameters 
may be taken as a prior probability, Cp is the observation 
which will enable an estimate to be made to be used for 
modified posterior probability and therefore the pharmaco­
kinetic parameters estimated via this procedure will be 
'individualised' due to the influence of Cp. (Fig 7.2) 
Sheiner et al (1979a) used a Bayesian technique 
to forecast individual pharmacokinetics in a group of 
patients taking digoxin; the parameters F, Vd and Cl 
were estimated and used to predict future Cp as dosage 
was changed. ^
In using population kinetics for a particular 
drug the use of co-variates eg. sex, weight, disease state 
can be used to modify the prior probability of eg. Cl., 
however the prediction will be open to considerable 
error because of the variation possible in the population. 
Full specification of the measurable features pertinent 
to an individual's kinetics (eg. GFR) was found to be 
of less significance than the input of one plasma 
drug level (Sheiner et al, 1979a) which allowed
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'feedback' and improvement in the forecast kinetics. 
Sheiner et al (1979a) validated their approach using 
digoxin and found that with two 'feedback' Cp's the 
accuracy and precision of forecast Cp's was very good 
and that estimates of Vd and Cl also improved.
7.4. THE OPT(IMISATION) PROGRAMME
This approach has been adopted and adapted as the 
microcomputer programme OPT (Kelman, Whiting and Bryson, 
1982a; Kelman, Whiting and Bryson, 1982b) which has 
been shown to be of significant predictive value in a 
clinical setting (3oel et al, 1983; Whiting et a-1,.1984; 
Howie et al, 1985). OPT is able to model the irregular 
dosing schedules seen in clinical practice, also it 
may not require that samples for Cp be taken at any 
particular time in relation to dosing (Howie et al,
1985) but is governed by compatability with the model.
The only requirements for effective use of the programme 
are : the individual's measurable features, the dosage, 
time of dosage and the time at which the sample was
taken in relation to the dose. Although Sheiner et al
(1979a) included the population variances for their 
individualisation of digoxin, the variances used in OPT 
are equal for all drugs and fixed (Kelman et al 1982a, b) 
although the authors state these may be reviewed if more
accurate studies are performed.
The programme as configured by these authors is 
applicable to : digoxin, disopyramide, lignocaine,
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procainamide, theophylline, carbamazepine, phenobarbitone 
and the aminoglycoside antibiotics, (Whiting et al, 1984) 
phenytoin is also available but only in steady-state as 
saturation kinetics require a different approach (Kelman 
et al, 1982a). The drugs included have been chosen on 
the basis of their relevance to good therapeutic drug 
monitoringpractice i.e. they are a l l w e l l  established 
drugs usually with a low therapeutic index where individ­
ualisation of dosage is important.
It was of interest to ascertain how generally 
applicable OPT could be, and to determine if Cp can be 
reliably predicted.
The intention was to assess the ability of OPT to 
predict serum levels when different numbers of Cp were 
available and to determine how acceptable a forecast 
could be achieved for C ^ M I N  and a point approximating 
to C MAX for two dosage regimens.
3 3
7.5. ESTIMATION OF POPULATION KINETICS
Analyses using the standard pharmacokinetic 
approach on reasonably well subjects is an expensive 
exercise in terms of assay time, bed occupancy and 
personnel; for severely ill patients the rigours required 
for assessing the change in pharmacokinetics in the 
diseased state may be unacceptable and thus reliable 
information could prove difficult to obtain. For these 
reasons Sheiner and others proposed statistically 
sophisticated analysis of fragmentary sets of well
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documented data from individuals. To do this requires 
a knowledge of population kinetics with an estimate of 
the parameter variances, this is obtained using NONMEM 
and has been succesfully used in the estimation of the 
kinetics of several drugs (Sheiner, Rosenberg and 
Melmon, 1972; Sheiner, Rosenberg and Marathe, 1977;
Beal and Sheiner, 1980; Sheiner and Beal, 1981b; Sheiner 
and Beal, 1984). Such population data can then be used 
as the basis for individualised Bayesian predictions.
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METHODS
7 .6 . COMPUTING
7.6.1. Software
OPT was kindly made available by Drs . A. Kelman 
and B Whiting (Dept. Materia Medica, Stobhill Hospital, 
Glasgow) originally for the meeting Clinical Drug 
Analysis, Techniques and Interpretation held in March 
1982 in Glasgow; Dr. B. Clark (Dept. Biochemistry,
Western Infirmary, Glasgow) made the software modifications 
required to enable OPT to be used on Apple lie plus 
computers. The procedure for use, and the files available 
were as described by Kelman et al (1982a, b).
Dr. B. Clark subsequently modi-fied the input to 
enable any drug with first order, one compartment 
open model kinetics to be considered.
7.6.2. Hardware
The OPT programme as used was transferred to a
Winchester disc. The following hardware was used:
an Apple lie plus microcomputer with a language card,
TMa floating point board, a buffered Grappler serial 
interface card, an additional memory card, a soft switch, 
one floppy disc drive and a Corvus Winchester disc 
drive (10Mb), a monitor and an Epson MX-100 dot matrix 
printer. The basic microcomputer and floppy disc drive 
were obtained from Scotlab Instrument Sales Ltd. (Bellshill, 
Scotland), all other hardware was obtained through Strathand 
Ltd. (Glasgow, Scotland).
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Full details of the software and hardware 
requirements may be obtained from Dr, B, Clark or 
D r . A . Kelman.
7 .6 .3 . Data
The ability of OPT to predict Cp for the individuals 
described in the TMP study in Chapter 4 were examined.
Using data from the 300 mg o.d. regimen, increasing 
numbers of Cp from 0 to 4 at 2, 1 2 , 4 8  and 72 hours 
were incorporated cumulatively in chronological order 
into the model; the bias and precision of the prospective 
Bayesian prediction were compared with the observed 
Cp at 96 (CssMIN) and 98 (C ' MAX ).■ hours; post commencement 
of the 300 mg o.d. regimen, in addition the accuracy of 
forecast Cp for the 200 mg b.d. regimen at 96 and 98 hours 
post initiation of dosing were also examined. The 
population kinetics used were obtained during the studies 
described in Chapter 4, the time averaged parameters
compared well with the averaged parameter values. The 
parameter values used were ka 2.5 h " 1, Vd 75 1 and 
Cl 5.4 1/h.
It is recognised that the use of data to test a 
prediction that also forms the reference base should 
result in a better than anticipated performance.
Predictive performance was evaluated for precision and 
bias using the statistical approach suggested by Sheiner 
and Beal (1981a). (Section 5.4.2.).
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RESULTS
7.7. OPT OUTPUT
Following 'optimisation* of an individual with 
population data a result table is printed, which gives 
details of dosage regimens, predicted and observed serum 
drug concentrations and derived parameter estimates.
A typical result table is shown in Fig 7.3. A graphical 
printout of serum concentration versus time is also 
available, a + indicates a measured point (Fig 7.4) .
7.8. PREDICTIVE PERFORMANCE OF OPT FOR Cp
7.8.1. Prospective Predictions of Cp for TMP in 
Steady State Versus Observed Cp 
1 Table 7.1 summarises the mean and range
of the prediction error for each Bayesian estimate
\ ' 
with increasing Cp. The systematic component of pe
is considered below under bias.
Mean pe decreased with increasing Cp input; the
ranges were wide, although they tended to decrease
with increasing Cp input. Subject 5 was excluded from
pe and bias calculations in 300 mg o.d. 96 hours due
to a very large pe suggestive of an observational Cp
error.
Comparison of precision and bias for each forecast 
Cp i.e. 300 o.d. 96 and 98 hours post commencement of 
the 300 o.d. regimen and 96 and 98 hours post commence­
ment of the 200 b.d. TMP regimen using 0, 1, 2, 3 or 
4 Cp or the naive standard (Section 5.4.2.) were often
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TABLE 7.1.
Percent prediction error for Bayesian forecasts of Cp 
compared with observed mean and range for TMP
No
Cp
.300 mg 
o.d. 96 hrs
300 mg 
o.d. 98 hrs
200 mg 
b.d. 96 hrs
200 mg 
b.d. 98 hrs
0
X
range .
34
-55 to 92
-17 
-30 to -4
6
-60 to 53
-3
-27 to 18
1
X
range
42
-50 to 109
1
-19 to 13
19
-52 to 77
18
-19 to 48
2
X
range
49
8 to 147
4
-10 to 26
22
-28 to 51
21
-1 to 42
3
X
range
19
-42 to 117
-6
-20 to 20
4
-45 to 25
6
-9 to 33
4
X
range
18
-12 to 109
-7
-13 to 16
3
-50 to 28
7
-13 to 31
* excluding subject 5
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not statistically significantly different. Statistical 
evaluations of the precision and bias of the forecasts 
are contained in appendix D. The number of input Cp 
resulting in the best and worst absolute precision and 
bias are contained in table 7.2.
i ) Precision
a ) absolute
The number of input Cp reported in table 
7.2 as yielding significant predictive imprecision 
are consequently poor predictors, although those noted 
for 3 and 4 Cp (300 mg o.d., 98 hours) had unusually 
tight confidence limits. The best mse for each group 
predicting steady-state Cp are also -summarised in table
7.2. Precision of the naive standard was comparable 
to that obtained for 3 or 4 Cp. ’
b) relative
In general the best precision was noted
with 3 or 4 Cp and the worst with 1 or 2 Cp.
ii) Bias
a ) absolute
Two occurrences of statistically significant 
absolute bias are noted in table 7.2, in the other groups the 
worst bias was associated with 2 Cp (300 mg o.d. 96 hours)
and 2 Cp (200 mg b.d., 96 hours). Best absolute bias is
also noted in table 7.2.
b) relative
Least bias was noted most often for 3 or
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V  Cp and most bias with 0, 1 or 2 Cp.
7.9. PREDICTIVE PERFORMANCE OF OPT FOR PHARMACOKINETIC 
PARAMETERS
7.9.1. Comparison of Observed and Predicted 
Parameters
The precision and bias of predictions for 
Vd, Cl and t£ when compared to those obtained using 
standard methods are presented in table 7.3. There 
was significant positive bias in estimates for Vd and 
significant imprecision in estimates for Cl. The 
performance of the prediction for each parameter in 
each individual are considered in the remainder of 
this section.
i ) Volume of distribution
The values for the observed Vd i.e. 
standard multiple sample method and that obtained by 
Bayesian estimate are compared in table 7.4-. Bayesian 
estimates were higher than observed values, three 
estimates were within one s . d ., three within two s.d. 
and two outwith two s.d. from the estimate,
ii) Clearance
A comparison of clearances obtained as 
above are presented in table 7.5'. Four subjects had 
estimates within 2 s.d. of the observed, however there 
were some marked differences between estimated and 
observed Cl for the remaining subjects,
iii) Elimination half-life-
Elimination half-life was considered
TABLE 7.4
Comparison of Vd (1) obtained by standard pharmaco­
kinetic method and Bayesian estimate (using 4 
observed Cp) _____     '
Subject Standard Bayesian
 ________ technique estimate (±sd)
1 82.6 100.5 (±13.6)
2 60.3 68.6 (± 7.3)
3 110.0 110.8 (± 6.4)
4 81. A- 127.2 (±17.3)
5 72.9 90.2 (±10.5)
6 . 67.2 7^.8 (±8.0)
7 64.1 70.6 (± 7.5)
8 60.9 71.2 (± 7.6)
TABLE 7.5
Comparison of Cl(l/h) obtained by standard 
pharmacokinetic method and Bayesian estimate 
(using 4 observed Cp) ______ ___________
Subject Standard Bayesian (±sd)
______________ technique  estimate _____ _
1 5.2 4.9 (±0.5)
2 3.6 4.8 (±0.4)
3 8.4 14.4 (±0.8)
4 9.3 7.1 (±0.6)
5 . 3.3 5.5 (±0.4)
6 4.5 5.2 (±0.4)
7 4.4 4.8 (±0.4)
8 4.8 4.8 (±0.4)
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as it is related to ke -^ (table 7.6), five estimates 
were different from the observed value by more than 15%.
7.9.2. Comparison of Final and Sequential 
Forecasting of Parameters
i ) Volume of distribution
The final forecast Vd with maximum (i.e.4) 
Cp input was not statistically significantly different 
for either absolute bias or precision from the estimate 
obtained with 0 Cp (table 7.7); least imprecision and 
bias were noted for 3 Cp and most for 0 Cp. The order 
of error in the units of measurement (r.mse) is large, 
of the order of 12-18% of the observed mean value 
(table 7.4).
ii) Clearance
i • -
There was no statistical difference for 
estimates of absolute bias or precision for forecast 
Cl (table 8.8), bias tended to be positive, the least 
imprecision was associated with 2 and 3 Cp. The rmse 
indicate errors of between 41-70% of the observed mean 
values (table 7.5).
iii) Elimination half-life
Precision was best; after 2 or more Cp, 
there was most bias with 1 Cp (table 7.7), in terms of 
the observed mean values (table 7.6) the error of 
prediction was between 29-45%.
iv) Absorption rate constant
Generally adjustments in forecast ka
showed minimal change with no significant bias or
TABLE 7.6.
Comparison of t£3 (h) obtained by standard 
pharmacokinetic method and Bayesian estimate 
(using 4 observed Cp) _• _________________
Subject Standard Bayesian
  technique____________ estimate
1 11.0 14.2
2 11.6 10.0
3 9.1 5.4
4 6.1 12.4
5 15.4 11.4
6 10.4 9.9
7 10.0 10.1
8 8.7 10.4
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Imprecision (table 7.7), least bias and best precision
was achieved with 3 Cp. There was a statistically
significant imprecision associated with 0 Cp, as subject
five was subsequently predicted to have a k of 0.23-
a
0.34 (h"1). If the typical k of TMP is 2.5 h ^ t h e na
the rmse errors are between 1.4-30.6%; the high rate 
includes subject 5, excluding this individual an rmse 
of 0.033 was found, the range of error then becomes 
1.3-3.0%.
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DISCUSSION
7.10. PREDICTIVE PERFORMANCE OF OPT FOR Cp
The intention of OPT is to predict appropriate
dosage from a minimum of pharmacokinetic information,
it follows from this that appropriate prediction of
Cp is an integral part of such strategy when effect
and Cp are related to a therapeutic range. The prediction
of Cp requires the optimisation of the parameters of
Vd, Cl and k ; given the approach used these are a
unlikely to have a unique solution but should tend 
towards to the correct values (Sheiner et al 1979a).
This evaluation was not intended to consider 
the mathematical and statistical modelling in OPT 
but to examine the predictive efficiency of OPT for a 
drug and to consider what utility such an approach 
might offer.
There is the underlying assumption in the assess­
ment of Cp that the reference value i.e. observed Cp, 
is correct and that prediction must attempt to achieve 
comparability with such a value. Inevitably there are 
a number of contributions to the variance of the 
observed Cp including pharmacokinetic and analytical 
factors, the extent of such variance around a point 
observation for this data is not known; if the data 
were to be submitted to NONMEM (Sheiner and Beal, 1981b,) 
then a population value could however be estimated.
With this caveat the prediction of Cp in a practical
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setting would be expected to cope with such difficulties 
and thus it is valid to assess predictive performance 
in relation to observed data.
7.10.1. Prospective Predictions of Cp versus
Observed Cp for TMP at Steady-State for 
Two Dosage Regimens
The mean prediction error decreased with
increasing entry of Cp, the ranges however were wide and
reflect the individuals with extreme errors, this may
relate to observational Cp error although only one
subject was excluded for that reason. (It is worth
noting that a 15% error is assumed for each Cp entered
into OPT) (Kelman et al, 1982b).
The errors in forecast Cp were worse for predicted
Cp at 96 hour concentrations (i.e. trough) than for
that predicted at 98 hours. This is surprising in
view of the fact that the observed Cp estimates of
Cl as the 12 hour and two trough level C p ’s (48 and
72 hours) are most influenced by Cl, whereas the 2 hour
sample point is the only observed estimate of k anda
any error would result in poor estimates of Cp at 98 hours. 
Error in forecasting 96 hour Cp was not influenced by 
drug induced changes in clearance as the steady state 
values were achieved and maintained (see Table 4.1).
The significance of these errors require consideration 
in terms of clinical relevance. Sheiner et al (1979a) 
suggested a "clinical acceptable error SD" based on the
therapeutic range, unfortunately while most would agree 
that the lower limit of the effective concentration of 
TMP is 2 mg/1 there is no indication of any desirable 
upper limit for TMP concentration. The highest observed 
TMP Cp was 5.3 mg/1, for the purposes of computation 
an upper limit of 6 mg/1 is .arbitrarily assumed to be 
acceptable. Using the assumptions and approach of 
Sheiner the clinically acceptable error SD is 1 mg/1
i.e. 95% of true Cp's will be within 2 mg/1. By this 
criterion the acceptable percentage errors are: 75%
(300 mg o.d. 96 hours) 26% (300 mg o.d. 98 hours),
48% (200 mg b.d. 96 hours) and 25% (200 mg b.d. 98 hours). 
On these criteria predictions using 3 or more Cp were 
acceptable with the exception of one individual at 
200 mg b.d. 98 hours and two individuals at 300 mg o.d.
96 hours. Where TMP is concerned the most important 
range is that about the lower reference level, where an 
error of 50% is unacceptable, since it would not allow 
differentiation between effective and ineffective 
therapy.
In assessing the performance of prediction it 
is necessary to consider the precision and bias of the 
forecast at the different levels of stipulated Cp. 
Statistically significant bias was found on two 
occasions, one positive and the other negative, there 
was thus no consistent systematic component to any 
error. Consideration of relative bias, particularly
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as it relates to the naive standard, which by definition 
has no bias, indicated that bias decreased with increasing 
Cp input; least bias was most consistently achieved with
3 or 4 Cp. Imprecision was most commonly associated with 
0 Cp with statistically significant imprecision on 3 of
4 occasions. As the number of stipulated Cp increased 
so precision improved although the naive standard has 
as good precision as Bayesian estimates up to 3 Cp or 4 
Cp. When statistically significant imprecision was 
noted, this was associated with unusually narrow confidence 
limits (table D.l).
Performance could have been adversely affected by 
the choice of observed Cp giving a poor mix of points 
and not enabling a good balance of influences on Cp 
to be assessed and not resulting in adequate posterior 
modification of the prior probabilities. This could 
be further compounded if the population data used as a 
reference base to establish the prior probabilities 
were inadequate; the values used were close to those 
obtained from time averaged parameters obtained from 
each of the studies described in Cpaters 3 and 4.
It is unlikely that significant error was entered 
through the population reference base although a larger, 
more independent (i.e. less correlated) population 
sample would be desirable.
On the basis of these results 3 or 4 Cp must be 
input for each individual in order to obtain the most
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precise and least biased forecasts of Cp, allowing 
dosing prediction, based on these Cp, to be performed 
with confidence. This finding is in accord with the 
findings of a recent review comparing predictive drug 
dosing methods which showed that Bayesian statistical 
predictions perform best (Burton, Vasko and Brater, 1985 ) . 
The authors implied that less than 3 Cp are required, 
although this does not coincide with the findings 
reported here it is most dependent on what the clinically 
acceptable level of error in dosing is.
7.10.2. Retrospective Predictions of Cp for TMP 
As OPT has a time weighted factor which decreases 
the influence of earlier Cp on prediction (Kelman et al, 
1982b) it is hardly surprising that the quality of
x . .
prediction of Cp retrospectively declines. This is of 
no consequence unless an attempt is made to interpret 
findings retrospectively; awareness of this limitation 
should avoid misinterpretation.
7.11 PREDICTIVE PERFORMANCE OF OPT FOR PHARMACOKINETIC 
PARAMETERS
The prediction of Cp requires that a balance
between the three main pharmacokinetic variables be
achieved. As described by Kelman et al (1982b) there are
variances. associated with each parameter. As Cl is more
likely to vary than Vd it is set at 50%, k has the
a
same weighting as Cl; reflecting potential variables 
in absorption. In addition an uncertainty principle
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is included to account for previous possibly non-compliant 
dosing and a variance of 15% is allocated to each Cp.
The balance of parameters and variances result 
in a ’model1 which fits the observed Cp, however the 
parameters produced need not reflect actual observed 
measurement as the solution for Cp using these parameters 
can have a number of solutions.
7.11.1. Comparison of Observed and Predicted 
Parameters
Sheiner et al (1979a) contend that 
estimates of observed Cl and Vd can be obtained from 
an individualised Bayesian pharmacokinetic approach, 
the degree of error reported in section 7.9.1. do not 
confirm this claim for any of the parameters (Cl, Vd, 
t|8) considered; all predictions have large s.d., this 
will result in the parameter being poorly determined 
(Boxenbaum, Riegelman and Elashoff, 1974).
7.11.2. Comparison of Final and Sequential 
Forecasting of Parameters
. Sheiner et al (1979a) found decreased
pe for Cl and Vd with increasing stipulated Cp. The
intention therefore was to consider how close to the
final point estimate each forecast was for the parameters
Cl, V d , t|3 and k , as more Cp were input.
a
There was a trend for decreasing positive bias 
for estimates of k'a , there was no systematic bias for 
the other parameters, as a Bayesian system has an
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inherent bias towards the prior probability this is 
perhaps surprising; such bias may not be statistically 
significant.
With the exception of Vd, in which no trend was 
discernable there was improved precision of estimates of 
Cl, t|8 and k with increasing Cp. A poor predictive
■3
performance for k (table 7.7) was due to the observed
value for Cp not being consistent with the expected
value, the error is therefore observational.
Although the performance improved with increasing
stipulated Cp the degree of error was large as reflected
in the rmse, these values reflect 20-30% of the final
point estimate, therefore the pharmacokinetic parameters
produced by OPT (Fig 7.1) are of little relevance and 
\ - 
should not be reported, although they are useful for
simulation of alternative doses.
7.12. PERSPECTIVES OF THE MODEL
Despite the use of fixed variances which may not
reflect the actual population variances reasonable
estimates of Cp could be obtained prospectively, and
the protagonists of Bayesian forecasting attest to its
efficacy in dosage prediction (Sheiner et al, 1979a);
Kelman et al 1982a,b; Ooel et al', 1985). Bayesian
forecasting has limitations; as with any pharmacokinetic
predictive model it is entirely reliant on good compliance
and without this prediction is meaningless. Inclusion
of an uncertainty factor in the model presupposes that
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subsequent measurements are performed in an environment 
in which compliance can be assumed, this is a reasonable 
assumption for some groups of hospital in-patients but 
not for out-patients or those attending their G.P.
Even in an 'educated1 group of bronchitics in general 
practice taking theophylline only 52-58% were fully 
compliant. When results were fed back to the patients 
non-compliance apparently dropped from 28 to 8% although 
this was subsequently found to be 38% on an unannounced 
domiciliary visit (Langan and Watson, unpublished work).
A valuable aspect of OPT in the above study was 
the education of the general practitioner about pharmaco­
kinetics and rational prescribing however after three 
months his clinical judgement had become sufficiently 
attuned to enable him to prescribe doses comparable to 
those predicted by OPT, provided both had Cp feedback.
7.13. CONCLUSION
OPT is useful in forecasting future Cp and dosage. 
The most fundamental limitation to the technique is 
compliance. OPT will perform satisfactorily provided 
adequate Cp data are available and care is excercised 
in interpreting its output. An appreciation of kinetic 
principles would be a desirable pre-requisite for a 
potential user.
Hard1 replied the Dodger.
As nails’, added Charley Bates
Charles Dickens 
Oliver Twist Ch.9.
CHAPTER 8
LIQUID CHROMATOGRAPHIC ASSAYS FOR 
CLAVULANIC ACID AND THE ISOMERS OF 
TICARCILLIN IN SERUM AND URINE
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INTRODUCTION
8.1. PENICILLINS
8.1.1. Microbial Assay
Typically penicillins, including ticarcillin (TIC) 
have been assayed by agar-diffusion microbiological assay 
which may be highly sensitive (Sutherland and Rolinson, 
1978), such an assay has been described for TIC (Bannatyne 
and Cheung, 1981) . Several workers have used Sarcina 
lutea as the test organism as clavulanic acid (CLAV) does 
not cause inhibition of this organism (Witkowski et al,
1982; Adam, De Visser and Koeppe, 1982; Schaad, Casey and 
Cooper, 1983).
8.1.2. Spectrophotometric Assay
Acid labile penicillins may be measured spectrophoto- 
metrically following isomerization to the corresponding 
penicillenic acids (De Week, 1962), which although labile 
may be rendered more stable by the addition of copper 
(Saccani and Pitrolo, 1969) or mercuric salts (Brandriss 
et al, 1963). However the penicillins undergo side reactions 
and the penicillenic acids are unstable (Bundgaard, 1971) .
Formation of the mercuric mercaptides of imidazole-', 
penicillenic acids results in a stable product that has 
been used as the basis for a procedure for the assay of 
penicillins (Bundgaard and liver, 1972), but was not 
applied to the estimation of penicillins in biological 
fluids.
Fluorimetric assays for ampicillin (Ousko, 1971) 
and amoxycillin (Davidson, 1976) suffer from the disadvantage
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that theyalso measure the penicillinoic acid metabolites.
8.1.3. Liquid Chromatographic Assay 
There are a number of reports of HPLC assays for 
penicillins including one for amoxicillin in biological 
fluids using post-column reaction with imidazole 
(Carlqvist and Westerlund, 1979), however only a few 
reports on liquid chromatographic assays relate to TIC. 
Gupta and Stewart (1980) examined a number of 31actams 
including TIC in a study on the stability of intravenous 
mixtures; they noted two peaks for TIC but did not 
investigate this finding further. Kwan et al (1982) 
claimed to obtain a single peak for TIC in their assays 
for serum and urine concentrations/ however they had noted 
two peaks which they suggested might be isomers. As the 
acetylating agent used in the preparation of semi- 
synthetic penicillins from 6-aminopenicillanic acid is 
isomeric it would be expected that the final product 
might contain isomeric penicillins (Salto, 1978) .
The assay developed by Kwan et al (1982) had 
absolute recovery of TIC of 76% and used a technically 
demanding extraction procedure and did not assay the 
isomers of TIC. These isomers are of particular interest 
in renal failure as one or both may accumulate, therefore 
an assay for the isomers applicable to both serum and 
urine was required.
8.2 CLAVULANIC ACID
8.2.1. Microbial Assays
Clavulanic acid (CLAV) is a relatively new compound.
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Its structure, established by X-ray crystallography 
(Howarth, et al 1976), has only been known for
eight years. There have not been many methods developed 
for its determination in biological fluids, microbial 
assays are commonly used. The principle of these assays 
is the inhibition of the $lactamase of the test organism 
resulting in it being susceptible to penicillin seeded 
in the medium (Adam et al, 1982).
8.2.2. Liquid Chromatographic Assays
CLAV is unstable at alkaline pH and in strong 
acids and therefore is difficult to extract from biological 
fluids for subsequent liquid chromatographic assay.
The first assay developed was by Haginaka et al (1981) 
and used UV absorbance for detection; usually CLAV 
does not absorb significantly above 210 nm, however a 
bathochromic shift is induced in methanol which permits 
measurement at higher wavelengths. This assay was further 
developed and refined; the use of methanolic sodium 
hydroxide degraded clavulanate to produce methyl-4- 
(2 hydroxyethyl)-pyrrole-3-carboxylate which absorbs 
at 270 nm, by using a methanolic HPLC eluant and a sodium 
hydroxide post-column reaction a sensitive assay for 
CLAV in serum and urine was developed (Haginaka, et al, 
1983). Although sample preparation was simple, minimal 
performance data were presented and only spiked samples 
were used. The chromatogram contained a number of 
peaks, but apparently none interfered with the measure­
ment of CLAV.
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CLAV can also be measured following derivatisation 
with imidazole, a procedure applicable to serum and urine 
has been described (Foulstone and Reading, 1982 ), 
derivatisation was achieved prior to injection. Assay of 
serum was carried out either directly or on ultrafiltrates.
The imidazole-CLAV product, l-(8 hydroxy-6-oxo- 
4-azaoct-2enoyl)-imidazole absorbs at 311 nm and thus 
potential interference is minimised. Surprisingly 
this assay was not validated for precision, sensitivity 
etc. An assay using elements of this work has been 
published with detailed validation (Watson, 1985) 
and is based on the work described in this thesis.
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MATERIALS AMD METHODS
8.3. MATERIALS
8.3.1. Chemicals
i ) T icarcillin
Ticarcillin sodium (Beecham Pharmaceuticals, 
Brockham, Surrey) (pure free acid equivalent 80.8%) 
was used to prepare calibrators, and thienylbutyric 
acid (Sigma Chemical C o ., London, England) was used as 
the internal standard. All other reagents used were BDH 
Analar grade unless specified. 3 Lactamase (E.C. 3.5.2.6.) 
was obtained from Whatman Biochemicals Ltd. (Maidstone, 
England) and reconstituted according to the manufacturers 
directions.
i i ) Clavulanic Acid
x
Clavulanate potassium (Beechams Pharmaceut­
icals) (pure free acid equivalent 82.5%) was used to > 
prepare calibrators. Imidazole reagent was used with and 
without mercuric chloride as described by Foulstone and 
Reading (1982) and detailed below. Imidazole was 
obtained from.BDH (for penicillin analysis grade) 
and Aldrich Chemical Co. (Gillingham, England).
8.3.2. Imidazole Reagents
*) Imidazole reagent with . mercuric chloride 
Imidazole (16.5 g) was dissolved in 24 ml 
distilled water plus 4 ml of 5M hydrochloric acid and 
4 ml of 1.35% mercuric chloride, the pH was adjusted 
to 6.8 and the volume then made up to 40 ml with distilled 
water.
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ii). Imidazole reagent without mercuric chloride 
Imidazole (8.25 g) was dissolved in 24 ml 
distilled water and 10 ml of 5M hydrochloric acid added, 
the pH was adjusted to 6.8 and the solution stored in 
an amber bottle at room temperature.
8.4. EQUIPMENT
8.4.1. U.V. Spectrophotometry
U.V. spectrophotometry was performed on a Beckman 
DU-7-HS spectrophotometer (Beckman RIIC Ltd, High Wycombe, 
England).
8.4.2. HPLC Equipment
A Gilson 302 B pump fitted with a series 5 head, 
latterly a series 50 head and a Gilson 802 manometric 
module (Gilson, Paris, France) was used with an Altex 
160 fixed wavelength filter detector (Beckman). Injections 
were made with a Waters 710B WISP autosampler (Waters 
Associates, Northwick, England) . Results were integrated 
using a Shimadzu C-R2AX integrator and latterly a 
Shimadzu C-R3A integrator (Dyson Instruments, Houghton- 
le-Spring, England). Columns were slurry packed using 
a Shandon column packer (Shandon Southern Products, Runcorn.)
i ) Ticarcillin
A 10 cm x 5 mm i.d. column packed with
Hypersil 3y 0DS was used for the assay of TIC.
ii) Clavulanic acid
A 25 cm x 4.6 mm i.d. Spherisorb 5p 0DS 
was used in the determination of the CLAV-imidazole
product. Prior to this Hypersil 5y 0DS in a 10 cm x
5 mm i.d. column had been used.
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8.5. DEVELOPMENT OF LIQUID CHROMATOGRAPHIC ASSAYS
8.5.1. ImidazoleReactions
i) Imidazole reagent with mercuric chloride 
To 4 ml of aqueous TIC or CLAV solution 
(50 mg/1) was added 1 ml of reagent and the mixture 
incubated at 60°C for 25 minutes. The solution was cooled 
and scanned versus a blank of water and reagent (4:1) 
over the range200-400 nm.
i i ) Imidazole reagent without mercuric chloride 
To 1 ml of aqueous CLAV solution (50 mg/1) 
was added 1 ml of reagent and after incubation at room 
temperature for 10 mins was scanned over the range 200- 
400 nm. /
8.5.2. Eluants
Eluant flow rates were 1 ml/min unless specified,
i ) Ticarci’llin
Initially a methanol/1% acetic acid (30:70) 
v/v eluant was used followed by methanol/l%acetic acid/ 
tetraethylammonium bromide (Aldrich) (30:70:0.05M) v/v/w 
with detection at 233 nm. Finally a methanol/0.05M 
phosphoric acid eluant v/v was used, the proportion of 
methanol used was 25 or 30% depending on required elution 
speed with a flow rate of 2 ml/min i
ii) Clavulanic Acid
The eluant used by Foulstone and Reading 
(1982)(methanol/0.1M phosphate buffer pH 3.2 (6:100)), was 
subsequently modified to methanol/0.1M NaH^PO^ containing 
0.05M pentane sulphonic acid (Fisons, Loughborough,
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England) (10:90). These eluants were used on the 5y 
HypersilODS material. On the change to Spherisorb ODS packing 
the eluant was changed to its final form of methanol/
0.1M NaH^PO^ containing 0.05M pentane sulphonic acid 
and 0.1M ethanolamine, this eluant was pumped at 1.5 ml/ 
min.
8.5.3. Sample Preparation
i ) Ticarcillin
Initially ultrafiltration of serum was 
attempted using the Syva 'Free' drug assembly (Syva, 
Maidstone, England). Subsequently an acid extract into 
diethyl ether was employed with evaporation of the 
organic phase to dryness, the residue being dissolved 
in the HPLC eluant prior to analysis.
The finalised extraction procedure is as noted
below:
To 1 ml of sample in a Z10 plain tube (Brunswick , 
Ballymoney, Northern Ireland) was added 50 ul of 1 g /, 1 
methanolic thienylbutyric acid and 6 ml of diethyl ether.
To each tube was then added 100 ul of 3M hydrochloric 
acid, the tube was immediately capped and inverted 2 or 3 
times to ensure complete mixing. It was essential to 
perform this step immediately as TIC was very labile in 
acid conditions. The tubes were shaken for 5 mins on 
a lateral shaker (Griffin and George, London, England).
The ether layer was transferred to a second Z10 tube 
containing 500 ul of 0.1M Phosphate buffer pH 7.0 and 
the ether removed under a stream of air at 40°C; of the
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remaining aqueous layer 200 ul was transferred to a 
PRO tube (Sarstedt Ltd., Leicester , England) from 
which the upper 5 mm had been removed, these were 
placed in the centre of a spring insert in the WISP 
autosampler vial and the septum screw caps applied, 
the carousel was then loaded, and the samples injected.
The procedures for serum,diluted urine and peritoneal 
fluid were identical.
i i ) Clavulanic acid
Apart from the substitution of the Syva 
’Free1 Drug Assembly for the Amicon MPS-1 system the 
sample preparation was similar to that described by 
Foul stone and Reading (1982).
The procedure used for serum was as follows: To
500 ul of serum in a Z10 tube was added 500 ul of 0.1M 
phosphate buffer, pH 7.0, after mixing this was trans­
ferred to the Syva 'Free' Drug Assembly and these were 
centrifuged for 20 mins at room temperature at 1500 g.
To 100 ul of ultrafiltrate in a PRO tube was added 100 ul 
of imidazole reagent without mercuric chloride, the tube 
was capped, mixed by flicking and inversion, the top 
5mm removed and inserted into the WISP autosampler as 
described above. The technique for diluted urine and 
peritoneal dialysate are as described for ultrafiltrate.
8.5.4. Sample Storage
Clavulanic acid is labile, as is ticarcillin to a 
lesser extent. CLAV is labile in alkali, strong acid 
and is also thermolabile, TIC is acid labile but
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relatively stable at room temperature.
In view of these problems the following precautions 
were taken.
i ) Serum
To allow good clot retraction the blood 
samples were stored at room temperature for one hour 
then centrifuged and the serum stored at -80°C prior to 
analysis.
ii) Urine
24 hour urine collections could not be used 
therefore urine was volumed following micturition and an 
aliquot taken and diluted 1 in 10 with 0.1M citrate 
buffer ,pH 6.5, the diluted samples were stored at -80°C 
prior to analysis.
8.5 ;5. Linearity and Calibration
From a freshly prepared stock of 1 g/1 ticarcillin 
sodium or clavulanate potassium were prepared serum 
calibrators covering the range 0-500 mg/1 for TIC and 
0-50 mg/1 for CLAV using horse serum No 3 (Wellcome 
Reagents, England). Urine calibrators were prepared 
in fresh human urine diluted 1 in 10 with 0.1M citrate 
buffer pH 6.5 covering the range 0-2000 mg/1 for TIC 
and 0-500 mg/1 for CLAV.
8.5.6. Recovery
Recovery of TIC relative to the internal standard 
was assessed from the ratio of peak areas of directly 
injected TIC/internal standard solution to comparable 
assayed serum standards at 80 mg/1 (n=20). For CLAV a
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comparison with directly injected aqueous standards at 
a concentration of 5 mg/1 was performed, fhe recovery of 
aqueous ultrafiltrate (n = 5) and serum ultrafiltrate 
(n=5) was compared to assess losses.
8.5.7. Precision
Precision was performed, within and between batch, 
at 5 mg/1 and 80 mg/1 for TIC (n=21 and n=60 respectively 
within batch and n=58 and n=62 respectively between 
batch) and at 1 mg/1 and 8 mg/1 for CLAV (n = 40 and n = 40 
respectively within batch and n=44 and n=48 respectively 
between batch).
8.5.8. Accuracy
Samples from individuals on a number of drugs were 
studied and the relative error determined (Equation 2.2) 
for TIC at 5 mg/1 and CLAV at 1 mg/1.
8.5.9. Quantitation
The concentration of TIC was calculated using 
equation 2.3 using total peak area as TIC eluted as 
two distinct peaks. In any calculation of TIC isomer 
concentration,peak height was used. Results obtained 
using summed peak height for isomers 1 and 2 were 
comparable to those obtained using total peak area.
The relative contributions of the two isomers was 
calculated by proportion of peak height to the total 
ticarcillin concentration assuming equal detector 
response on a weight for weight basis.
As an internal standard was not used in the CLAV 
.assay external standardisation was used in a manner
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analogous to that described for TMP in section 2.7.5.
The use of a target calibrator (section 2.7.5.) 
also served to correct for within-run degradative losses 
and was applied to both TIC and CLAV assays. The target 
calibrator is prepared in 0.1M phosphate buffer pH 7.0 
at concentrations of 250 mg/1 and 20 mg/1 for TIC and 
CLAV respectively.
8.5.10. Ticarcillin Isomer Equilibration 
The equilibrium of the TIC isomer was investigated 
by collecting the leading or trailing edge of the first 
or second TIC peak respectively and re-analysing it, 
this was repeated on the original fractions until the 
ratio of the two peaks, as determined- by peak height, 
had reverted to that originally found.
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RESULTS
8.6. DEVELOPMENT OF LIQUID CHROMATOGRAPHIC ASSAYS
8.6.1. Imidazole Reaction Products
Both TIC and CLAV react with imidazole reagent, 
and products absorbing in the UV would be useful in 
enhancing specificity. TIC only reacts with imidazole 
containing mercuric chloride, CLAV reacts with either of 
the reagents described in section 8.3.2. to produce a 
product with an identical UV spectrum and chromatographic 
characteristics.
Derivatives of CLAV were routinely made using the 
procedure outlined in section 8.5.1. (ii ) and for TIC 
by the 'procedure in 8.5.1. (i)> the UV spectra for the 
products are similar (Fig 8.1) and are an improvement 
on their UV spectra as there is no UV absorbance  above 
220 nm for either compound prior to derivitisation.
The procedure outlined in section 8.5.1. (ii) was 
routinely used in all subsequent investigations of CLAV 
and the product measured by HPLC.
Adequate sensitivity was available using UV detection 
of TIC at 214 nm and the derivitisation technique 
was not further developed.
8.6.2. Eluants *
i ) Ticarcillin
Chromatography of TIC with methanol/1% acetic 
acid (30:70) revealed two peaks (Fig 8.2a); confirmation 
that both of these peaks were penicillins was achieved 
by the addition of penicillinase to the TIC solution
0-450
0-225
O.D.
350 X• 225 250 300275 325
FIGURE 8.1. Ultraviolet scans of the imidazole reaction products 
of ticarcillin and clavulanic acid.
FIGURE
0 025 AUFS
0 k'24
T-OIC ACID
0 025 AUFS
8.2. LC of ticarcillin : eluant Methanol/1% acetic acid
(30:70).
a) ticarcillin enantiomers,
b) ticarcillinoic acid (s).
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which would result in the disappearance of any peak(s) 
relating to TIC and produce ticarcillinoic acid; both 
peaks were absent and a large, earlier eluting peak was 
detected which was ascribed the identity of ticarcillinoic 
acid (Fig 8.2b). The k' for ticarcillin isomer 1, 
isomer 2 and ’ticarcillinoic acid1 were 2.6, 3.6 and 0.85 
respectively. This was a chromatographically efficient 
system (TIC isomer 2, h=0.6), the addition of tetre- 
ethylammonium bromide to the eluant resulted in a 
reduction in efficiency for this peak to h=1.9.
Serum ultrafiltrates were studied using spiked 
horse serum with the second eluant. Fig 8.3 shows a 
serum containing TIC and Fig 8.3b shows a drug free 
serum, there was a peak that co-eluted with TIC isomer 1 
(a=1.0) and also late eluting endogenous material. Due 
to these problems the methanol/acetic acid eluant was 
preferred, however sensitivity at the wavelength used 
(233 nm) was inadequate for adequate pharmacokinetic 
profiling and a fixed wavelength detector with a zinc 
lamp and a 214‘ filter was commissioned. Acetic acid 
absorbs at this wavelength and to improve the signal/ 
noise ratio, 0.05M phosphoric acid was used instead, 
ii) Clavulanic acid
Using methanol/0.1M phosphate buffer pH 3.2 
(6:100) the CLAV imidazole product had a k ’ of 9, but 
there were some peaks that co-eluted. Addition of 0.05M 
pentanesulphonicacid resulted in an increase in k' to 
29. The eluant was amended to methanol/0.1M sodium
0 001 AUFS
,----- r---- r~----1---
6 4 2 0 k '
FIGURE 8.3a LC of TIC : serum ultrafiltrate , 20 mg/1 TIC i serum
b0001 AUFS
6 4 2 0  k'
FIGURE 8.3b. LC of TIC : serum ultrafiltrate , TIC free serum
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dihydrogen phosphate containing 0.05M pentanesulphonic 
acid (10:90), a typical chromatogram of an aqueous 
standard is shown in Fig 8.4-. The imidazole reagent 
gave rise to a number of peaks; one of these co-eluted 
with the CLAV peak.. This problem only occurred with 
imidazole supplied by Aldrich, use of imidazole (for 
penicillin analysis) (BDH) avoided this problem. As 
shown in Fig 8.5 there was significantly more UV 
absorbing material in the former than the latter.
Following an experiment involving the direct 
injection of serum the column performance was degraded 
(Asio^=2.0). Previously the had been 1.5, (the
CLAV peak was symmetrical but with tailing) however on 
replacement of the column with 5u 0DS spherisorb there 
was very significant asymmetry (Fig 8.6) using the 
solvent of Foulstone and Reading (1982). The use of 
pentane sulphonic acid as ion-pair resulted in the 
chromatogram shown in Fig 8.7, however addition of a 
counterion, ethanolamine, resulted in a marked improve­
ment in peak symmetry (Fig 8.8) and reduction in k !. The 
eluant was slightly modified thereafter for routine use.
8.6.3. Sample Preparation
i ) Ticarcillin
a) ultrafiltration
There was a 2% loss of TIC on the filters, 
but recovery in the ultrafiltrate was 54% (the remaining 
44% being protein bound). Preliminary investigation of 
the precision indicated that the CV was greater than 10%
0 0 1  A U F S
68 24
FIGURE 8.4. LC of CLAV : aqueous CLAV imidazole product, other peaks
from Aldrich imidazole. Eluant methanol/0.1M phosphoric
acid (6:94); column 5yHypersil ODS.
FIGURE 8.
3-50
ALDRICH
1-75
O.D.
BDH
275 290 305 320 335 350
5. Ultraviolet spectrophotometry of 20% aqueous solutions 
of imidazole supplied by Aldrich and BDH.
CLAV
T 0-1 AUFS
FIGURE 8,6. LC of CLAV : aqueous CLAV-imidazole product, eluant 
methanol:0.1M phosphoric acid (6:94); column 5}i 
Spherisorb ODS.
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FIGURE 8.8. LC of CLAV : aqueous CLAV-imidazole product, eluant
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therefore this approach was abandoned.
b) liquid/liquid extraction
As penicillins are acids, an acidic extraction
into diethyl ether was appropriate, however TIC, in common
with other penicillins is acid labile. Initially recoveries
were very variable, but addition of ether to the TIC sample
prior to the addition of the acid followed by IMMEDIATE
inversion improved the consistency of recovery, however
losses were found at the evaporation stage, caused by
residual acidity from the evaporated ether phase.
Removal of the organic phase over 0.1M phosphate buffer,
pH7,circumvented this difficulty. Further imprecision
was associated with variable recovery of the internal
standard; mechanisation of extraction on a lateral shaker 
\ *
ensured reproducible recovery of this component.
Absolute recovery was then dependent on the amount of 
organic phase transferred.
ii) Clavulanic acid
Only serum samples required ultrafiltration 
prior to CLAV analysis. It was possible to analyse 
serum for CLAV by injecting serum on column following 
reaction with imidazole, (Fig 8.9), as noted earlier 
(section 8.6.2. ii) this rapidly led to a loss of column 
performance. Buffering of serum prior to ultrafiltration 
counteracted the alkaline pH of the ultrafiltrate 
( pH 8.0) which resulted in degradation of CLAV.
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8.6.4. Sensitivity
Sensitivity, defined as twice the signal/noise 
ratio was lOOng on-column weight for each TIC isomer, 
i.e. total TIC sensitivity is 200 ng on-column weight 
and 4 ng on-column weight for CLAV. These levels are 
equivalent to 4 mg/1 and 40 mg/1 TIC and 0.1 mg/1 and
0.5 mg/1 CLAV for serum and urine respectively.
8.6.5. Linearity
i ) Ticarcillin
The summed area of the ticarcillin peaks 
was found to be linear over the range 0-30 ug on- 
column weight, this is equivalent to 0-600 mg/1 for serum 
samples and 0-6000 mg/1 for urine samples,
ii) Clavulanic acid
i
Linearity was established for CLAV peak 
area over the range 0-20 ug on-column weight, this is
equivalent to 0-500 mg/1 for serum and 0-2500 mg/1 for
the urine assay.
8.6.6. Recovery
Recovery ‘relative to the internal standard for 
80 mg/1 TIC was 98.1*8.3% (n=20). The absolute recovery
of CLAV from serum was 79.2±4.2% (n = 5 ) . It was determined
that the average losses were 6.2%'due to ultrafiltration 
and 12.6% due to protein binding.
, 8 . 6 . 7 .  P r e c i s io n
i) Ticarcillin
The within batch precision at 5 mg/1 and
80 mg/1 was 7.8% and 6.0% respectively; between batch
precision was 12.4% and 8.4% respectively,
ii) Clavulanic acid
The within batch precision at 1 mg/1 and 
8 mg/1 was 4.5% and 3.0% respectively; between batch 
precision at these levels was 6.6 and 4.3% respectively.
8.6.8. Accuracy
i ) T icarcillin
Tne relative error was not statistically 
significant (t=l.0). The co-eluting endogenous peak 
had an area equivalent to 3.5 mg/1 TIC. No medication 
has yet been encountered which has given rise to spurious 
results.
- i i ) Clavulanic acid
The relative error was not statistically 
significant (t=0.02). Samples from patients on a great 
variety of co-medication have been assayed with no 
apparent interference.
8.6.9. Assay in Biological Fluids 
i ) Serum
dhromatograms of CLAV obtained from serum 
ultrafiltrates prior to dosing and following dosing are 
shown in Fig 8.10.
Using a 25% methanol eluant the endogenous peak 
was separated from the TIC isomers, and eluted between 
them; chromatograms obtained pre and post dose are shown 
in Fig 8.11.
ii) Urine
Slower chart speeds were used to obtain the
a0 001 
AUFS
FIGURE 8.10a LC of CLAV : serum ultrafiltrate prior to dosing 
eluant, methanol:0.1M sodium dihydrogen phosphate: 
pentanesulphonic acid:ethanolamine (10:90:0.05M:0.1M), 
flow rate 1.5 ml/min, column Spherisorb 5p 0DS.
b0001
AUFS I
CLAV
l ~ / \
T
8
T
6 4
k 1
0
FIGURE 8.10b LC of CLAV : serum ultrafiltrate 8 hours post dose.
Conditions as in FIG. 8.10a.
0001
AUFS
“ 1--------1-------1-------1-------1----- 1
10 8 6 4 2 0
k'
FIGURE 8.11a LC of TIC : serum extract prior to dosing. Eluant
methanol:0.05M phosphoric acid (25:75), flow rate 2 ml/min,
column Hypersil 3p ODS. Internal standard (ISw) thienylbutyric acid.
0001
AUFS
T "-------1------ 1------ 1------- 1------ 1
10 8 6 4 2 0
k'
FIGURE 8.11b. LC of TIC : serum extract 8 hours post dose,
conditions as in FIG 8.11a.
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chromatograms of CLAV and TIC in urine (Figs 8.12 and 
8.13). The 30% methanol eluant was used for the TIC assay. 
8.6.10 Ticarcillin Isomer Equilibration 
Equilibria between the isomers of TIC are rapidly 
re-established following perturbation by collection.
TIC^ re-established equilibrium with a half-life of 
6.0 minutes, and TIC2 with a half-life of 1.4 minutes, 
a plot of log peak height deviation versus time was 
linear and had apparent first-order re-equilibration 
kinetics.
FIGURE 8.
CLAV
0 0 0 1  T  
AUFSl
/v
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^ LC of CLAV : Assay of CLAV in urine 8 hour post dose.
Conditions as in FIG. 8.10a.
IS
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FIGURE 8.13. LC of TIC : Assay of TIC in urine 8 hours post.dose.
Eluant : methanol:0.05M phosphoric acid (30:70) other 
conditions as in FIG 8.11a.
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DISCUSSION 
8.7. ASSAY FOR TICARCILLIN
Of interest in the assay described for TIC was the 
ability to separate and quantitate the two ticarcillin 
isomers. Kwan et al (1982) eluted the TIC isomers as 
a fused peak having noted that the isomers had been the 
cause of earlier asymmetric peaks, although they found 
that by close control of the eluant pH it was possible 
to obtain TIC as two fused peaks. Gupta and Stewart 
(1980) separated the isomers of TIC, but did not apply 
the assay to biological fluids. The assay of Kwan et al 
(1982) had similar sensitivity to that reported here and 
was applicable to both serum and urine although the 
sample procedure was somewhat involved; the performance 
characteristics are very similar to the TIC assay 
reported here and elsewhere (Watson, 1985), however 
the major difference is the ability to quantitate the 
isomers, in addition this assay is simpler.
It has not proved possible to independently isolate 
the enantiomers to enable identification as they rapidly 
re-equilibrate in solution; the R-isomer is slightly 
more active than the S although this is pH dependent, 
it is most probable that the R isomer elutes first 
(B. Slocumbe, personal communication).
However if immediate analysis of urine by direct 
injection were to be perfomed it would be possible to 
investigate any differential excretion of TIC isomers 
although this is unlikely to be important.therapeutically.
2 09
The interference by the small serum peak could be 
avoided by increasing the retention to allow resolution, 
by subtraction of the peak area found in a pre-dose 
sample or by running a penicillinase blank; the second 
option was most rapid and was routinely adopted.
As would be anticipated manual measurement and 
summation of TIC peak height for total TIC was less 
precise than integrated summation of area with correction 
of background, especially if faster elution times are 
used. However, measurement of peak height for each 
isomer and summation compared well with blank corrected 
integrated area; using peak height in this way a negligible 
contribution from the endogenous peak was noted.
Despite investigating a number of penicillins and 
their penicillinoic acids none had a k* appropriate for 
a useful internal standard, Kwan et al (1982) used 
carbenicillin which is also an isomeric mixture (Gupta 
and Stewart, 1980) and although the eluant used by 
Kwan et al (1982) is substantially different from that 
used here it might prove to be a more appropriate internal 
standard, particularly as there was internal standard 
induced imprecision introduced into the assay reported 
here. Thienylbutyric acid was suitable in terms of its 
chromatographic behaviour but it was not until a lateral 
shaker was used for extraction that acceptably repro-r 
ducible recoveries of internal standard were obtained.
In addition to this problem there were other areas 
of potential error: in the extraction step it was found
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to be essential to add the acid after the diethyl ether 
and mix immediately as delay resulted in significant 
losses of the acid-labile TIC. Losses could also occur 
due to residual acidity when the organic phase was 
evaporated to dryness, extracts were therefore concentrated 
by evaporation in phosphate buffer.
The sensitivity and precision of the LC assay for 
TIC is superior to that reported for a TIC bioassay 
(Bannatyne and Cheung, 1981) although the latter only 
required 40 ul of serum.
8.8 ASSAY FOR CLAVULANIC ACID
The sample preparation procedure used here was closely 
related to that of Foulstone and Reading (1982) but 
had not been validated by them for a routine procedure.
The Syva assemblies used are very similar to the Amicon 
MPS-1 system and acceptable results should be obtainable 
using this. The buffer used prior to ultrafiltration 
was required to stabilise CLAV, derivitization prior to 
injection was preferred although it should be possible 
to develop a satisfactory post-column reaction procedure 
as has succesfully been done for amoxicillin using a 
mercuric-imidazole reagent (Carlqvist and Westerlund,
1979). A novel post-column reaction procedure for CLAV 
has been reported by Haginaka et al (1983) in which 
post- column alkaline degradation was used; these authors 
exhaustively examined a number of CLAV degradation 
product and procedures. An ion-pair separation of CLAV 
followed by alkaline degradation was found- to provide
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sufficient sensitivity to allow pharmacokinetic studies 
to be performed. Interesting though this assay is, it 
has limitations, direct injection of serum was used 
and this has been found to degrade column performance 
(Watson, 1985). Two different eluants were required for 
analysis of serum and urine and there were problems of 
noise associated with the post-column reactor. After 
each run, to protect the post-column reaction equipment 
and plumbing, it was necessary to flush out the alkali 
with dilute nitric acid. Thus although sensitivity and 
precision appear comparable to those reported here this 
would appear to be a more demanding system to operate.
An ion/counter-ion eluant was developed for the assay 
described in this work. The reasons for its composition 
are as follws:- The phosphate salt was used to maintain 
an acid pH at which the clavulanate derivative was 
relatively stable, methanol was an organic modifier, 
pentane sulphonic acid was required to ion-pair the 
reaction product (1-(8-hydroxy-6-oxo-4azaoct-2-enoyl)- 
imidazole) to improve its retention and ethanolamine 
acted as a counter-ion. No products were found for TIC 
or its penicillinoic acid when incubated with imidazole 
reagent.
When a well capped reverse phase material was used 
some tailing of the peak shape resulted, however if 
'end-capping ' was incomplete it was found that peak 
tailing was excessive; in either case excellent peak 
shape could be obtained by the addition of a cation
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which covered the residual silanol groups and also acted 
as a counter-ion, ethanolamine was found to be satisfactory 
and adjustment of its concentration could be used to 
control the retention of the clavulanate-imidazole reaction 
product; an increase causing a decrease in k' and a 
decrease on increased k'. The use of longer chain alkyl 
cationic surfactants resulted in excessive desorption 
with a decrease in solute retention to a k* <1.
An internal standard was unnecessary as there was 
little sample preparation for urine samples and a simple 
preparation for serum with a reproducible recovery. The 
product stability was such that adjustment for degradation 
loss within run was necessary although reproducible within
the run; this was well identified with the repeat sampling
\
of the 'target1 standard.
The precision of the assay was better than that 
previously noted with a microbiological assay (Bennet 
et al , 1983 ).
8.9. CONCLUSION
Since both TIC and CLAV are labile, correct storage 
and handling of samples are essential for accurate 
results; the use of liquid chromatography provides an 
ideal approach for the fast, reliable, precise and 
accurate assay of both analytes in serum and urine.
The assays developed are suitable for estimation 
of both CLAV and TIC (and its isomers) in clinical 
studies.
The whole is more than the sum of the parts.
Aristotle 384-322BC 
Metaphysica 1045a .10
CHAPTER 9
CLAVULANATE POTENTIATED TICARCILLIN : 
PHARMACOKINETICS IN PATIENTS WITH RENAL FAILURE 
AND IN PATIENTS UNDERGOING DIALYSIS
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INTRODUCTION
9.1. CLINICAL USE OF CLAVULANIC POTENTIATION OF PENICILLINS
Clavulanic acid is a 3-lactam first isolated from 
Streptomyces clavuligerus. It is an antimicrobial agent 
with a very low specific antimicrobial activity (Cole,
1980), however it has a very high affinity for 8 -lactamases 
especially the plasmid mediated TEM enzymes (Reading 
and Cole, 1977); its action may be reversible or irrever­
sible (Fisher, Charnas and Knowles, 1978: Cole, 1980).
Thus CLAV can be used in combination with 8-lactamase- 
sensitive agents to potentiate their action (Cole, 1980).
9.1.1. Amoxycillin/CLAV
A' number of 8 -lactams have been* shown to be 
potentiated by CLAV in vitro (Wise, Andrews and Bedford, 
1978; Reeves, Bywater and Holt, 1978; Cole, 1980), one 
that was particularly effective was CLAV and amoxycillin, 
this was shown to have significant activity against 
amoxycillin-resistant organisms ijr vitro (Miller, Baker 
and Thornsberry, 1978) and in vivo (Ninane at al, 1978).
The combination of amoxycillin/CLAV has since 
been used to treat a wide variety of infections including 
respiratory tract infection (Ninane et al, 1978; Stevens 
and Abbas, 1980) and simple, complicated or recurrent 
urinary tract infection (Reeves et al, 1980; Gurwith,
Stein and Gurwith, 1983; Brumfitt and Hamilton-Miller,
1984-).
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9.1.2. Ticarcillin/CLAV
In complicated urinary tract infection significant 
re-infection may occur, in one study using amoxycillin/ 
CLAV,17% of ’cures’ suffered re- infection by Pseudomonas 
aeruginosa (Leigh et al, 1980) which is not susceptible 
to amoxycillin. More recently CLAV in combination with 
ticarcillin (TIC) has become available; TIC is a broad- 
spectrum penicillin with activity against Pseudomonas 
aeruginosa, unlike amoxycillin it is acid labile and can 
therefore only be administered intravenously.
Carbenicillin and TIC were the earliest penicillins 
to be shown to be effective against P. aeruginosa, in 
vitro testing indicated that TIC was 2-3 times as potent 
as carbenicillin against this organism (Klastersky and 
Daneau, 1972; Fuchs et a l , 1977; King et al, 1980).
Both drugs are effective against gram-negative organisms 
with--TIC the more active. Although not primarily 
intended for such use,TIC and carbenicillin may be used 
against gram-positive organisms, carbenicillin is more 
active (Fuchs’et al, 1977).
Resistance to TIC, by a variety of species eg.
E. Coli (Rodriguez et al, 1973) is due to its suscept- 
ability to their $ lactamases (for E.Coli, TEM $ lactamase) 
CLAV irreversibly inhibits this enzyme and therefore 
combining it with TIC would be expected to broaden its 
spectrum. The combination of TIC and CLAV is more 
active than TIC alone i_n vitro (Paisley and Washington II,
1978; Chattopadhyay and Hall, 1984; Clarke and Zemcov, 
1984; Fuchs et al, 1984) and has succesfully been used 
in vivo (Cox, 1983; Williams ,Horobin and Price, 1984; 
Kosmidis et al, 1984)
9.2. PHARMACOKINETICS OF CLAVULANATE/PENICILLIN
COMBINATIONS IN NORMAL SUBJECTS
9.2.1. Amoxycillin/CLAV
The kinetics of amoxycillin and CLAV are comparable 
whether administered alone or in combination (Oackson 
et al, 1980; Ball et al, 1980; Adam, et al,
1982; Witkowski et al, 1982). Elimination half-life 
for both amoxycillin and.-CLAV is about 1.1 hours !
(Adam et al, 1982; Witkowski et al, 1982), there is 
approximately a 20% reduction in CLAV recovered in 
urine if the dose is administered orally rather than 
intravenously (Oack'son et al, 1980) which may be due 
to lability in the gut or to a first-pass effect.
9.2.2. TIC/CLAV
The combination of TIC/CLAV is newer than the 
amoxycillin/CLAV combination and consequently there 
is a lack of data on the TIC/CLAV combination. It 
has been reported that the kinetics of TIC and CLAV 
in combination are comparable in * combination to those 
obtained when the drugs are given independently 
(Bennett et al, 1983) and this has recently been 
confirmed (Tetzel et al, 1984)
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i) Volume of distribution
Bennett et al (1983) found a Vd of 10.8 1 
for TIC, this compares with other reports (Libke, et 
al, 1975; Findlay et al, 1981; Davies et al, 1982), 
these values are in contrast to the Vd reported by 
Mayers et al (1980) of 41.8 1/100 kg. All the values 
quoted in these studies were obtained using microbio- 
ligical assays.
The Vd reported for CLAV (20 1) by Bennett et al 
( 1 9 8 3 ) compares with those computed from earlier 
reports (Adam et al, 1982; Witkowski et al, 1982) 
ii) Elimination half-life 
•' The elimination half-life for TIC and
CLAV in normal subjects was reported as 1.1 hr and
1.5 hr respectively Bennett et al (1983); their TIC 
half-life is compar'able to that reported by Libke et al 
(1975), however the CLAV half-life is double that 
reported by other workers (Adam et al, 1982; Witkowski, 
et al, 1982), Ball et al (1980) found a CLAV half-life 
of around one hour and Tetzel et al (1984) a half-life 
of 1 .3 hours .
iii) Clearance
According to Bennett et al (1983) in 
normal subjects serum clearance of TIC is 7.0 1/h 
of which 5.2 1/h is renal and for CLAV the serum 
clearance was 14.5 1/h of which 6.4 1/h was renal.
Libke et al (1975) found a total serum clearance for
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TIC of 9.2 1/h of which 7.9 1/h was renal, serum 
clearances for TIC of 6.5 1/h and 11.8 1/h have been 
reported by Findlay et al (1981) and Meyers et al 
(1980) respectively, the data of Tetzel et al (1984) 
agree with the former figure.
The serum clearance for CLAV was calculated from 
the data of Adams et al (1982) and Witkowski et al 
(1982) and found to be approximately 14 1/h and 16 1/h 
respectively. The serum clearance calculated from 
the data of Staniforth et al (1983) was 12.4 1/h with 
a renal clearance of 5.3 1/h, Tetzel et al (1984) 
reported a serum clearance of 9.5 1/h.
9.3. RENAL FAILURE AND TICARCILLIN/CLAVULANIC ACID
THERAPY
9.3.1. Clinical
There are a wide variety of chemotherapeutic 
agents available for the treatment of infections of the 
urinary tract. These include TMP either alone or in 
combination with a sulphonamide, a penicillin (often 
amoxycillin),.a cephalosporin, and possibly nitrofurantoin 
or nalidixic acid. The quinolone derivatives eg. 
norfloxacin, ofloxacin are derived from nalidixic 
acid, are new broad spectrum antibiotics with significant 
activity against P. aeuroginosa. These drugs have been 
used succesfully for the treatment of urinary tract 
infection in pre-launch clinical trials (Bint, Pedler 
and Marshall, 1984; Leigh and Emmanuel 1984) and may
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be taken orally. How long it will take for significant
-   a
resistance to develop is matter for conjecture.
In renal failure, due to the impairment of 
excretion, care is required with dosing, particularly 
for drugs with a narrow therapeutic index. Patients 
with renal failure tend to be infected with organisms 
with multiple resistance, in which circumstance treatment 
with an aminoglycoside is often used; monitoring of 
the serum levels may avoid toxicity but the use of a 
nephrotoxic agent on patients with renal failure is 
less than desirable. Due to problems of resistance, 
cephalosporins and penicillins are not favoured, 
however with the claims that CLAV lowers the MIC of 
penicillins in amoxycillin resistant organisms, (Miller 
et al, 1978; Fuchs et al, 1984-), then clavulanate 
potentiated 8-lactams could prove useful in these 
situations. To date there have been no reports of 
either combination being extensively used in patients 
with renal failure.
9.3.2. * Pharmacokinetics
i ) Renal Function
As noted in section 9 .2 .2 . i'ii . , nearly 
75% of TIC and 4-5% of CLAV are cleared by renal excretion 
and consequently accumulation would be expected in renal 
failure. Probenecid, which blocks secretion of organic 
acids, has been shown to cause accumulation of TIC 
(Libke et al, 1975), but not CLAV, although there was
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a statistically significant decrease in renal clearance 
(Staniforth et al, 1983).
TIC has been available for a number of years and 
its disposition investigated (Davies, Morgan and Anand 
1974-; Parry and Neu, 1976; Hoffler, Dalhoff and Koeppe, 
1978). There was a relationship between the degree of 
renal failure, as assessed by creatinine clearance and 
TIC elimination half-life (Parry and Neu, 1976, Hoffler 
et al, 1978; Boelaert et al 1984-; Dalet et’al, 1984-3; 
Watson and Boulton-lones, 1984) dosage regimes to 
avoid TIC accumulation have been proposed (Parry and 
Neu, 1976; Hoffler et al, 1978). Pharmacokinetic 
parameters other than elimination half-life were not 
noted.
There are limited reports on the effect of renal 
failure on CLAV kinetics. There is an increase in 
CLAV half-life with increasing renal failure (Dalet 
et al, 1984-b) and although insufficient patient numbers 
were examined no difference between patients for Vd 
was noted, this has been confirmed in studies on 
TIC/CLAV (Boelaert et al, 1984-; Dalet et al, 1984-a;
Watson and Boulton-Oones, 1984-) .
ii) Haem.odialysis and peritoneal dialysis 
Removal of TIC during haemodialysis is 
relatively efficient with half-lives of around 4- hours 
(Davies et al, 1974-; Wise, Reeves and Parker, 1974-;
Parry and Neu, 1976) although clearance via peritoneal
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dialysis is poor (Wise et al, 1974-; Parry and Neu, 1976). 
There is a considerable difference of opinion as to 
the required dosing frequency for patients undergoing 
dialysis: Davies et al (1974-) recommend dosing half-way 
through dialysis, Wise et al (1974-) recommend dosing 
every fifteen minutes and Parry and Neu (1976) recommend 
dosing at the end of dialysis.
The reports on the haemodialysis of CLAV suffer 
from lack of data; Dalet et al (1984-b) studying 
amoxycillin/CLAV, reported a half-life of 1.1 hours 
in 5 patients and recommended dosing half-way through 
dialysis with a further dose. The efficiency of CLAV 
removal has been confirmed in a report on a single 
patient. (Slaughter, Kohli and Brass, 1984-) and Dalet 
et al (1984-a) confirmed their earlier findings. There 
is currently no information available on CLAV in 
peritoneal dialysis although it is known to rapidly 
penetrate into peritoneal fluid (Wise et al, 1983a).
The aim of this work was to determine the 
pharmacokinetics of the TIC/CLAV combination in patients 
with varying degrees of renal impairment and patients 
undergoing either haemodialysis (HD) or continuous 
ambulatory peritoneal dialysis (CAPD) and to devise 
an appropriate dosing schedule for use in these patient 
groups.
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MATERIALS AMD METHODS
9.4-. CLINICAL
9.4-. 1. Subjects
All subjects received a single IV bolus injection 
consisting of 3 g TIC and 200 mg CLAV, blood samples 
were obtained from the cephalic vein of the arm not used 
for drug administration.
All subjects were volunteers and informed consent 
and ethical permission were obtained.
Patients with either known hypersensitivity to 
cephalosporins, or concurrent infection were excluded.
9.4-.2 . Study Design
/ i) Renal failure
The degree of renal impairment was 
categorised by creatinine clearance (CrCl) it was 
proposed that 6 subjects in each of the following
categories be investigated: with a CrCl >60 ml/min,
CrCl 30-60 ml/min, CrCl 10-30 ml/min, CrCl <10 ml/min 
and no urine flow (anephric).
i i ) Haemodialysis
Six patients undergoing routine 
haemodialysis treatment would be used with haemodialysis 
starting two hours after dosing and lasting for four 
hours.
iii) Continuous ambulatory peritoneal dialysis 
It was proposed to examine the return 
dialysate levels of TIC/CLAV following an I.V. bolus
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administration and also to examine the penetration of 
TIC/CLAV to the systemic circulation when administered 
in the dialysate. Patients with peritoneal scarring 
from previous episodes of infection were excluded 
from the study. Six patients in each group were to 
be studied with three bag changes each with a four 
hour dwell time, CAPD to commence at time of dosing.
Bags may be 1 or 2 1 depending on body size.
9 .4-. 3 . Sampling Protocols
i ) Renal failure
a ) serum
Blood samples (10 ml) were drawn from 
an indwelling catheter situated in the cephalic vein, 
patency was maintained with heparin. Samples were 
obtained pre-dose and at 0.083, 0.33, 0.67, 1, 1.5,
2, 4-, 8 , 12 and 24- hours post dose. The samples 
were separated soon after collection and stored at 
-80°C prior to analysis (see 8.5.4-.1.).
b) urine
The bladder was emptied prior to dosing 
and then aliquoted, diluted and stored as described 
in section 8 . 5 .4-. ii .
i i ) Haemodialysis
a ) serum
A sample was obtained pre-dose, then at
1.5 hours post dose at which- point dialysis was 
commenced and lasted for 4- hours, samples were obtained
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0.25, 0.5, 1, 2 and 4- hours post-commencement of 
haemodialysis, following cessation of dialysis samples 
were collected at 1 and 4- hours post completion of 
dialysis.
b) urine
Although most patients were anephric, any 
urine passed was collected and stored for analysis as 
described in section 8.5.4-.ii.
H i )  Continuous ambulatory peritoneal dialysis
a ) serum
A pre-dose sample was obtained, dosing and 
commencement of dialysis coincided and samples (10 ml) 
were obtained at 0.083, 0.5, 1 and 4- hours post commence­
ment of dialysis , following the first bag change (i.e. 
at 4- hours) a sample was obtained and a further sample 
just prior to completion of dialysis with the second 
bag. Following instillation of the third bag a sample 
was obtained, finally a sample at 24- hours post dose 
was obtained (i.e. 16 hours post 3rd bag instillation).
b ) dialysate
Return dialysate was collected (10 ml) at 
0.25, 0.5, 1. 2 . 3 and ^ hours post commencement of 
dialysis. Aliquots were taken of dialysate upon 
completion of the first, second and third bag changes, 
these were immediately frozen at - 80°C and stored 
until analysis.
c) urine
Any urine passed was stored as described 
in section 8 .5.4-.il.-
224
9.5. ANALYTICAL
9.5.1. Assays
The assays for TIC and CLAV in serum, urine and 
dialysate were used as described in section 8 .5.3.
9.5.2. Pharmacokinetics
The studies used single i.v. bolus doses only.
The design of the sampling protocols used in the HD 
and CAPD studies did not allow estimates other than 
elimination half-life to calculated, 
i ) Clavulanic acid
The ratio of the a and 8 slopes for 
CLAV did not differ by more than 2 and thus use of a 
single compartment model was appropriate (Curry 1980). 
Estimates of t^8 , Vd, Cls and Clf were performed using 
equations 3.1, 3.2, 3.3 and 4.1 respectively,
ii) Ticarcillin
The a /8 ratio for TIC was greater than 
2 and a two compartment model was applied.
The equation which applies to a two compartment 
model is :
Cpt = Ae + Be ^  * Equation 9.1
where A and B are the intercepts on y axis (i.e. 
concentration at time t = 0) from the plot of log Cp
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versus t, a and 3 are the slopes (rate constants) of 
the exponential components of the curve. The parameters 
Vd, Clg and t£$ were obtained from a computer programme 
using least squares regression to obtain the best curve 
described in general terms by equation 9.1.
The programme was VASP (Nonlinear regression) 
with calculation of Vd, Cl and tlft by the MICRO 2 
programme, access to these programmes at Dept. Materia 
Medica, Stobhill Hospital, Glasgow was through Dr. P. 
Meredith.
Renal clearance was calculated from the equation
below:
/
■ C l = k e^..fe. Vd Equation 9.2.
When Vd is noted for TIC without a sub-script 
this is the sum of the Vds of compartments 1 and 2 
(Vdx + Vd2 =* Vd) .
Elimination was assumed to occur only from the 
central compartment (Vd^).
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RESULTS
9.6, PHARMACOKINETICS IN RENAL FAILURE
Unless otherwise noted all results reported in 
tables etc are mean values, the individual data are 
contained in appendix E,
9.6.1. Serum Concentration Ratios
The serum concentration ratio of TIC/CLAV was not 
statistically significantly different between the 
different categories of renal impairment at the different 
times (t-test). As can be seen in Fig 9.1 there is nearly 
an order of magnitude difference at 20 minutes post 
dose, the range being between 10 and 70, the ratio 
deteriorated with time with the spread becoming wider
and the ratio tending to increase. Clearance during
\
HD was rapid, but in CAPD was less so, similar trends 
as to concentration ratios could however be detected.
9.6.2. Serum Kinetics
i ) Clavulanic acid
The pharmacokinetics of CLAV are given 
in table 9.1. The indices of elimination decrease 
with increasing renal impairment, however in the 
anephric group there is a statistically significant 
improvement in clearance (p <0.05, t-test) when compared 
with the CrCl <10 ml/min group.
Omitting the anephric group, there was significant 
linear association between CrCl and Cls or tl$ (r = 0.74-7 
and r=-0.728, df = 2 2 ) (p <0.001, linear regression).
Vd was independant of renal function, - no relationship 
was found.
0J I-----
20mins
i------ 1
2hrs
i------ 1 i------ 1
8hrs 24hrs
FIGURE 9.1. Range of TIC/CLAV ratio with time for different categories 
of renal function.
o <10 ml/min, A 10-30 ml/min, a 30-60 ml/min, + >60 ml/min 
• Anephric. No plot if CLAV not detectable.
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ii) '■ T icarcillin
The pharmacokinetics of TIC in the 
different renal impairment groups is given in table
9.2.
There was an association between a decrease in
estimates of elimination (CrCl v Cl : r = 0.84-2:
s
CrCl v t£(3 : r = -0.761, df = 21) and decreasing 
renal function, the differences between the following 
groups were not statistically significant (a = 0 . 0 5 )  :
CrCl <10 ml/min and 10-30 ml/min, anephric and <10 ml/min 
10-30 ml/min and 30-60 ml/min. There was no change in 
total Vd vvith changing renal function, nor with the Vd
J  '
of either compartment.
9.6.3. Urine Kinetics
i
i ) Clavulanic acid
The renal clearance, fe, and cumulative 
amount of CLAV excreted are summarised in table 9.3.
There was a statistically significant association 
(r = 0 .805; 22 df) between decreasing renal clearance 
and decreasing renal function (p <0 .0 0 1 , linear regression) 
there was correlation between the fraction excreted 
unchanged (fe) and renal function (r = 0.691, 31 df)
(p <0 .0 1 ),renal excretion predominated only in the 
>60 ml/min group.
i i ) Ticarcillin
The urine kinetics of TIC are given in 
table 9.4-, there was a significant linear correlation 
between Cl -and CrCl (r = 0.83.l, df 21) (p<0.001),
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but the relationship between fe and CrCl is less 
clearcut (r = 0.468, df 2 1 ) (0.01<p<0.05). As with 
CLAV renal excretion only predominated in the >60 ml/min 
group.
9.7. DISPOSITION DURING DIALYSIS
9.7.1. Disposition During Haemodialysis
Three patients were studied during HD; disposition 
prior to dialysis was assumed to be as previously 
found in the anephric group.
i ) Clavulanic acid
The half-life of removal following the 
commencement of HD was 0.6, 0.55 and 0.5 hours respectively 
(Fig 9.2). Only one patient (patient 3) had ’rebound1 
serum levels following cessation of therapy (0.3 mg/1 ,
0.9 hours after dialysis).
ii) Ticarcillin
The half-lives of removal for TIC were 
slower than for CLAV and were 2.9, 1.7 and 2.1 hours 
respectively, all patients had rebound serum levels 
(Fig 9.3) although the extent of the rebound varied.
9.7.2. Disposition During CAPD
There was great difficulty in recruiting 
CAPD patients consequently only two patients were 
studied following i.v. administration of the TIC/CLAV 
combination.  ^ The concentrations for TIC and CLAV in 
serum and dialysate are given in appendix F. 
i ) Clavulanic acid
There was steady accumulation of CLAV
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FIGURE 9.2. Disposition of CLAV during haemodialysis.
Dotted line is the approximate time course of 
the ’rebound’ levels.
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FIGURE 9.3. Disposition of TIC during and following haemodialysis.
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in the dialysate over the first 4 hour period (Fig 9.4), 
following the first bag change there was a drop in 
dialysate CLAV levels for patient 2 at changeover 
however no sample was taken immediately following the 
second bag for patient 1 ; CLAV apparently did not 
accumulate during the second period of dialysis as the 
dialysate CLAV concentration was less after the second 
period of dialysis.
The serum CLAV concentrations indicate a rapid 
fall during the first dialysis period, a sample was 
not drawn following changeover to the second bag nor 
during the residence time of the second bag, but serum 
CLAV concentrations had fallen below* the detectable 
limits of the assay by 8 hours post dose. Although the 
half-life of removal of CLAV in patient 2 is approximately 
0.6 hr, the elimination in patient 1 appears biphasic 
with half-lives of 0.3 and 7 hours respectively, although 
too few measurements were made to substantiate this, 
however it is worthy of note that the rate of accumulation 
in the dialysate of patient 1 is slower and more 
pronouncedly biphasic than for patient 2 , however the 
extent of recovery was similar at 115.2 mg (5 7 .6%) and 
100.3 mg (50.2%) from patients 1 and 2 respectively, 
i i ) Ticarcillin
Ticarcillin accumulated continuously 
in the dialysate during the first period of dialysis 
(Fig 9.5) for both patients, patient 2 had a more
Bag change
• i i
100-1
10-
Hours post dose
FIGURE 9A. Disposition of CLAV during CAPD.
o = Serum concentrations 
•■= Dialysate concentrations
Bag change
* i i■ i i■ i i
t I ♦
•lOOCh
IQ-
20 24
Hours post dose
FIGURE 9.5. Disposition of TIC during CAPD
o = Serum concentrations 
• = Dialysate concentrations
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rapid and greater accumulation of TIC than patient 1 .
In the second four hours the dialysate TIC level 
dropped on dialysate changeover but there was some 
accumulation by four hours (patient 2 ), there was little 
change in this individual in the third period although 
some accumulation was noted for patient 1 .
There was good recovery of TIC, 1637 mg (54.6%) 
and 2377 mg (77.9%) respectively from patients 1 and 2.
The elimination was however not reflected in 
rapid elimination half-lives, estimated at between 
13-24 hours for patient 1 and approximately 10 hours for 
patient 2 , i.e. similar to the anephric group elimination 
half-lives.
9.8 . DOSING REGIMENS IN 'RENAL FAILURE AND DIALYSIS
\
Having cognisance of the kinetics of TIC and CLAV 
in the dosage combination used in this study, a recom­
mended dosage schedule has been designed (table 9.5) .
The CAPD group have been excluded as there is 
insufficient consistent information to allow prediction 
of serum levels following dosage.
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DISCUSSION
9.9. PHARMACOKINETICS IN RENAL FAILURE
9.9.1. Serum Concentration Ratios 
In the discussion of TMP/sulphonamide serum 
concentration ratios (section 3.9.4.) the significance 
of the ratios achieved centred round whether these were 
within the range of optimal synergy and the implications 
of this for therapeutic effect. The combination of 
TIC/CLAV is administered in the ratio of 15:1, in plasma it was 
found to be between 10:1 and 70:1 twenty minutes after 
administration, the latter is over double that noted 
by Bennet et al (1983) in normal males, The ratio 
increased with time to up to 1000:1 in some instances, 
the highest ratios occurred in the anephric group 
followed by the groups with the least renal function.
The cause of these wide ratios is the notable difference 
in elimination between TIC and CLAV in renal failure,
CLAV is more rapidly eliminated than TIC, the differential 
increasing with increasing renal failure.
If the TIC/CLAV ratio were of the same significance 
as the TMP/sulphonamide ratio then supplementation of 
CLAV during dosing might be necessary, however the mech­
anisms of action of these two formulations are in the 
general case fundamentally different. In TMP/sulphonamide 
there is reversible competitive inhibition at the 
enzyme(s) active site whereas, in susceptible organisms, 
the mode of action of CLAV is by irreversible competitive 
inhibition, thus it is not the ratio of TIC/CLAV that is
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significant but the level of CLAV that is achieved.
The length of duration above the required threshold 
maybe significant, but when CLAV action is due to 
irreversible inhibition the inevitable drop in CLAV 
concentration due to distribution/elimination will not 
be so significant. The relationship between pharmaco­
kinetics and bacterial growth kinetics requires much 
closer examination especially for the novel combination 
of clavulanate potentiated penicillins.
In vitro studies have indicated that concentrations 
of at least 5 ug/ml must be achieved for potentiation 
of TIC against TIC resistant strains (Paisley and 
Washington II, 1978) and in vitro potentiation of TIC 
at this concentration of CLAV has been confirmed (Clarke 
and Zemcov, 1984); reflecting expected in vivo levels 
Fuchs et al (1984) recommended in vitro testing of CLAV 
at 2 ug/ml. Bennet et al (1983) suggest however that 
CLAV need only be present for a short period of time 
in vivo to exert its effect basing this on pharmacokinetic 
and clinical experience, it is probable therefore that 
the lower levels achieved in vivo are effective and thus 
the TIC/CLAV ratio is not important and supplementation 
of dosing is not required.
9.9.2. Kinetics
i) Clavulanic acid
a) volume of distribution
Bennett et al (1983) found a Vd for normal 
volunteers 20.3 ± 8.0 1 and calculation from the data
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of Witkowski et al (1982) gives a Vd of approximately 
1 7 . 5 ± 5  1 and from the data of Adam et al (1982) gives 
a Vd of 17 1, these compare with the Vd for CLAV 
reported here although the range of values is wide but 
is comparable to values reported by Bennett et al(1983).
In one study of CLAV in renal failure, the Vd in 
5 patients was found to have a mean Vd of 11.1 ± 1.4 1 
(Dalet et al 1984b), data from a study on the effect of 
probenecid on CLAV kinetics (Staniforth et al 1983) 
was calculated to give a Vd double that found by Dalet 
et al (1984b), subsequently Dalet et al (1984a) found 
a Vd of 22.9 1 in patients with renal failure on a 
TIC/CLAV combination, in a similar study an equivalent 
Vd was found (Boelaert et al 1984), these V d 1s are 
slightly higher than reported here. Although this work 
reports the kinetics of 31 subjects with renal failure 
and is the most wide ranging study to date on these 
subjects these differences may not be significant. 
Comparability between other reports on normal subjects 
and the lack of effect of probenecid all suggest that 
the Vd of CLAV is not affected by renal failure,
b ) elimination
The elimination half-life of CLAV in the 
CrCl >60 ml/min group, when compared with that reported 
for individuals with renal function, is lower than that 
reported by other workers for normal subjects, most 
estimates giving a half-life of about 0.7 hours (Adam
234
et al, 1982; Witkowski et al, 1982; Schaad, et al,
1983) and indeed some half-lives have been reported 
as being approximately one hour (Ball et al, 1980).
The main difference between this study and the values 
reported in the literature is the use of a specific 
liquid chromatography procedure instead of the microbio­
logical assays used by other workers. If a microbio- 1
logically active metabolite were present then this would 
also be measured with an apparent increase in half-life, 
currently there is little information on CLAV metabolism.
All of the above studies used a one-compartment 
model for CLAV kinetics, Bennett et al (1983) used a two- 
compartment model and obtained tla = 0.42 hours and 
t|B = 1.5 hours, the observed difference between the slopes 
a and 8 did not approach 2 and the use of two-compartment 
model was not deemed to be justified (section 9.5.2.i.).
Probenecid increased the half-life of CLAV from 
1.23 hours to 1.32 hours but this was not statistically 
significant (Staniforth et al 1983).. An increase in 
t|8 was noted with increasing renal failure by Dalet 
et al, (1984b) and also by Boelaert et al, (1984) but 
although an association was noted it was not examined 
statistically; a report arising from this work 
(Watson and Boulton-dones, 1984) summarised the 
findings in sections 9.6.2.i. and 9.6.3.i., there is 
statistically significant association between indices
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of elimination (t?8, k ^ ,  Clg) and decreasing renal 
function for CrCl from <10 ml/min to >60 ml/min and 
this association holds for indexes of renal elimination 
(Cl 'and fe), i.e. increasing renal failure leads to 
decreased elimination of CLAV. These results for 
clearance etc are similar to those reported by Boelaert 
et al (1984- ).
In the anephric group a faster rate of elimination 
was noted than for the CrCl <10 ml/min group, this has 
not previously been noted, the probable explanation is 
that hepatic metabolism is induced, this view was 
supported by other workers when originally proposed 
(Watson and Boulton-Oones, 1984) at the 4th Mediterranean 
Conference on Chemotherapy.
ii ) Ticarcillin
a) volume of distribution
As for CLAV it was found that the Vd for 
TIC was unaffected by the degree of renal dysfunction.
As a and 8 differed by more than two, a two-compartment 
model was applied, the volumes of distribution of the 
peripheral and central compartments were not influenced 
by renal failure, although such Vd's do not relate 
directly to physiologically valid compartments. In 
normal volunteers, using two-compartment open models the 
following Vd's have been reported (Libke et al, 1975),
9.9 ± 2 1' (Findlay et a l , ’1981) and 10.8 ± 4 . 3 1  
(Bennett, 1983), the last study being performed on a
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TIC/CLAV combination, these values compare with total 
Vd as reported in this work; there is one report of a 
Vd of 41.8 l/100Kg (^30 1) for TIC in normal volunteers 
(Meyers et al, 1980), this is almost certainly erroneous 
the AUC reported for this study seem low and it is 
probable that under estimation of serum concentrations 
was the cause; a microbiological assay was used.
One report of TIC Vd in renal failure gave a 
mean Vd of 14.8 1 in a study of 61 patients, a one- 
compartment model was used, there was no apparent 
relationship between Vd and dose but any association 
with degree of renal function was not discussed (Hoffler 
et al,1978). Mean Vd's for TIC in renal failure 
have been reported of the same order as those found in 
normals (Boelaert et al, 1984; Dalet et al, 1984a).
b ) elimination
The half-life of elimination of TIC for 
the group CrCl >60 ml/min of 0.94 ± 0.21 hours compares 
with half-lives obtained in subjects with normal 
renal function of 1.1 ± 0.1 hours, 1.2 hours, 1.3 ± 0 . 1 6  
hours and 0.96 hours (Bennett et al, 1983; Libke et al, 
1975; Findlay et al 1981 and Meyers et al, 1980) 
respectively. *
Ticarcillin, as a penicillin, would be expected 
to accumulate in renal failure due to decreased renal 
clearance and the increase in elimination half-life 
with increasing renal failure has been well established
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(Davies et al 1974; Parry and Neu, 1976; Hoffler et al, 
1978) and probenecid decreases TIC clearance(Libke et 
al 1975; Davies et al, 1982). In keeping with these 
findings decreasing clearance was found with increasing 
renal impairment; the association was statistically 
significant between CrCl and t£|3, kg  ^ and Cls , the 
association between CrCl and Clf was also highly 
significant although the relationship between CrCl 
and fe was equivocal although this is probably an artefact 
as the TIC kinetics reported by Boelaert et al (1984) 
are very similar to those reported here and they found 
a decrease in fe with a decrease in renal function.
Unlike CLAV the anticipated increase in half-life
in the anephric group was observed for TIC, the elimination
\ ■
rate being an order of magnitude lower than found in 
normals.
As noted in Section 8.6.10.equilibration between 
the TIC epimers is rapid, thus any difference in elimination 
could not be detected using the storage and assay 
procedures described here; difference in the clearance 
of penicillin epimers in renal failure has been noted 
for temocillin which is.structurally similar to TIC, half- 
lives on normals were R epimer 3.5 hours, S epimer 5.5 
hours, the rates reflecting the degree of protein 
binding, activity varies to some extent with pH (Slocumbe, 
personal communication).
9.to ELIMINATION DURING DIALYSIS
Study of TIC/CLAV disposition during dialysis was
238
hampered by lack of patients and limitations placed 
on sampling.
The haemodialysis study suffered limitations as 
to the number of blood samples the clinical staff 
were willing to allow, thus limiting the amount of 
pharmacokinetic information•attainable. In addition 
recruitment was slow and the numbers available were 
further diminished by the loss of two complete sets 
of samples due to a freezer failure.
Recruitment to the CAPD study was minimal, only 
two patients agreeing. Exclusion due to peritoneal 
scarring from previous episodes of infection, and 
problems of access to facilities undoubtedly reduced 
numbers ; the principle factor was the reluctance of 
patients and staff to interrupt sterile dialysis to 
obtain dialysate samples during dwell time, as this 
could lead to a significant risk in infection and 
possible loss of perfusable peritoneal surface for 
dialysis, in the worst case this could lead to CAPD 
being ineffective and most patients were unwilling to 
take the risk. Dropping the requirement for dialysate 
samples and using an aliquot of exchanged dialysate 
did not, however, lead to further recruitment. In 
addition there was reluctance to obtain too many 
blood samples again limiting the amount of obtainable 
pharmacokinetic information.
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9.10.1. Haemodialysis
The elimination of CLAV was far more rapid than 
TIC once haemodialysis commenced, respective mean 
half-lives of elimination 0.55 and 2.23 hours. Elimination 
during dialysis depends on rate of blood flow and 
membrane surface area and thus figures for elimination 
in the literature may not be strictly comparable. TIC 
elimination half-life has been reported as being 4.7 ±
0.8 hours (Davies et al, 1974), 4.9 hours (Wise et al, 
1974), 3.4 ± 0.8 hours (Parry and Neu, 1976) and 2.2 hours 
(Dalet et al, 1984a). Clinically haemodialysis is 
expected to be equivalent to a creatinine clearance 
of around 40 ml/min, this is consistent with the half-
life found.
\
The effect of haemodialysis on CLAV elimination 
is less well documented. Dalet et al (1984b)in a paper 
in Spanish described the kinetics of an amoxycillin/
CLAV preparation during haemodialysis, Vd was comparable 
to that found in a group with renal failure and half- 
life of elimination was 1.15 hours, the same group 
later reported a half-life of 1.0 hour (Dalet-'et al 
1984a). In a report of a single case Slaughter et al 
(1984) were unable to determine CLAV half-life during 
dialysis due to "erratic absorption" of the oral dose, 
although this was 3 hours post dose.
None of the above papers comments on the redist­
ribution of TIC from the peripheral to central compartments
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following cessation of haemodialysis, although this was 
consistently observed in this study, this feature 
of TIC disposition has been noted by others (Dalet, 
personal communication). Slaughter et al (1984) did 
not note redistribution of CLAV at the end of dialysis, 
this was noted in one patient in this study, but the 
rate of elimination of CLAV during haemodialysis 
and the fact that these subjects are probably anephric 
and therefore liable to have a greater metabolic 
clearance will make detection of redistribution less likely.
9.10.2. CAPD
Peritoneal dialysis has been reported as having 
a moderate effect on TIC elimination (Wise et al, 1974),
the extent of removal was not studied although Parry
\
and Neu (1976) claims only a small fraction of the dose 
(amount unspecified) was recovered with dialysate levels 
10-30% of simultaneous serum levels; however only 0.17- 
0.25 hour dwell times were used and the rate of 
penetration may have been too slow to allow equilibration 
in this short time. Certainly ampicillin has been shown 
to penetrate peritoneal fluid effectively (Wise et al, 
1983b) and TIC has been shown to be stable in peritoneal 
dialysate (Sewell and Golper, 1982).
There is no comparable data on CLAV penetration 
into peritoneal dialysate although CLAV levels in 
patients with normal renal function undergoing elective 
abdominal surgery had peritoneal fluid levels 66% of
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serum levels indicating good penetration through the 
normal peritoneum (Wise et al 1983a).
The recovery of TIC is remarkable as is that of 
CLAV and interpretation should be cautioned on two 
counts : the accuracy of the volume of dialysate instilled
and the adequacy of the flushing of the line prior to 
sampling; the stability of CLAV in dialysate fluid is 
a further variable.
If TIC/CLAV is a useful antibiotic for use in 
CAPD patients, further studies are required, not only 
comparing peritoneal penetration following i.v. or 
dialysate administration, but also examining their 
penetration through inflamed or scarred peritoneum.
9.H . DOSING REGIMENS IN RENAL FAILURE AND DIALYSIS 
The dosing regimens described in section 9.8. 
are based on the following assumptions : that CLAV will
be ^5 ug/ml and that TIC will not accumulate excessively; 
although patients will be subjected to higher TIC levels 
than would be the case using the standard regimen in 
individuals with normal renal function.
A common method of dosage adjustment in renal 
failure is to halve the frequency of dosing or to halve 
the dose while maintaining the frequency, The former 
has been proposed (Dalet et al, 1984b) but will lead to 
unacceptable long periods without antibiotic cover, the 
approach recommended in table 9.5. was compared with that 
of Dalet al (1984a) at the 4th Mediterranean Congress
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on Chemotherapy and the schedules proposed in table 9.5 
and elsewhere (Watson and Boulton-3ones, 1984) were 
agreed.
Approaches as to the optimisation of drug dosage 
has recently been reviewed (Chennavasin and Brater,
1981) who noted that procedures based on nomograms 
could be useful but that they could under-or over-predict 
quite markedly but that a combination approach to 
lowered dose, decreased frequency and 'targeting' of 
Cp MAX, MIN and/or AVE) was preferrable, however the
3 3
best solution was to measure Cp.
The design of this dosing schedule was complicated 
by the need to balance the requirements of two drugs 
with diverging rates of clearance with increasing renal 
impairment yet to yield a dosing schedule with logical 
progression. Thus two decrements in frequency of 
4 hours each and one halving of the dose led to the 
recommended maintenance dose for the anephric and 
CrCl <10 ml/min group; although the anephric group 
have a higher Cls for CLAV than the CrCl <10 ml/min 
group the CLAV is still >6 ug/ml and thus no
change is necessary if the assumption of Bennett et al 
(1983) is correct that CLAV levels >5 ug/ml are only 
required for short periods of time; CLAV C AVE was
3 3
noticeably lower than for the CrCl <10 ml/min group 
but should not carry a penalty; the TIC C AVE is also
3 3
lower but is a function of using the mean data
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for the anephric group and should not be considered as 
being statistically different from the CrCl <10ml/min 
group.
The regimen recommended for haemodialysis is 
designed on the assumption that clearance following 
haemodialysis of TIC and CLAV is effectively complete, 
therefore a loading dose must be given, as the maintenance 
dose for anephrics is 1.6 g TIC/CLAV per 12 hours then 
the maintenance dose is double this; low levels of TIC 
will be found in the serum post-dialysis from dosing 
prior to dialysis, this factor has been taken into 
account when calculating the projected levels quoted 
in the table. It is probable that a similar approach 
can be adopted for CAPD but further detailed kinetic 
studies are required.
9.12. CONCLUSION
TIC and CLAV have decreasing clearance with 
increasing renal impairment but CLAV clearance is 
increased in anephrics possibly due to induction of 
metabolism. Haemodialysis and CAPD both clear TIC and 
CLAV effectively, the former more efficiently than 
the latter. Allowing for the different kinetics in 
the groups with renal failure and those undergoing 
dialysis a pharmacokinetically valid, 'logical' dosing 
schedule for a TIC and CLAV combination consisting 
of 3 g of the former and 200 mg of the latter is proposed.
In science, read, by preference, the newest 
works, in literature the oldest.
i
Edward Bulmer-Lytton 1803-1873 
Caxtoniana Essay X
CHAPTER 10 
GENERAL DISCUSSION
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10.1. SPECIFIC CHEMICAL METHODS
This thesis has been concerned with the measurement 
of drugs having antimicrobial activity. In the past 
these drugs have been measured using biological assays, 
which have been criticised for many years as being both 
imprecise and inaccurate (Boxer et al 1948; Reeves 
and Wise, 1978). The errors in such assays may be 
further compounded in the case of agents with active 
metabolites and when drugs are used in combination.
Until recently most alternative assays were photometric 
(eg. Rieder, 1972) and could be liable to inaccuracy and 
imprecision.
•' To date most pharmacokinetic studies on anti­
microbials have been performed using such assay procedures.
\ • ’
Departments of Microbiology are infrequently equipped
with gas or liquid chromatographs, which, with suitable
sample preparation can yield accurate and precise
quantitative results, allowing the determination of
definitive pharmacokinetics and possibly leading to
a more critical interpretation of the relationship
between plasma concentration and clinical effect.
Due to the inadequacies of analytical technique 
and, in some cases, poor study design, it was felt 
that a re-examination of the pharmacokinetics of 
antimicrobial agents using newly developed accurate, 
precise and sensitive liquid chromatographic assays 
would be worthwhile. As a start the performance of
the colorimetric procedure of Rieder (1972) was evaluated 
and found to be adequate, not all antimicrobial agents 
lend themselves to photometric assay, liquid chromatography 
is a good alternative to microbiological assay.
Comparison of the kinetics obtained for TMP 
and the sulphonamides showed equivalence with some 
studies and marked differences with the results from 
others; it is probable, but not absolutely certain, that 
these differences are due to the use of inadequate 
methodology. The methods used for studying trimethoprim 
and the sulphonamides were usually fluorimetric and color­
imetric respectively.
To date all values for the kinetics of ticarcillin 
and clavulanic ; acid in the literature have been produced 
using microbiological assays. In one publication the 
Vd for clavulanic acid is underestimated and in one the 
Vd for ticarcillin was overestimated. It may be 
that these 'outliers’ reflect some systematic error in 
the assays used. The Vd found in this study for 
clavulanic acid is slightly lower than reported by 
others in the literature and it may be that this 
reflects greater specificity in the determination of 
clavulanic acid by LC, however the- values of Vd obtained 
for ticarcillin are comparable with other reports.
The addition of an extraction stage can improve the 
accuracy of chemical assays such as that of Rieder 
without a notable loss in precision.
There are several major advantages in the use 
chromatographic assays. Of prime importance is the
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separation of parent drug from metabolites and other 
sources of interference. The disadvantage however is 
the sequential nature of LC assay and the time taken 
to complete the large number of analyses required for 
pharmacokinetic studies when compared to the batch 
analysis approach usually used in bacteriological 
assays which have a higher throughput. The rate of 
analysis could be improved for LC by using 3p packing 
and high flow rates, which could notably reduce 
chromatography time. Sample preparation procedures 
would then become rate-limiting; automation of this step 
is possible and use of the Du Pont PREP system was 
attempted for CLAV and TIC but it was not flexible 
enough to deal with the CLAV sample preparation.
If the sensitivity and selectivity of chromatography 
is required to be retained with the advantages of batch 
analysis an alternative approach to LC is high 
performance thin-layer chromatography with scanning 
densitometry. This approach has not yet been developed 
widely. A useful source of reference on the subject is 
available (Zlatkis and Kaiser, 1977).
This present study has demonstrated the applic­
ability of LC to the analysis of several different 
chemical species of antimicrobial agent. During the 
course of this work an increasing number of publications
on assays of antimicrobials in particular and other
247
drugs in general using LC indicate that this is a trend 
which will continue.
10.2. PHARMACOKINETICS
10.2.1. General
Along with increasing appreciation of the 
importance of analytical factors in determining the 
disposition of antimicrobials there has been an increased 
awareness of the necessity for the application of 
appropriate pharmacokinetic analysis. Whilst the use 
of one-compartment open models with first-order kinetics 
is sufficient for most purposes, the need for more 
accurate models has become clear. As effective chemo­
therapy of either of infection or neoplasia is dependent 
on drug penetration to the site of action, it may be
i . . . .
that consideration of the kinetics of such agents 
needs to go beyond simple descriptive kinetics. The 
rate of penetration into various compartments is 
characterised by rate constants and the compartments 
have nominal volumes which do not relate to any 
physiologically measurable compartments. Some physio­
logical variables may be considered as appropriate 
to certain compartments, an approach which has been 
used in identifying the kinetic factors which predispose 
to toxicity during chemotherapy with methotrexate 
(Reich et al, 1977).
If the rate of penetration of an agent to a 
desired site of action can be described then, from a
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model, it should be possible to design an optimal dosing 
regimen that would enable the desired effect to be 
achieved while minimising toxicity. It has been proposed 
that pharmacodynamics be modelled in conjunction with 
pharmacokinetics (Sheiner et al, 1979b; Whiting and 
Kelman, 1980) . The models considered hitherto have 
been for drugs which have a directly measurable 
pharmacological effect eg. the force of thumb adduction 
following d-tubocurarine (Sheiner et al, 1979b); QT 
prolongation following disopyramide and left ventricular 
ejection time following digoxin (Kelman and Whiting,
1980).
J
10.2.2. Fixed Dose Combinations of Antimicrobial 
Agents
\
From the results of the kinetics of TMP/ 
sulphonamide combinations it Is clear that the optimum 
synergistic concentrations determined from in vitro 
studies were not attained in vivo, but this fact was 
masked by the overall efficacy of the preparation, 
whereas the TIC/CLAV kinetics suggest that the required 
levels can be attained in vivo. The significance of 
the findings awaits clarification.
What is quite clear is that although SMZ was 
chosen to match TMP on the basis of kinetics, the 
kinetic data used in making the decision were inadequate. 
As the comparison of in vivo Cp ratio with the desired 
in vitro concentration ratios shows, no account of
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penetration from the central compartment was considered. 
Allowing for such a limitation, thenTMP and SMZ did 
show roughly parallel elimination kinetics, however 
TIC and CLAV did not, especially in patients with 
renal failure. The underlying principle of action is 
however different and it is. probable that TIC/CLAV ratio 
is of little importance, even in vitro. There may be 
lessons here for antineoplastic chemotherapy when, 
as seems inevitable, new combinations of drugs are 
designed to be pharmacologically and kinetically 
compatible. It is possible that the drug delivery 
systems that are now being investigated for anti­
neoplastic agents might be able to deliver such agents
in combination and achieve the the optimum target concen-
\ * • 
tration ratios. Such delivery systems might also be
used for delivery of combinations of antimicrobial
agents.
Even allowing the necessity for fixed combinations 
the continuation of potentiation may be difficult to 
sustain for agents that rely for their actijon on 
reversible competitive inhibition, in such circumstances, 
unless there is parallel kinetic behaviour, particularly 
penetration and elimination, then supplementation of 
one or other of the components may be necessary prior 
to the next combined dose.
10*2.3. Prediction of Cp and Dosing
There is an underlying assumption in kinetics 
that Cp proportionally reflects the concentration at
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the site of action allowing for temporal effects, thus 
using indirect measurement of Cp eg. saliva,or by 
measurement of a few Cp, it should be possible to predict 
either Cp at the time of observation or future Cp 
respectively.
There is a temporal relationship between saliva 
and serum concentrations; however predictions using the 
equation of Matin et al (1974) do not describe the 
relationship adequately for a drug, such as TMP, that is 
significantly ionised at physiological serum and saliva 
pH. The limitations of the equation are its reliance on 
time-independent factors to describe the partition 
relationship, no time-related factor -such as salivary 
flow-rate or penetration lag time being included, 
although there is parallelism with serum and saliva 
drug concentrations. Thus while saliva may be used to 
indirectly measure total TMP plasma concentration the 
same information cannot be obtained using the Matin
equation despite the extra data required, nor can it be
relied upon to give reasonable estimates of the free 
fraction.
Bayesian prediction has proved satisfactory 
provided that sufficient observations (three or more) 
are obtained. If the intent is to forecast Cp and 
hence dosage the technique is useful with good precision
and bias and predicts well for individuals. It must
be understood that the parameters produced, although
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'individualised1 are not true parameters and must not 
be construed as such,however they are useful for the 
simulation of alternative dosage regimens and calculations 
for predicting Cp from such regimens. As noted in 
Chapter 7 use of OPT resulted in the 'education' of a 
G.P.in therapeutic monitoring but had limitations on 
its forecasting due to non-compliance.
Consideration of compliance and informed clinical 
judgement with Cp feedback would suggest that the need 
for OPT becomes less apparent from a service aspect 
and thus commitment to the cost or the upgrading of the 
required hardware, if not already available, may be 
difficult to justify,but experience over three years 
with OPT routinely available has shown it to be 
invaluable on occasions. Therefore if Cp forecasting 
is required then Bayesian forecasting is undoubtedly 
the procedure of choice, as has already been noted 
(Burton et al 1985).
Prediction of Cp allows prediction of dosage 
an alternative aspect to this was the prediction of 
dosing for patients with different degrees of renal 
failure who had received the TIC/CLAV combination.
The recommended dosing regimens were dependent on
the degree of renal failure and on the use of dialysis.
The prime requisite for any such dosing regimen is 
that it progress logically and be relatively 
uncomplicated; this was achieved. Within each sub-set
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individualised prediction would have suggested an 
alternative dose, but it is doubtful whether this 
would have differed significantly from that which is 
practicable due to dosage formulation.
If adequate effect and minimal toxicity can be 
attained with a ’standard1 dose then this should be 
used, only if this is not the case is 'individualisation' 
required........
10.2 .4- . Antimicrobial and Antineoplastic 
Chemotherapy
In vivo cell death is a measure of 
chemotherapeutic efficacy, however the modes of action 
employed to achieve this are many and varied. There
are similarities between the intent and action of
\
antimicrobial and antineoplastic chemotherapeutic agents 
but there are also fundamental differences; cell wall 
disruption, such as occurs with penicillins is not 
appropriate for antineoplastic drugs, their chief line 
of attack is aimed at factors governing cell division 
eg. mitotic microtubule inhibition by vinca alkaloids .
The differences between malignant eukaryotic cells 
and host cells are much less than between host and 
bacterial cells, thus antineoplastics will tend to 
have a low therapeutic index, while this may be true 
for some antimicrobials eg. the aminoglycosides, this 
is more an exception.
The target cells and therapeutic strategies
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are more easily manipulated and comprehended in 
antimicrobial chemotherapy, since for antineoplastic 
chemotherapy there is a comparative lack of flexibility 
imposed by the nature of the disease process, however 
it is a reasonable concept that consideration of 
antimicrobial chemotherapy may allow insight into the 
potential for developments in antineoplastic chemotherapy.
In both types of therapy failure may occur due 
to the emergence of a resistant cell line, however 
it is at this point that the differences in the maturity 
of the respective therapeutic strategies are revealed, 
in vitro microbiological testing determines to what 
agents the resistant cell line is susceptible and therapy 
is then instituted. There is no parallel in oncology; 
further microbiological regimens may be so designed as 
to 'cover' the emergence of resistance eg. fixed 
combination therapy, again there is no parallel in 
oncology. The reason for these differences is that 
therapy in infection is, if required, staged i.e. 
an initial best guess therapy which if not succesful is 
examined in vitro, therapy is amended accordingly and 
the system re-examined and amended again as necessary, 
in other words the chemotherapy of infection is 
individualised. In contrast due to the lack of adequate 
effective in vitro methods such an approach has not 
been adopted in antineoplast'ic therapy. The agents are 
always used in combination to a set regimen of cycles
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and certain specified regimens are applied to specified 
neoplasms.
If a resistant line emerges as is often the 
case, or the degree of cellular differentiation is such 
as to be associated with poor response any flexibility 
in the chemotherapeutic regimen is often empirically 
imposed although other clinical and histopathological 
evidence may be considered. Anti cancer drugs are 
used in combinations and times that are intended to 
attack the malignant cells at different stages of 
the cell cycle so histological and biochemical evidence 
is therefore of limited value. There is therefore a need 
for individualisation of antineoplastic chemotherapy,
if only to attack the problem of resistance.
\
Relapse following antineoplastic chemotherapy 
due to tumour regrowth requires the identification of 
the causative factors, and may be related to the degree 
of cell differentiation, the ability of the cell to 
bypass the site of drug action and the achievement and 
maintenance of adequate levels at the neoplastic site.
The degree of penetration will depend on the rate of 
drug delivery and thus exceptional routes of adminis­
tration eg. intrathecal may be utilised; if the tumour 
is poorly vascularised or necrotic drug penetration 
will be slow and possibly inadequate and such difficulties 1 
require individualisation of therapy not only kinetically 
but in terms of the drugs employed.
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If individualised in vitro testing could indicate 
the patient's requirements and knowledge of the required 
drug concentrations at the site of action were known, 
then measurement of drug levels at the site and also 
in plasma could be of value in assessing the adequacy 
of therapy.
Current investigations on the penetration of 
chemotherapeutic agents tend towards measuring achieved 
drug concentrations in various sites eg. sputum, C S F , 
peritoneal fluid, lung tissue etc. such point estimates 
are virtually meaningless and require systematic 
study of their kinetics of penetration, this information 
is gradually becoming available but the ethical limitations 
inherent in such studies inhibits investigation. The 
modelling and investigation of penetration of chemo­
therapeutic agents to their site of action requires 
more work.
If this knowledge could be obtained then consid­
eration of fixed dose combination antineoplastic 
therapy might become a viable proposition, eg. the use 
of nitroimidazole to 'sensitise' hypoxic cells to a 
second agent eg. methotrexate. If this is a synergistic 
effect then there is a need for parallel kinetic 
behaviour c/f the arguments of TMP/sulphonamide ratios.
If the potentiation is due to independent effects then 
the situation with clavulanic acid and the penicillins 
is the closer analogy.
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10.3. FUTURE PERSPECTIVES
All of the above discussion has centred on the 
attainment and maintenance of Cp or tissue concentrations 
which are adequate for effective action. For routine 
purposes this may be appropriate, however in chemotherapy 
the intention is to kill cells, to do this requires 
that the agent penetrate the cells and disrupt some 
vital metabolic function thereby rendering them non- 
viable, susceptible to the host’s immune defence system 
or at least unable to generate resistance to chemotherapy. 
Such resistance can arise in a number of ways,but lack 
of cell-wall penetration and intra-cellular metabolic 
adjustment are significant problems, these problems 
can be identified in vitro, through tissue culture but 
rely more on growth kinetics than direct examination.
In bacteria resistance may be acquired by plasmid 
transfer,this mechanism does not apply to cancer cells, 
but a sub-population of cells may be inherently resistant 
to a chemotherapeutic agent. It may prove possible by 
examination of a cell population to determine how cell 
resistance is most likely to be made manifest, thus 
enabling therapy to be designed to avoid resurgence.
As antimicrobial chemotherapy is usually more succesful 
than antineoplastic chemotherapy it may prove to be 
that the latter would benefit most from a knowledge of 
the intra-cellular milieu, i.e. direct examination.
With current technology direct examination of
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cellular contents is not feasible. However developments 
in LC technology suggest this may not be impossible; 
it will be feasible in the foreseeable future to 
design detectors that can detect 1 0 6 molecules (Poppe, 
1984-), such a number of molecules is equivalent to 
femtogram amounts, these are detectable with todays 
technology using open tubular LC with laser fluorescence 
detection (Novotny, 1984-). Although examination of a 
single cell is not yet possible it has been suggested 
as a realistic prospect for the future (Oorgensen et 
al, 1984-), this may not be achievable, however monoclonal 
techniques make it possible to consider cloning a single 
cell line to examine its products.
Combining capillary LC and human cell culture
\
methods for antineoplastic agents or bacteriological 
cell culture methods for antimicrobial agents could 
prove to be a highly informative progression.
It is possible to envisage that research into 
chemotherapy involving a combination of more 
physiologically descriptive pharmacokinetic models,
(using accurate, precise assays), limited point estimates 
of drug concentrations in tissue and other sites,
Bayesian predictive forecasting and highly efficient 
capillary LC investigations into intra-cellular 
chemotherapeutic action ,will result in significant 
advances in the design of chemotherapeutic regimens.
APPENDIX A
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TABLE A .1
Sex and weight of subjects
Subject Sex Weight (kg)
1 A.3. M 63
2 A .B . F 62
3 R.McD. M 58
b M.B. F 66
5 3. M c K . M 73
6 C.R. F 65
7 R.C. F 60 0
8 G.T. M 80
9 S.B. F 6b
10 G.B. M 71
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TABLE A.2
Time to steady state (hrs) for SDMO, SMZ and TMP 
co-trifamole or co-trimoxazole therapy
following
SUB3ECT SMZ SDMO TMP
co-trimoxazole co- trifamole
l' 72 24 72 24
2 72 24 24 48
i
3 00 48 48 48
4 72 24 48 24
5 72 24 72 24
6 24 24 24
1 ^8 24 24 4 8
8
CO<1-. 24 48 24
9 24 24 24 24
10 48 24 48 48
median 4 8 24 48 24
range 24-72 24-48 24-72 24-48
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TABLE A.3
Individual areas under the serum concentration 
for TMP, SDMO and SMZ following co-trifamole or 
co-trimoxazole therapy (n=10) (AUC in mg h 1~1)
time curve
SUB3ECT SMZ SDMO TMP
CO-trimoxazole co- trifamole
i
1 1377 1204 64.2 35.8
2 907 997 29.8 34.4
3 877 1146 57.3 31.3
4 804 1453 30.9 33.6
5 811 477 24.5 25.1
6 905 997 32.1 32.6
1 917 1193 57.7 35.4
8 649 526 21.8 24.1
9 590 634 *23.8 37.9
10 902 1677 28.6 28.0
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TABLE A.4
Observed peak serum concentration (mg/1) for SDMO, SMZ 
and TMP following co-trifamole or co-trimoxazole 
initial dose
SUB3ECT SMZ SDMO TMPj #
co-trimo'xazole co-trifamole
V
1 69 74 1*7 1 .7
2 74 105 2.1 2.2
3 76 82 1.8 1.7
4 56 96 2.0 2.0
5 61 58 1.4- 1.3
6 69 132 2.0 1.6
7 70 96 1.9 1.9
8 58 65 2.3 1.4-
9 91 89 - 1.8 2.3
10 57 80 1.5 1.3
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TABLE A. 5
Time to peak serum concentration (hours) for SDMO, SMZ 
and TMP following co-trifamole or co-trimoxazole______
SUBJECT
. j
SMZ SDMO TMP
co-trimoxazole co -trifamole
\
1 3 2 2 3
2 2 1 2 12
3 2 4 2 3
4 4 2 4 1
5 2 1 1 1
6 3 2 2 2
7 2 2 2 3
8 2 3 1 2
9 2 1 12 1
10 2 2 2 2
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TABLE A.6
Apparent volume of distribution for SDMO, SMZ and TMP 
following co-trifamole or co-trimoxazole (Vd (1))
SUB3ECT SMZ SDMO TMP
co-trimoxazole co-trifamole
1, li.6 10.4 65.4- 72.6
2 10.4 7.4 59 .8 59.7
3 9.9 9.0 64.4 78.5
4 13,5 7.9 56.4 64.6
5 13.8 14.2 109.0 106.5
6 • 10.5 7.7 63.3 80.1
7 11.1 8.2 65.6 63.5
8 14.0 10.8 71.9 92.1
9 9.2 910 71.1 61.8
10 16.2 9.2 86.3 98.8
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TABLE A.8
Urinary SDMO concentrations (mg/1)
TIME (HRS) 0-12 12-24 24-48 48-72 72-96 96-108
SUBJECT
1 146 169 144 93 122
2 205 186 124 194 255 106
3 103 280 276 211 255 206
4 153 179 219 266 135 211
5 100 61 53 62 57 60
6 203 171 194 229 189 178
7 118 140 115 188 152 124
8 231 86 48 85 50 551
9 177 135 91 53 69 93
10 115 98 77 65 77 78
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TABLE A.9
Urinary SMZ levels (mg/1) following co-trimoxazole therapy
TIME (HRS) 
SUB3ECT
0-12 12-24 24-48 48-72 72-96 96-108
1 V 14-7 251 169 244 330 168
2 129 219 176 177 118 119
3 252 357 361 292 396 349
* 268 135 265 215 96 -
5 51 78 109 90 85 90
6 * 390 245 115 179 247 211
7 - 103 180 95 207 153
8 201 92 136 89 148 133
9 108 144 187 290 264 326
10 62 228 178 80 166 258
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TABLE A.10
Urinary TMP levels (mg/1) following co-trifamole therapy
TIME (HRS) 
SUB3ECT
0-12 12-24 24-48 48-72 72-96 96-108
78 113 84 58 75 -
2 67 110 72 64 65 34
3 41 118 89 72 85 84
4 54 78 114 71 52 52
5 36 Si 72 85 75 74
6 72 84 91 93 95 108
7 82 99 63 86 46 42
8 104 165 73 94 54 57
9 70 107 73 51 89 79
10 59 67 65 65 60 63
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TABLE A.11
Urinary TMP levels (mg/l) following co-trImoxazole therapy
TIME (HRS) 0-12 12-24 24-48 48-72 72-96 96-108
SUB3ECT •
1 , 80 101 128 125 175 129
2 83 165 99 118 121 103
3 90 17? 122 148 105 100
4 101 225 215 222 167 -
5 30 200 140 134 119 88
6 114 143 181 227 186 174
7 44 174 118 143 107 112
8 62 231 113 136 98 98
9 80 105 99 197 127 107
10 41 103 126 98 148 100
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TABLE A.7
Elimination half-life, elimination rate constant and serum clearance for SDMO, SMZ and TMP 
following co-trifamole or co-trimoxazole (tl(h), kc^(h-T), Cl(lh-l))______________  ______
SMZ SDMO TMP
co-trimoxazole co-trifamole
SUBJECT t} k , el Cl ti k , el Cl t| k , el Cl ti el Cl
1 13.9 0.050 0.6 11.0 0.063 0.7 18.2 0.038 2.5 11.3 0.062 4.5
2 8.2 0.084 0.9 6-.4 0.108 0.8 7.7 0.090 5.4 8:9 0.078 4.7
3 7.6 0.092 0.9 8.9 0.078 0.7 16.0 0.043 2.8 10.6 0.065 5.1
4 9.4 0.074 1.0 10.0 0.069 0.6 7.5 0.092 5.2 9.4 0.074 4.8
5 9.7 0.072 1.0 5.9 0.118 1.7' 11.6 0.060 6.5 11.6 0.060 6.4
6. ' 8.2 0.0S4 0.9 6.6 0.104 0.8 8.8 0.079 5.0 11.3 0.061 4.9
7 8.9 0.078 0.9 8.4 0.082 0.7 15.7 0.042 2.8 9.8 0.071 4.5
8 7.9 0.088 1.2 4.9 0.141 1.5 6.8 0.102 7.3 9.6 0.072 6.7
9 4.7 0.148 1.4 5.0 0.140 1.3 7.3 0.095 6.7 10.2 0.068 4.2
10 12.6 0.055 0.9 13.2 0.052 0.5 10.7 0.065 5.6 12.0 0.058 5.7
APPENDIX B
TABLE B.l.
Demoqraphic data for su bjects
Subject Sex Age Weight (k g )
1 M 33 79.5
2 M 29 55.5
3 M 29 110.0
M 30 101.0
5 M 22 56.5 v
6 F 22 63.5
*7 F 53 56.0
8 F 26 55.0
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TABLE B.2.
Maximum concentration and time to maximum
concentration ( T ^ ^ )  for the 200 mg b.d. and 300 mg o.d 
preparations following the initial dose.
^ \ P A R A M E T E R
S U B 0 E C T " ' ' \ ^
o > X t m a x
i 200 b.d. 300 o.d. 2.00 b.d. 300 o.d.
1 2.0 2.9 1.0 0.5
2 2.4 3.4 1.0 1.0
3 1.7 2.6 4.0 1.0
4 I-7 2.3 2.0 4.0
5 2.5 2.8 1.0 4.0
6 2.3 3.4 1.0 1.0
7 2.5 3.5 1.0 1.0
8 2.8 4.6 2.0 1.0
TABLE B .3
Individual area under the serum 
concentration-time curve for each 
preparation following the initial 
dose (mg.h.l"^)
S U B O E C T ' ^ ' - ^
200 mg 300 mg
1 '39.8 57.9
2 . 37.8 83.2
3 28.9 35.9
4 32.3 32.4
5 65.1 91.3
• 6 51.6
©
•
vo
7 34.8 67.9
8 30.1 62.1
PREDICTED 56.5 86.5
TABLE B.4.
Volumes of distribution for each subject for 
200 mg and 300 mg doses following the initial 
dose (1)
— ^ D O S A G E  
S U B 3 E C r " ^ \ ^ ^ 200 mg 300 mg
1 86.2 82.6
2 69.2 60.3
3 91.1 110.0
4 99.7 81.4
5 64.0 72.9
6 67.8 67.2
7 62.8 64.1
8 62.5 60.9
mean
sd
75.4
14.7
74.9
16.6
Vd calculated from: co-trifamole 77.8*16.6 1
co-trimoxazole 71.3*15.6 1
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TABLE B .5
Pharmacokinetic elimination parameters for each subject 
following the initial dose of either 200 mg or 300 mg
^ ^ ^ P A R A M E T E R
S U B 3 E C T ^ ^ - ^ _ t|3(h ) ke l (h -1 ) C1s (lh "I)
200 300 200 300 200 300
I
1 11.9 11.0 0.058 0.063 5.0 5.2
2 9.1 11.6 0.077 0.060 5.3 3.6
3 9.1 9.1 0.076 0.076 6.9 8.4
4 11.2 6.1 0.062 0.114 6.2 9.3
5 14.4 15.4 0.048 0.045 3.1 3.3
6 12.1 10.4 0.057 0.067 3.9 4.5
7 . 7.6 10.0 0.092 0.069 5.8 4.4
8 6.5 8.'7 0.107 0.079 6.7 4.8
mean 10.2 10.3 0.072 0.072 5.4 5.4
sd 2.6 2.7 0.020 0.020 1.3 2.2
values for:
co-trifamole 10.5±1. 0 0.067±0 .007 5.1±0. 8
co-trimoxazole 11.0±4. 2 0.071±0
<M 
• O
 • 5.0-1. 7
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TABLE B .6
Normalised values for apparent volume of distribution 
(l.kg-1) for each subject following both dose regimens
^ - ^ R E G I M E N
S U B 3 E C T ^ ^ - ^ _
200 mg 300 mg
1 1.08 1.04
2 1.25 1.09
3 0.83 1.00
4 0.99 0.81
5 1.13 1.29
6 1.07 1.06
7 1.12 1.14
8 1.14 1.11
mean 1.08 1.07
sd 0.12 0.14
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TABLE C.4
Mean individual salivary flow rate (ml/min) over 
both legs of study ________ ______________________
/
200 300
\ . . . .
Subject x sd x Isd
1 1 • 3i 0.21 1.28 0.16
2 0.93 0.19 1.07 0.28
3 1.84 0.41 2.21 0.19
4 * 1.20 0.26 1.04 0.28
3 1.72 0.21 1.38 0.21
6 1.66 0.31 1.74 0.25
1 1.11 0.15 0.97 0.28
8 1.48 0.17 1.22 0.08
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TABLE C .5
Mean individual salivary hydrogen ion concentration 
(nmol/1) over both legs of the study ________ _
f
- . 200 300
Subject x sd x sd
1 30. 4 24.8 31.5 14.0
2 34.8 27.4 24.4 21.9
3 26.0 :8,2 22.0 10.8
4 . 24. 8 10.7 22.8 12.4
5 29.2 14.1 45.2 26.6
6 58.4 21.0 48.0 22.9
7 37.6 20.8 26.2 15.1
8 19.6 9.2 19.2 13.4
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APPENDIX E
TABLE E.l
Volume of distribution of CLAV
291
ibject No Vd
(1)
Weight
(Kg)
Vd
(1/Kg)
MK 1 10.9 55.2 0.20
VD 2 9.5 5k.8 0.17
AS 3 18.1 81.8 0.22
EB 4 8".7 48.6 0.18
3P 5 17.1 84.0 0.20
S3 6 10.5 57.0 0.18
HL 7 12.0 56.0 0.21
AA 8 11.1 65.0 0.17
AL 9 lk.2 77.3 0.18
DS 10 15.2 66.4 0.23
RMcL 11 10.4 85.8 0.12
SK 12 -  . 85.0 INAPPROPRIATE
MC 13 64.0 SAMPLING
MR 14 18.5 47.0 0.39
DH 15 11.3 61.0 0.19
DM 16 11.2 60.0 0.19
MS 17 21.6 50.0 0.43
3H 18 12.6 81.9 0.15
3MI 19 22.9 82.0 0.28
NW 20 17.1 76.6 0.22
PMcN 21 lk.k 66.1 0.22
EM 22 17.0 66.1 0.26
3MA 23 27.0 65.0 0.42
AH 24 7.7 48.6 0.16
PS 25 HAEMODIALYSIS
FMcL 26 it
NMcD 27 22.0 88.9 0.25
UK 28 9. k 50.7 0.19
MS 29 8.1 69.1 0.12
PM 30 9.3 49.7 0.19
MP 31 HAEMODIALYSIS
3McL 32 9.7 64.5 0.15
TMcK 33 13.0 70.0 0.19
- 3k STORAGE FAILURE
3T 35 CAPD
KS 36 4.4 75.0 0.06
AG 37 CAPD
LMcD • 38 17.8 55.2 0.32
MA 39 k'.l 77.8 0.05
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Volumes of Distribution of TIC
Vdf=Vd CENTRAL compartment, Vd2=Vd PERIPHERAL compartment
ibject No Weight
(Kg)
Vdj
(1)
Vd2
(1)
VdTOT
(1)
VdL
(1/Kg)
Vd2
(1/Kg)
VdT01
(1/Kg
MK 1 55.2 7.9 6.0 13.9 0.14 0.11 0.25
VD 2 54.8 5.4 11.1 16.5 0.10 0.20 0.30
AS 3 81.8 1.6 6.5 8.1 0.02 0.08 0.10
EB 4 '48.6 2.0 2.2 4.2 0.04 0.05 0.09
OP 5 84.0 9.9 4.9 14.8 0.12 0.06 0.18
SO 6 57.0 5.2 2.0 7.2 0.09 0.04 0.13
HL 7 56.0 6.2 2.9 9.1 0.11 0.01 0.12
AA 8 65.0 5.5 2.3 7.8 0.08 0.04 0.12
AL 9 77.3 6.6 6.3 12.8 0.09 0.08 0.17
DS 10 66.4 4.4 4.4 8.8 0.07 0.07 0.13
RMcL 11 85.8 3.0 8.6 11.6 0.03 0.10 0.14
SK 12 INAPPROPRIATE
MC 13 SAMPLING
MR ' 14 47.0 4.4 3.4 7.8 0.09 0.07 0.16
DH 15 61.0 4.9 4.6 9.4 0.08 0.08 0.16
DM . 16 60.0 9.7 10.8 20.5 0.16 0.18 0.34
MS 17 50.0 12.3 11.2 23.5 0.25 0.22 0.47
OH 18 81.9 6.2 6.8 13.0 0.08 0.08 0.16
OMI 19 82.0 8.8 7.0 15.8 0.11 0.09 0.20
NW 20 ' 76.6 6.7 3.1 9.8 0.09 0.04 0.13
PMcN 21 66.1 7.9 9.4 17.3 0.12 0.14 0.26
EM 22 66.1 6.9 7.0 13.9 0.10 0.11 0.21
OMA 23 65.0 5.0 5.8 10.8 0.08 0.09 0.17
AH 24 48.6 5.5 7.6 13.1 0.11 0.16 0.27
PS
FMcL
25
26
HAEMODIALYSIS
NMcP 27 88.9 8.3 7.3 15.6 • 0.09 0.08 0.17
UK 28 50.7 4.3 11.5 15.7 0.08 0.23 0.31
MS 29 69.1 2.7 9.9 12.6 0.04 0.14 0.18
PM 30 49.7 5.1 2.6 7.8 0.10 0.05 0.15
MP 31 HAEMODIALYSIS
OMcL 32 64.5 4.1 9.0 13.1 0.06 0.14 0.20
TMcK 33 70.0 6.2 6.1 12.2 0.09 0.09 0.18
- 34 STORAGE FAULT
OT 35 CAPD
KS 36 75.0 8.3 4.6 12.9 0.11 0.06 0.17
AG 37 CAPD
LMcD 38 55.2 2.4 6.1 6.5 0.04 0.11 0.12
MA 39 77.8 2.2 5.0 7.2 0.03 0.06 0.09
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TABLE E.3
Clearance and elimination half-lives of TIC and CLAV
Subject No CrCl tl$ 
(ml/min) (h)
MK 1 6.8 3.3
VD 2 14.0 3.1
AS 3 34.0 1.0
EB 4 4.8 2.8
OP 5 49.0 1.5
S3 6 13.0 1.7
HL 7 9.4 2.3
AA 8 6.8 2.8
AL 9 78.0 0.6
DS 10 19.0 2.0
RMcL 11 55.0 1.4
SK 12 INAPPROPRIATE
ML 13 SAMPLING
MR 14 6.0 2.3
DH 15 9.5 1.9
DM 16 AN 1.3
MS 17 AN 3.1
OH 18 97.0 0.9
3MI 19 22.0 3.2
NW 20 26.0 1.2
PMcN 21 70.0 0.6
EM 22 40.0 3.4
DMA 23 20.0 1.8
AH 24 6.0 3.8
PS 25 HD 0.3
FMcL 26 HD 0.5
NMcP 27 AN 1.4
UK 28 AN 1.3
MS 29 14.0 1.0
PM 30 AN 1.3
MP 31 HD 0.3
OMcL 32 AN 1.5
TMcK 33 108.0 0.3
- 34 STORAGE FAULT
3T 35 CAPD .. -
KS 36 110.0 0.14
AG 37 CAPD.
LMcD 38 118.0. 0.24
MA 39 125.0 0.10
CLAV TIC
kei Cls tl3 kel Cls 
(h'i> (i/h) (h) (hSi) d / h )
0.210 2.3 2.4 0.289 1.9
0.224 2.1 5.3 0.131 1.4
0.693 12.8 3.0 0.231 1.3
0.248 2.1 7.9 0.088 0.3
0.462 7.7 2.5 0.277 2.7
0.408 4.4 6.1 0.144 0.9
0.301 3.7 6.2 0.112 0.8
0.248 2.7 5.5 0.126 1.0
1.155 15.5 0.8 0.866 8.7
0.347 5.3 1.4 0.495 3.9
0*495 5.0 1.6 0.433 ; 4.6
0.301 5.5 9.9 0.070 0.6
0.364 4.1 6.0 0.116 0.9
0.533 5.9 12.2 0.057 0.8
0.224 4.9 16.7 0.041 1.1
0.770 9.7 1.1 0.630 8.2
0.217 4.9 6.9 0.100 2.1
0.578 10.0 4.6 0.151 4.1
1.155 16.1 1.1 0.630 13.4
0.203 3.4 6.4 0.108 1.4
0.385 16.1 7.0 0.099 1.5
0.182 3.8 10.2 0.068 0.9
- - 1.2 - -
- ■ - ■ 1.7 • - . ' -
0.495 12.4 7.3 0.095 1.8
0.533 4.8 5.6 0.124 1.9
0.693 5.4 6.8 0.102 1.9
0.533 "4.8, 7.9 0.088 0.7
. - 2.0
0.462 9.9 7.2 0.096 1:1
2.310 30.5 1.1 0.630 6 . £
4.950 20.9 0.85 1.155 8.7
2.890 25.6 1.0 0.693 5.7
6.930 19.7 0.35 1.980 6.9
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TABLE E.4
Urine Kinetics of TIC and CLAV
CLAV TIC
AMOUNT EXCRETED AMOUNT EXCRETED
ibject No CrCl
(ml/min)
Cl
(1/h)
Mg fe Cl
(1/h)
mg fe
MK 1 6*8 0.21 18.4 0.09 0.47 470 0.16
VD 2 14.0 0.74 70.0 0.35 0.27 370 0.12
AS 3 34.0 5.00 78.2 0.39 0.34 570 0.19
EB 4 4.8 0.31 28.4 0.14 0.10 840 0.28
OP 5 49.0 3.30 83.6 0.42 2.32 1698 0.57
S3 6 13.0 0.25 11.6 0.06 0.16 570 0.19
HL 7 9.4 0.79 43.8 0.22 0.20 576 0.19
AA 8 6.8 0.42 30.8 0.15 0.12 537 0.18
AL 9 78.0 9.41 122.4 0.61 1.67 453 0.15
■DS 10 19.0 1.38 52.4 0.26 0.51 360 0.12
RMcL 11 55.0 2.60 101.0 0.51 0.40 270 0.09
SK 12 INAPPROPRIATE
ML v 13 SAMPLING
MR 14 6.0 2.03 72.8 0.36 0.11 600 0.20
DH 13 9.5 1.56 75.6 0.38 0.24 660 0.22
DM 16 AN 0.00 00.0 0.00 0.00 0 0.00
MS 17 AN 0.00 00.0 0.00 0.00 0 0.00
OH 18 97.0 5.60 115.0 0.58 5.90 2160 0.72
OMI 19 22.0 1.76 70.8 0.35 0.46 \ 861 0.29
NW 20 NO URINE COLLECTED
PMcN 21 70.0 9.30 115.4 0.58 5.85 1611 0.54
EM 22 40.0 0.52 30.2 0.15 0.18 357 0.12
OMA 23 20.0 4.28 82.4 0.41 0.43 1224 0.41
AH 24 9.2 0.43 22.4 0.11 0.33 1104 0.37
PS 25 HD *
FMcL 26 HD ■ — —  . —  .
NMcP 27 AN 0.00 00.0 0.00 0.00 0 0.00
UK 28 AN 0.00 00.0 0.00 0.00 0 0.00
MS 29 14.0 1.20 42.8 0.21 0.50 1176 0.39
PM 30 AN 0.00 00.0 0.00 0.00 0 0.00
MP 31 HD . - . - - , . -  .
OMcL 32 AN 0.00 00.0 0.00 0.00 0 0.00
TMcK 33 108.0 22.30 148.4 0.74 5.62 2232 0.74
34 STORAGE 1FAULT
OT 35 CAPD. - ’ ^ . >-
KS 36 110.0 17.2 157.6 0.79 8.3 2370 0.79
AG 37 CAPD.. - r • ' - r -
LMcD 38 118.0 19.2 104.5 0.52 5.4 1216 0.41
MA 39 125.0 20.7 41.3 0.21 .8.4 1560 0.52
APPENDIX F
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TABLE F.l.
- Serum and peritoneal dialysate concentrations of ticarcillin and clavulanic 
acid during CAPD (mg/1).____________
TIME
(h)
S U B 3 E C T
SERUM 
TIC CLAV
1
DIALYSATE 
TIC CLAV
S U B 3 E C
SERUM 
TIC CLAV
T 2
DIALYSATE 
TIC CLAV
0 ND ND _ _ ND ND _ _
0.083
■ * 
730 160.9* - - - 194 H.3 -
0.025 . - - 57 14.4 - 104 11.7
0.5 142 29.3 75 23.6 130 8.8 187 15.2
1 125 9.2 102 42.4 117 3.3 319 8.3+
2 - - 141 46.6 - - 640 19.5
3 - - 225 50.2 - 846 22.6
4 113 6.6 303 52.6 90 0.1 2230 28.2
(pre exchange) 
4 87 <0.1 536 17.9
(post exchange) 
8 104 ND 70 ND 662 9.6
(pre exchange) 
8 42 ND 130 11.6 30 ND 288 ND
(post exchange) 
12 165 ND 272 ND
(post exchange) 
24 18 ND - ■ - 10 ND - . -
.* Sample rejected - contamination from line?
t " storage inadequate
ND - not detected 
- no sample
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